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Hematopoiesis and the CD34+38- hematopoietic stem cell
Hematopoiesis and hematopoietic stem cells
Hematopoiesis is the continuous process of proliferation and terminal differentiation of 
hematopoietic stem cells (HSC) into the different blood cell lineages (myeloid, erythroid 
and lymphoid). Hematopoiesis is supported by pluripotent HSC defined as cells with the 
capacity to engraft, selfrenew and support multilineage differentiation into committed 
progenitors and subsequently into all types of blood cells. Characteristically, HSC, like all 
other stem cells have the ability to divide assymetrically. Through this process, the division 
of a stem cells results in the formation of two daughter cells, one of which is another stem 
cell and the other is a committed progenitor cell that is capable of further differentiation and 
proliferation but lacks selfrenewal capacity. HSC reside predominantly in the bone marrow 
although low numbers are also found in the peripheral blood. Although they were previously 
thought to be resting cells recent evidence from mouse experiments show that 8-10 % of 
HSC randomly enter the cell cycle every day with all HSCs entering the cell cycle in 1-3 
months(1). HSC respond to a variety of conditions by entering the cell cycle, expanding 
their numbers by self-renewing proliferation and mobilizing into the bloodstream. These 
conditions include myelosuppressive treatment with agents such as cyclophosphamide 
and cytokines such as granulocyte colony-stimulating factor (G-CSF) and granulocyte 
macrophage colony stimulating factor (GM-CSF).
CD34+38- hematopoietic pluripotent stem cells
HSC and committed progenitor cells in human bone marrow as well as umbilical cord 
blood can be identified by their expression of the CD34 membrane phosphoglycoprotein(2). 
CD34+ cells account for approximately 1.5% of normal adult mononuclear cells and 
contain erythroid, granulomonocytic, megakaryocytic, B and T lymphoid and dendritic cell 
precursors. The observation that CD34+ cells provide sustained multilineage hematopoiesis 
after allogeneic and autologous transplantation(3), a characteristic of hematopoietic stem 
cells, showed that CD34+ cells also contain HSC. These hematopoietic stem cells in 
human have subsequently been shown to have a CD34+ CD38- phenotype(4,5), comprising 
only 1-10% of CD34+ cells. CD38 is a 45 kDa transmembrane glycoprotein that appears 
to play a role as a differentiation molecule(6) and inductior of apoptosis(7,8); CD34+38+ cells 
contain the committed progenitor cell types. Additionally CD38 is expressed on most 
mature blood cells (majority of B and T-lymphocytes, NK cells and subsets of monocytes, 
granulocyes, erythroid cells and platelets)(9-11). CD34+38- cells have a lymphocyte-like 
morphology(12), weakly express Thy1(13) and the tyrosine kinase receptors c-kit(14) and Flt-
3(15) but lack antigens displayed on mature hematopoietic cells(16). It appears that CD38 is 
a better marker for HSC purification than a cocktail of so-called “lineage markers” which 
are antigens expressed on mature blood cells because CD34+ cells undergoing early 
differentiation first express CD38 and than lineage markers(17). Evidence that CD34+38- 
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hematopoietic cells contain pluripotent hematopoietic stem cells has come from both in 
vitro and in vivo assays; the CD34+38- cell population is enriched for long-term culture 
initiating cells (LTC-IC)(18-20) and extended LTC-IC(21), which proliferate later and have a 
greater regenerative potential. No such cells were found in the CD34+38+ population. 
Definite assessment of HSC function(22,23) has come from in vivo assays demonstrating 
that CD34+38- cells from adult bone marrow were able to engraft and generate sustained 
(re) transplantable multilineage human hematopoiesis in fetal sheep(24) and NOD/SCID 
mice(25,26) illustrating the characteristics of stem cells i.e. engraftment, self-renewal and 
multilineage cell generation.
Acute myeloid leukemia as a hematopoietic stem cell disease
Acute myeloid leukemia originates from hematopoietic stem cells
Acute myeloid leukemia is characterized by the accumulation of large numbers of blast 
cells that fail to differentiate into functional granulocytes or monocytes. The leukemic blasts 
have limited proliferative potential suggesting that a small subpopulation of leukemic cells 
with extensive proliferation and the capacity for self-renewal must maintain the leukemia(27-
29). This concept of tumorigenic leukemic stem cells has emerged from findings that only a 
small subset of leukemic cells is capable of extensive proliferation in vitro and in vivo. 
In recent years it has become evident that leukemic stem cells exist and reside within the 
CD34+38- cell population in AML. The involvement of CD34+38- cells in leukemogenesis 
is demonstrated by the presence of cytogenetically aberrant cells in the CD34+CD38- 
compartment(30,31). Additionally, leukemic cells with long-term proliferative ability have 
been identified as CD34+CD38-(32). Concluding evidence for the existence for a leukemic 
stem cell in acute myeloid leukemia has come from studies using the nonobese diabetic/
severe combined immunodeficient mice (NOD/SCID) mouse model showing that cells with 
leukemic stem cell characteristics, defined as capacity for self-renewal and engraftment 
potential are present in AML(33,34). These cells were referred to as SCID leukemia initiating 
cells or SL-IC. The SL-IC were found exclusively in the primitive CD34+38- fraction of all 
patient samples regardless of the lineage markers expressed by the leukemic blasts, the 
percentage of CD34+ blast cells or the FAB subtype (with exception of AML-M3). SL-IC 
were not found in more committed CD34+38+ progenitors or CD34- cells. These studies 
stress that leukemia initiating transformation and progression associated genetic events 
occur at the level of these primitive CD34+38- cells. This parallels the hierarchy in normal 
bone marrow in which a rare population of CD34+38- cells have stem cell characteristics(35), 
supporting the hypothesis that malignant transformation takes place in normal HSC and that 
the nature of the genetic event itself determines the differentiation program of the leukemic 
clone (Figure 1). A similar role for the CD34+CD38- compartment in leukemogenesis has 
been suggested for chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) 
and the myelodysplastic syndrome(36-38)
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Figure 1: Acute myeloid leukemia originates from the normal hematopoietic stem cell. In human normal 
hematopoiesis a CD34+CD38- hematopoietic stem cell (HSC) gives rise to the SCID repopulating cell (SRC) 
which is capable of self renewal and the production of all forms off mature blood cells through the subsequent 
differentiation into multipotential progenitors and committed CD34+38+ hematopoietic progenitors. In AML 
leukemic transformation of the HSC leads to the occurrence of a SCID leukemia initiating cell (SL-IC) that is 
capable of self renewal and produces both the clonogenic and non-clonogenic blast cells that form the bulk of the 
tumor, similar to the hierarchy in normal bone marrow. Adapted from reference 32 © (1997) Macmillan Magazines 
Ltd.
Cancer as a stem cell disease
It is increasingly recognized that other forms of cancer, including solid tumors, may arise 
from normal stem cells as well(39-42). A subset of cancer cells may have the properties of 
cancer stem cells, with self renewal capacity to generate progeny cancer cells with limited 
proliferative potential. Normal stem cells have the machinery for self renewal, which is 
a hallmark of cancer, already activated and therefore may require fewer mutations for 
malignant transformation in comparison to mature cells. In addition, normal stem cells persist 
throughout life and undergo an increased number of cell divisions and therefore have greater 
chance for the acquisition of mutations required for malignant transformation than short-lived 
cells. Cancer stem cells have been characterized using NOD/SCID engraftment and serial 
transplantation models in breast cancer(40) and neuronal tumours(43-45). In these diseases 
surface markers have been identified that recognize cells which are highly enriched for the 
ability to form tumors following transplantation relative to bulk tumor cells. 
HSC 
CD34+CD38-
SRCSL-IC
Self-rewal
Leukemogenic 
event
Clonogenic 
leukemic 
progenitors
Multipotent 
progenitors
Committed 
progenitors 
CD34+CD38+
Lymphocytes Granulocytes Erythrocytes Platelets
Leukemia
14
_____ CHAPTER 1 _____________________________________________________________________________________________________ __________________________________________________________________________________________ GENERAL INTRODUCTION _____ 
15
Committed progenitors as leukemic stem cell in leukemia
Although HSC are now increasingly recognized as the target of genetic events leading 
to malignant transformation, committed progenitors or even differentiated cells may also 
become leukemia-initiating cells through the activation of oncogenic pathways that re-
establish stem cell (self-renewal) capacities. Proof of principle for this concept has been 
established in mouse models of leukemia(46,47). Additionally transgenic mice models using 
promoter regions of myeloid specific genes have shown that myeloid leukemias can also 
arise from committed progenitors, since leukemic fusion proteins such as BCR/ABL, 
PML-RARa and MLL-ENL(48-50) can be transforming at the level of myeloid progenitors 
and are able to give rise to leukemia without HSC involvement. This is likely the case in 
promyelocytic leukemia in which the specific t (15,17) PML/RARa reciprocal translocation 
is found in CD34+38+ committed progenitors but not in CD34+38- cells(48). Similarly, 
recent evidence indicates that the CML stem cell compartment might be dynamic when 
it progresses to blast crisis(51); self renewal properties were observed in vitro within the 
granulocyte-monocyte progenitor population, a compartment that normally lacks the ability 
for self renewal. These results indicate that this progenitor compartment may attain self 
renewal properties upon further transformation that are responsible for the expansion of 
acute leukemic blasts.
Therapeutical implications of AML as a stem cell disease
The concept that AML arises from the malignant transformation of normal HSC has 
important implications for the treatment of the disease; Therapies directed against mature 
leukemic cells may produce clinical improvement and responses but are unlikely to be 
curative if leukemic stem cells that are responsible for maintenance of the disease are not 
targeted or are resistant to therapy (Figure 2). Incomplete chemotherapeutical eradication 
of these cells will ultimately result in disease relapse, as is frequently observed in AML. 
Cellular antigens or signaling pathways expressed by leukemic cells may not be optimal 
therapeutic targets if immature leukemic cells do not express these targets. The leukemic 
stem cell is thus the most crucial target in the treatment of AML and therefore elucidation 
of the mechanisms conferring resistance against chemotherapy to these cells is of great 
importance. Additionally, further characterization of cancer stem cells may lead to improved 
diagnostics and therapies by allowing us to better identify and target these crucial cells 
within the tumor hierarchy.
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Figure 2: Stem cell model of drug resistance in AML. Leukemic stem cells (LSC) might be naturally resistant 
to chemotherapy through conserved ABC transporter expression, quiescence or other mechanisms such as 
DNA repair and anti-apoptotic mechanisms. Incomplete chemotherapeutical eradication of these tumor initiating 
stem cells through this innate resistance will eventually lead to recurrence of disease after an initial response to 
chemotherapy (which is induced through eradication of the sensitive bulk of tumor cells) as is frequently observed 
in AML.
ATP-binding cassette (ABC) transporters
ABC Protein and Gene Organization 
The ATP-binding cassette(ABC) transporters represent the largest family of transmembrane 
proteins involved in the transmembrane transport of a huge variety of substrates including 
sugars, peptides, inorganic anions, amino-acids, oligopeptides, polysaccharides and 
proteins vitamins and metallic ions(52,53). ABC transporters use the energy of ATP binding to 
drive the transport of these molecules across all cell membranes(54). Proteins are classified 
as ABC transporters based on the sequence and organization of their ATP-binding domains, 
also known as nucleotide-binding folds NBFs. The NBFs contain characteristic motifs, 
Walker A and B, separated by ~90-120 amino acids, found in all ATP-binding proteins. 
ABC transporters also contain an additional element, the signature C motif, located just 
upstream of the Walker B site(55). The functional protein typically contains two NBFs and 
two transmembrane (TM) domains (Figure 3). The TM domains contain 6-11 membrane-
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remission induction but  
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spanning α-helices and provide the specificity for the substrate. The NBFs are located in 
the cytoplasm and transfer the energy to transport the substrate across the membrane. In 
eukaryotes, most ABC transporters transport compounds from the cytoplasm to the outside 
of the cell or into an extracellular compartment (endoplasmic reticulum, mitochondria, 
peroxisome). The eukaryotic ABC transporters are organized either as full transporters 
containing two TMs and two NBFs, or as half transporters(55). The latter must form either 
homodimers or heterodimers to constitute a functional transporter. ABC genes are dispersed 
widely in eukaryotic genomes and are highly conserved between species, indicating that 
most of these genes have existed since the beginning of eukaryotic evolution. The human 
superfamily of ABC transporters currently consists of 48 members. The genes can be 
divided into subfamilies based on similarity in gene structure (half vs. full transporters), 
order of the domains, and on sequence homology in the NBF and TM domains, resulting in 
seven mammalian ABC gene subfamilies (ABCA, B, C, D, E, F and G family). 
Figure 3: Schematic representation of a typical ABC transporter protein (ABCB1). ABC transporters consist 
a varying number of transmembrane domains. ATP binding that drives the transmembrane transport takes place 
in the nuclear binding folds (NBF). The picture represents the motifs found in a full transporter such as ABCB1 
(N-TM-NBF-TM-NBF-C). Half transporters with TM-NBF or NBF-TM configuration also exist (e.g. ABCG2).
Multidrug Resistance (MDR)
MDR is defined as resistance to many different drugs with different chemical structures 
and different mechanisms of action. Many different mechanisms for the arisal of MDR have 
been elucidated including failure of apoptotic mechanisms, alterations in cell cycle check-
points, repair of damaged cellular targets and reduced drug accumulation. Some members 
of the ABC transporter family have the ability to export a wide variety of structurally 
unrelated chemotherapeutical compounds from cancer cells, thereby conferring MDR 
to these cells(56). The best studied ABC transporters that have been implicated in drug 
transport are ABCB1, ABCC1 and ABCG2. 
NH2
COOH
NBF NBF
in
TM domains
out
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ABCB1 
The best characterized ABC transporter is ABCB1, formerly known as MDR1 or P-
glycoprotein(57). The ABCB1 gene maps to chromosome 7q21.1. ABCB1 was the first 
human ABC transporter cloned and characterized through its ability to confer a multidrug 
resistance phenotype to cancer cells that had developed resistance to chemotherapy 
drugs(58). ABCB1 has been demonstrated to be a promiscuous transporter of hydrophobic 
substrates, hydrophobic drugs including drugs like colchicine, VP16, adriamycin and 
vinblastine as well as lipids, steroids, xenobiotics, and peptides(59). 
ABCB1 is a classical ABC transporter composed of two homologous halves, each 
containing six transmembrane (TM) domains and an ATP-binding domain, separated by 
a flexible linker region (Figure 3). The two halves interact to form a single transporter(60,61). 
The major drug binding domains reside in the transmembrane domains. However, the 
mutations in mammalian P-glycoproteins that affect substrate specificity are found 
throughout the molecule including the TM regions, soluble intra – and extracellular loops 
and the ATP-binding domains(60,62). Mutational analysis further showed that the conserved 
NBF (walker A and B and signature regions) and the linker region is critical for the 
transport function of the protein(63-65). Glycosylation appears to be required for the proper 
trafficking of the transporter to the cell surface but is not required for transport function of 
P-glycoprotein(66,67). P-gp has phosphorylation-sites but mutants lacking these sites exhibit 
normal transport function(68). Recently, polymorphisms in the gene have been described 
that are associated with both altered substrate specificity and decreased transport function 
of the protein(69). ABCB1 is expressed in tissues with a barrier function such as epithelium of 
the liver, kidney, small and large intestine and capillary endothelial cells in brain, ovary and 
testis. Data from ABCB1 knockout transgenic mice strongly support a physiological role for 
ABCB1 in drug absorption, elimination and detoxification pathways(70,71). 
ABCC1 
The ABCC1/MRP1 gene, located on chromosome 16p13, was identified in the small-
cell lung carcinoma cell line NCI-H69, a multidrug resistant cell that did not overexpress 
ABCB1(72). The ABCC1 transporter confers resistance to doxorubicin, daunorubicin, 
vincristine, colchicine and several other compounds, a very similar profile to that of ABCB1. 
Unlike ABCB1, however, ABCC1 transports drugs that are conjugated to glutathione by the 
glutathione reductase pathway(73). Studies in ABCC1 -/- mice demonstrated hypersensitivity 
to etoposide and ABCC1 protected the oropharyngeal mucosa and testicular tubes 
indicating that it plays an important role in drug detoxification(74,75). ABCC1 can also 
transport leukotrienes, such as leukotriene C4 (LTC4). LTC4 is an important signaling 
molecule for the migration of dendritic cells. Migration of dendritic cells from the epidermis 
to lymphatic vessels is defective in ABCC1 -/- mice(76). 
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ABCG2 
ABCG2, or Breast Cancer Resistance Protein (BCRP), is a 655-aa member of the ABCG 
subfamily of ABC- membrane transporters first described in drug resistant cell lines that do 
not overexpress ABCB1 or ABCC1(77 78,79). BCRP is a half transporter, likely functioning as a 
homodimer and confers multidrug resistance to topotecan, mitoxantrone, doxorubicin and 
related compounds by ATP dependent drug extrusion(80,81). BCRP is expressed in placental 
syncytiotrophoblasts, intestinal epithelium, liver canicular membrane(82) suggesting a 
physiological role in detoxification. This is substantiated by studies in bcrp1 -/- mice 
which are normally viable without pronounced abnormalities but display abnormalities in 
pharmacokinetics and disposal of carcinogens(83-85)
Other ABC transporters involved in extrusion of chemotherapeutical 
compounds and drug resistance
The highly conserved homology between different ABC transporters predicts that additional 
members may be involved in the extrusion of structurally unrelated chemotherapeutical 
compounds. Indeed, an increasing number of ABC transporters have been demonstrated 
to cause resistance to cancer chemotherapeutical agents(86,87) (Table 1). Additionally, 
recent studies examining ABC transporter gene expression in drug-selected cancer cell 
lines demonstrated overexpression of a number of transporters not previously recognized 
as associated with drug resistance (ABCA4, ABCA7, ABCB2, ABCB6, ABCB8, ABCB9 
and ABCG1)(88). Together, these data outline the emerging picture that ABC transporter 
mediated multiple drug resistance may be conferred by simultaneous activity of many 
redundant family-members in addition to ABCB1, ABCC1 and ABCG2.
Table 1: ABC transporters involved in the extrusion of chemotherapeutical compounds and drug 
resistance.
Transporter Alternative name Drug substrates
ABCA2 estramustine
ABCB1 MDR1/ p-glycoprotein anthracyclins, etoposide, imatinib, taxanes, mitoxantrone, vinca 
alkaloids
ABCB4 MDR2 paclitaxel, vinblastine
ABCB11 BSEP paclitaxel
ABCC1 MRP1 anthracyclins, etoposide, methotrexate, 
ABCC2 MRP2/cMOAT cisplatin, doxorubicin, , etoposide, methotrexate, mitoxantrone, 
vinca alkaloids
ABCC3 MRP3 cisplatin, doxorubicin, etoposide, methotrexate, vinca alkaloids
ABCC4 MRP4 methotrexate, thiopurines
ABCC5 MRP5 6-mercaptopurine, 6-thioguanine
ABCC6 MRP6 anthracyclins, etoposide, teniposide
ABCC10 MRP7 docetaxel, paclitaxel, vinca alkaloids
ABCC11 MRP8 purine and pyrimidine nucleotide analogs
ABCG2 BCRP/MXR mitoxantrone, methotrexate, topetocan, SN-38, imatinib, 
flavopiridol, anthracyclins
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ATP-binding cassette transporters and stem cells
ABC transporters as markers of stem cells
Human (hematopoietic) stem cells are characterized by their ability to efflux fluorescent 
dyes. Isolation of stem cells based on this efflux is an efficient method to purify stem cells 
from different sources. It has been demonstrated that rhodamine 123 retention is low in the 
most primitive hematopoietic cells(89,90). While the rhodamine 123-dull fraction provides long-
term reconstitution following injection into lethally irradiated mice, the rhodamine 123-bright 
fraction provides only short term repopulation(91,92). Hoechst 33342 is another fluorescent 
dye used for isolation of stem cell fractions, which is called the side-population(93,94). In 
combination with rhodamine123 staining, Hoechst 33342-dull rhodamine 123-dull cells are 
highly enriched for stem cell function(95). The molecular basis of this phenotype is has long 
been unclear but recent studies indicate that ATP-binding cassette (ABC) transmembrane 
transporters that efflux the fluorescent dyes are responsible for the dull phenotype of 
hematopoietic stem cells. ABCB1 is highly expressed on CD34+ hematopoietic cells 
suggesting that efflux pump activity could be responsible for the low retention of rhodamine 
123 in primitive cells(96). More recent studies in knock-out mice have indeed shown that 
ABCB1 attributes to the rhodamine dull phenotype of hematopoietic stem cells(97-99). 
Recently, BCRP has been shown to be highly expressed in a wide variety of stem cells(100) 
including immature human hematopoietic progenitors(101) and confer the side population 
(SP) phenotype.
Physiological function of ABC transporters in stem cells
The physiological function of ABC transporters in human stem cell biology is currently 
unknown. A role for ABC-transporters in the protection from genetic damage by naturally 
occurring xenobiotics that are substrates for the transporter have been suggested for 
HSC(102,103) and has recently been substantiated by the observation of increased cytotoxicity 
to normal bone marrow in ABCB1(104) and ABCG2/BCRP knock-out mice(105). 
In addition to protection of these long-lived cells to naturally occurring xenobiotics, a 
fundamental role in stem cell biology has been suggested based on studies in Dictyostelium 
demonstrating that a rhodamine-123 cellular efflux pump (RhT) with the properties of 
a ABC-transporter prevents differentiation of prespore cells(106), possibly by exporting 
differentiating factors from the cell interior. This led to the hypothesis that a cell’s response 
to a signal that can diffuse across the plasma membrane depends, in part, on the cell’s 
ability to remove it from the cytoplasm. According to this hypothesis, HSC might escape the 
effect of differentiation factors present in the bone marrow. The idea that ABC transporters 
regulate the cellular concentration of signaling molecules may prove to be a general way for 
developing organisms to control their response to signals and regulate cell fate decisions. 
However, no such a role has been demonstrated for the ABC-transporters identified on 
human (hematopoietic) stem cells; Retroviral-induced overexpression of ABCB1 resulted 
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in increased hematopoietic repopulating activity and myeloproliferative disease in mice(107-
109). However, when extrapolating these experiments to a primate model, no detectable 
adverse consequences have been observed(110) and MDR1 induction in hematopoietic 
cells in clinical trials, in an attempt to protect these cells for chemotherapeutical damage, 
have not resulted in abnormal hematopoiesis(111,112). Furthermore liver and marrow of adult 
mdr1a/1b -/- mice show normal generation, function and multi-tissue trafficking of primitive 
hematopoietic cells(113). 
In contrast to ABCB1 overexpression studies, overexpression of BCRP/ABCG2 in a mouse 
model significantly blocked hematopoietic development and resulted in less progeny in the 
bone marrow and peripheral blood(114). However, similarly to ABCB1, ABCG2 -/- null mice 
display no defects in steady state hematopoiesis and that, though ABCG2 expression is 
required for the SP phenotype, with the loss of ABCG2 repopulating hematopoietic stem 
cells are maintained outside the SP-region(115). Recently experiments using ABCB1/ABCG2 
double knock-out mice confirmed a lack of effect on hematopoiesis, excluding possible 
redundant activity of these transporters(116). The combined data do not support a role for 
ABCG2 or ABCB1 in hematopoiesis but support the idea that they protect stem cells 
from genetic damage of naturally occurring xenobiotics that are the substrate for these 
transporters(117). This seems particularly important for HSC given their life-long presence 
in the bone marrow and high proliferative activity during this period. In this context, it 
is noteworthy that an anti-apoptotic role for ABCB1 has been demonstrated recently 
promoting cell survival by inhibiting caspase activation(118-121). 
ABC transporter modulation in the treatment of AML
Expression of ABC transporters ABCB1, ABCC1 and ABCG2 has been widely studied 
in leukemic blasts in AML. Targeting of these molecules in clinical trials in an attempt to 
enhance chemosensitivity of leukemic blast, however, has been limited to ABCB1. 
ABCB1 is frequently expressed in elderly patients with AML. It is detected in 17% of 
adults younger than 35 years, 39% in patients between 35 and 50 years and in 71 % of 
patients older than 65 years(122). This is accompanied by a rising prevalence of the CD34+ 
surface phenotype with advancing age(123). AML specimens that express ABCB1 display 
reduced cellular accumulation and relative in vitro resistance to antineoplastics such as 
anthracyclins(124). Additionally, in the majority of reports investigating de novo AML, ABCB1 
is a prognostic variable associated with reduced probability for remission induction and in 
some reports, although debatable, inferior leukemia-free and overall survival(125-127). These 
observations have led to the introduction of ABCB1 modulators in the treatment of AML 
in an attempt to circumvent drug resistance by targeting ABCB1 mediated drug efflux 
in leukemic blasts. Initial trials using agents with pleiotropic effects on drug resistance 
(Quinine and cyclosporin) showed promising results with increased CR and OS in some 
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trials(128). Although concern existed about the effect of ABCB1 modulation on pharmokinetics 
as a confounder in these studies, these results fostered the development of second 
generation ABCB1 modulators such as PSC 833. PSC 833, a cyclosporin D analog, is a 
second generation modulator with increased specificity and potency (10-fold greater than 
cyclosporin). Recent phase III trials using PSC 833 (Valsopar) in 2 clinical trials adjusting 
the dosing of chemotherapeutical agents are disappointing; An ECOG trial investigating 
the addition of PSC to mitoxantrone, etoposide and cytarabine in patients with relapsed 
or refractory AML(129) was suspended prematurely after an interim-analysis revealed no 
improvement in rate of CR in the experimental arm. In the CALBG study investigating PSC 
833 in combination with cytarabin, etoposide and daunorubicin in previously untreated 
patients of 60 years and older(130) demonstrated excessive induction mortality with PSC 
833, necessitating closure of the study. Both studies showed increased non-hematological 
toxicity in the PSC 833 arm and failed to demonstrate beneficial effects on remission 
induction in ABCB1 expressing subsets of patients. The outcome of these trials suggest 
the presence of other, yet unidentified mechanisms of drug resistance in leukemic cells in 
AML but despite these negative results, clinical trials using third generation modulators 
(including tariquidar, zosuquidar and laniquidar, all characterized by high-affinity for the 
ABCB1 protein and minimal activity against other members of the ABC transporter family) 
are in development for clinical use arguing that the disappointing results of earlier trials 
may be due to chemotherapy underdosing or schedule disparity(131).
Goal and outline of current thesis
The recognition of AML and other forms of cancer as diseases originating from normal stem 
cells dictates a paradigm shift in the treatment of leukemia away from targeting the blast 
cells and towards targeting the LSC. The high expression of ABC-transporters involved in 
the extrusion of chemotherapeutical compounds on normal (hematopoietic) stem cells could 
have major consequences for the treatment of leukemia. If ABC transporter expression and 
function is conserved after malignant transformation of stem cells, this would be a major 
mechanism of drug resistance to these cells and prevent chemotherapeutical eradication 
of this tumor-initiating cell population. In the paradigm shift for the treatment of leukemia, 
ABC drug transport inhibitors might thus be thought of as “leukemia stem cell sensitizing 
agents” that allow the most crucial and drug-resistant cells in the leukemia-hierarchy 
to be destroyed. Whether ABC expression and function is conserved after malignant 
transformation of hematopoietic stem cells, however, is currently unknown. Though 
expression and function of ABCB1 and ABCG2 have been widely studied in AML, there is 
a remarkable lack of studies addressing expression and function in the critical CD34+38- 
hematopoietic stem cell population. Additionally, no studies exist aimed at comparing ABC 
transporter function between normal and malignant hematopoietic cells.
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The goal of the research performed and described in this thesis was to gain insight into 
the expression, function and role in drug resistance of ABC transporters in CD34+38- 
hematopoietic stem cells in AML in comparison to their normal counterparts. We 
emphasised on studying ABCB1 and ABCG2 since these transporters are highly expressed 
on a variety of human stem cells and their wide substrate specificity includes drugs used 
in the treatment of AML (i.e. anthracyclins, mitoxantrone, vinca alkaloids). Additionally we 
aimed to study the effect of modulation of these transporters on LSC eradication in AML 
and identify additional ABC transporters involved in drug extrusion and chemoresistance of 
leukemic CD34+38- stem cells.
Outline of this thesis
Hematopoietic CD34+38- stem cells have a very low frequency in the human adult bone 
marrow (approximately 0.1 % of mononuclear cells). The study of these rare hematopietic 
stem cells requires the development of adapted assays to study ABC transporter gene 
expression and biological activity of these molecules. The first two chapters of this thesis 
are dedicated to the development of such stem cell assays.
Chapter 2 describes the development of a novel method to accurately and quantitatively 
assess gene expression in highly purified, low cell number samples of CD34+38- cells 
from human normal bone marrow and AML. Quantitative assessment of gene expression 
in the CD34+CD38- cell population is essential for understanding the molecular events 
underlying normal and malignant hematopoiesis. Though real-time -PCR is a sensitive 
and flexible mRNA quantitation method, the small number of cells available for analysis 
precludes the use of standard methodologies, necessitating alternative strategies like 
global cDNA amplification or nested RT-PCR.
A novel real-time quantitative RT-PCR approach using adapted RNA isolation is described. 
This assay is validated and the relevance for appropriate reference genes for the study 
of gene expression in hematopoietic stem cells is discussed. Using this method the 
expression of drug resistance related genes is assessed in these cells in human normal 
bone marrow. Chapter 3 describes the development of a method to enable assessment of 
the biological activity of ABC transporters in highly purified CD34+38- cells on the single 
cell level using fluorescence microscopy and image analysis. Using this method ABCB1 
mediated transport is quantitatively assessed in normal CD34+38- hematopoietic cells 
in comparison to CD34+38+ committed progenitors. The next two chapters investigate 
the expression, biological activity and role in drug resistance of the known ABC stem cell 
transporters in CD34+38- cells in AML. Chapter 4 investigates ABCB1 expression and 
function in the CD34+38- cell population in AML using monoclonal antibodies and inhibition 
assays among which the assay described in chapter 3. Additionally, ABCB1 mediated 
transport is studied in hematopoietic stem cells in the pre-leukemic syndrome refractory 
anemia.
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In Chapter 5 the role of ABCG2 in drug accumulation and chemoresistance of leukemic 
CD34+38- cells is addressed. ABCG2 expression and function is studied in CD34+38- stem 
cells in AML in comparison to normal bone marrow and the effect of in vitro modulation of 
ABCG2 on chemoresistance of leukemic CD34+38- stem cells is tested. The finding that 
drug transport in leukemic CD34+38- cells occurs in the presence of blockage of ABCB1 
and ABCG2 as described in chapters 4 and 5 suggested the presence of yet unidentified 
drug transporters in leukemic CD34+38- cells. To address this question Chapter 6 describes 
the results of profiling of the entire family of ABC transporters in CD34+38- hematopoietic 
cells using real-time quantitative RT-PCR on micro-fluidic cards. This technique is validated 
corroborating on the results described in chapter 2 and ABC transporter profiles of normal 
(G-CSF mobilized and bone marrow) and leukemic CD34+38- cells are described in 
comparison to committed CD34+38+ progenitors. 
Finally, flow-cytometric analysis of CD34+38- cells as described in the previous chapters 
yielded additional data in another CD34 and CD38 defined cell type: the CD34-CD38++ 
plasma cells. In the second part of this thesis (Chapter 7 and 8) results are described on 
drug resistance proteins in these plasma cells in normal bone marrow and the plasma 
cell malignancy multiple myeloma. Chapter 8 investigates the role expression and clinical 
significance of the lung resistance related protein (LRP) in multiple myeloma. Chapter 8 
investigated the role of ABCG2 in primary drug resistance of malignant plasma cells
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Abstract
Objective
Quantitative assessment of gene expression in stem cells is essential for understanding 
the molecular events underlying normal and malignant hematopoiesis. The aim of the 
present study was to develop a method for the precise quantitating of gene expression in 
small subsets of highly purified CD34+CD38- stem cell populations.
Methods
Real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) was 
used to quantitate housekeeping and drug resistance gene expression in cDNA obtained 
from 300 CD34+CD38- cells without cDNA amplification or nested PCR techniques. 
Results
Validation experiments in cellines showed efficient, representative and reproducible gene 
amplification using 300-cell real-time quantitative RT-PCR. Sensitivity was confirmed in 
dilutional experiments and by the detection of the low-copy gene PBGD. GAPDH was found 
a useful reference gene in normal and leukemic CD34+CD38- cells but 18S rRNA content, 
in contrast, varied 100-1000-fold in these populations. Moreover, expression of 18S rRNA 
was significantly lower in leukemic CD34+CD38+ cells compared to normal CD34+CD38+ 
cells (p=0.002). Expression of MDR-1(18-fold, p<0.0005), MRP-1 (3.8-fold, p<0.05) and 
LRP (1.8-fold, NS) was higher in normal CD34+CD38- compared to CD34+CD38+ cells. 
Conclusion 
Real-time quantitative RT-PCR is a valuable tool for precise quantitating of gene expression 
in small subsets of hematopoietic cells. Using this method we show the inappropriateness 
of 18S as a reference gene in these progenitors and the downregulation of drug-resistance 
related genes early in hematopoiesis. 
Introduction
In human normal hematopoiesis, a small subpopulation of immunophenotypically defined 
CD34+CD38- cells have stem cell characteristics as shown by in vitro proliferation 
characteristics, self-renewal and engraftment potential(1,2). Additionally to its established role 
in normal hematopoiesis, accumulating evidence documents a role for the CD34+CD38- 
compartment in malignant hematopoiesis. Cells with leukemic stem cell characteristics in 
AML are found in the CD34+CD38- subpopulation(3,4), similar to the hierarchy observed 
in human normal bone marrow. The CD34+CD38- compartment plays a similar role in 
the leukemogenesis of CML, APL and ALL(5-7). This implicates that the leukemia-initiating 
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transformation and progression associated genetic events occur in these primitive cells 
and not in committed progenitors.
Cellular decisions concerning differentiation are reflected in altered patterns of gene 
expression(8). Quantitative assessment of gene expression in the CD34+CD38- cell 
population is essential for understanding the molecular events underlying normal and 
malignant hematopoiesis. Though RT-PCR is a sensitive and flexible mRNA quantitation 
method, the small number of cells available for analysis precludes the use of standard 
methodologies, necessitating alternative strategies like global cDNA amplification or nested 
RT-PCR(9-12). Quantitation of mRNA transcripts using these strategies in hematopoietic 
stem cells thus far have been performed by end-point amplicon measurement quantitating 
mRNA signals after blotting. 
Real-time PCR has been established as a method for rapid and precise quantitation of nucleic 
acids using an integrated system for thermal cycling, real-time fluorescence detection and 
subsequent analysis(13,14). Real-time PCR quantitates PCR products in the exponential phase 
of amplification by the detection of fluorescent hybridisation probes which are degraded 
by the 5’nuclease activity of Taq polymerase. This technique has shown to be superior to 
end-point quantitation both in accuracy and reproducibility(15). We report the use of real-time 
quantitative RT-PCR for molecular analysis of rare CD34+CD38- stem cells without the need 
for prior cDNA amplification or nested PCR. Using this method we examined the expression 
of two of the most commonly used RNA’s to normalise patterns of gene expression, the 
housekeeping gene glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) and 18S 
ribosomal RNA (18S rRNA) in both normal and leukemic bone marrow. Furthermore, we 
investigated the expression of multidrug resistance related genes MDR-1 and MRP-1 and the 
LRP (lung-resistance related protein) gene in normal CD34+CD38- cells.
Methods
Human normal and leukemic CD34+ bone marrow cells
Bone marrow was obtained from six healthy bone marrow donors and six patients with 
AML at diagnosis after informed consent. Mononuclear cells were isolated by Ficoll 
1.077 g/mL (Pharmacy Biotech, Uppsala, Sweden). From normal bone marrow samples, 
CD34-positive cells were selected using directly conjugated CD34 antibody- coupled 
immunomagnetic beads (M-450 coated with ‘561’ a class III epitope anti-CD34, Dynal, 
Oslo, Norway). Isolation, cryopreservation and thawing procedures of the CD34+ cells 
have been described previously(16). Purity of CD34 cells was controlled by labelling with 
CD34-Cy5 monoclonal antibody (Beckton Dickinson, BV, Etten- Leur, The Netherlands) 
using flow cytometry. CD34+ bead selected cells were stained with CD34- CY5 and 
CD38-phycoerythrin (PE) monoclonal antibodies (Beckton Dickinson, BV, Etten-Leur, The 
Netherlands) for 30 minutes at 4ºC, and washed in HBSS with 10% FCS.
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Definition and sorting of CD34+CD38- and CD34+CD38+ cells
A Coulter Epics Elite Flow cytometer was used to sort cell populations. Gating on forward 
and right angle scatter was used to exclude dead cells and debris. In AML samples CD34+ 
cells from the mononuclear fraction were pre-sorted in HBSS 10%FCS. CD34+CD38- 
cells of both normal bone marrow and AML were defined as the 1% of CD34+ cells 
with the lowest CD38 density. Normal CD34+CD38- cells appeared in a consistently 
restricted light-scattering region confirming the lymphoid appearance of these primitive 
progenitors(17). The CD34+CD38+ cells were sorted from a gate positioned in the bulk of 
CD34+ cells (containing approximately 25% of CD34+ cells) and showed heterogeneous 
light-scattering properties, reflecting the morphologically different lineages present in this 
progenitor population. The primitive character of both normal and leukemic sorted cells was 
confirmed by their rhodamine dull phenotype(18) in rhodamine 123 accumulation and efflux 
studies in comparison to the rhodamine-bright appearance of CD34+CD38+ cells (data not 
shown).
Cell-lines 
The MDR-1 negative RPMI 8226 myeloma parental cell-line and the doxorubicin resistant 
subclone RPMI 8226 Dox 40 expressing the MDR-1 phenotype(19) were maintained as 
a suspension in RPMI 1640 medium supplemented with 10% (v/v) fetal calf serum, 1% 
penicillin (100U/mL), 1% streptomycin (100ug/mL) and 1% L-glutamine at 37ºC in a 
humidified atmosphere with 5% CO2 in the presence of 400nM doxorubicin. Experiments 
were performed on cells in an exponential growth phase and cultured for 1-2 weeks without 
doxorubicin. Heterogeneity in the expression of P-glycoprotein in RPMI 8226 cells used for 
experiments was excluded by flow cytometric assessment of P-glycoprotein expression 
using the monoclonal antibody MRK 16. 
Cell-lysis based RNA preparation and RT-PCR 
Using the Elite flow cytometer with an Autoclone Cell Deposition Unit (Coulter, Hiale, 
FL), 300 cells were sorted using phosphate buffered saline (PBS) as a sheath solution 
into PCR tubes containing 7 µl of lysis solution ( I) (Superscript first-strand buffer, Life 
Technologies, Gaithersburg, Md, USA) NP-40 (0.90% vol/vol), 10 mM dithiothreitol (DTT, 
Life Technologies), 10 U RNAse inhibitor ( Promega, Madison, Wisc., U.S.A.) and distilled 
water. Directly after cell sorting an RT-solution (II) containing 5 µM random hexamer primers 
(dN6, Pharmacia, Uppsala, Sweden), 1.25 mM dNTP’s (Pharmacia, Uppsala, Sweden) 
10 U RNAse inhibitor and 100 U Mo-MuLV reverse transcriptase (Life Technologies, 
Gaithersburg, Md., U.S.A.) was added to a final volume of 10 µl. Lysis solution I and RT-
solution II were kept on ice during the entire procedure. Tubes were centrifuged for 15 s 
before entering the cDNA synthesis reaction, performed for 10 minutes at 20°C, followed 
by 42°C for 45 minutes and a 10 minute incubation step at 95°C. The total cDNA volume of 
10 µl was centrifuged and frozen at –80°C until real-time quantitative PCR was performed. 
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After thawing for PCR experiments the cDNA was diluted in distilled water to a final volume 
of 50 µl. 2.5 µl of diluted cDNA was used for each PCR reaction. 
Real-time quantitative PCR and PCR conditions 
The use of real-time PCR has previously been described by our group(20,21). In brief, PCR 
reactions were performed in the ABI PRISM 7700 sequence detector in a 50 µl final volume. 
The PCR mixture contained buffer (Perkin Elmer/ Applied Biosystems, Foster City, CA, 
U.S.A.)) with 5 mM MgCl2, 250 µM dNTP (Pharmacia, Uppsala, Sweden), 1.25 U Amplitaq 
Gold-TM (Perkin Elmer/ Applied Biosystems), primers, probe and passive reference dye 
Rox. For GAPDH 4.5 mM MgCl2 and 2.5 U Amplitaq Gold- TM was used. The primer and 
probe sequences for gene amplification were:
PBGD: 
FP 5’-GGCAATGCGGCTGCAA-3’ 
RP 3’-GGGTACCCACGCGAATCAC-5’
Probe: 5’-CTCATCTTTGGGCTGTTTTCTTCCGCC-3’
18S: Applied biosystems; part number 4308329
GAPDH: Applied biosystems; part number 402869
MDR-1: Applied Biosystems 
MRP-1
FP: 5’-GCCCTGTTTGCGGTGATC-3’
RP: 3’-GATGTTGGTTTCCATTTCAGATGA-5’
Probe: 5’-CCGAACCAGCCAGTTCAAGTACGTGG-3’
LRP:
FP: 5’-GGCAGGACAATGAGAGGGTACT-3’
RP: 3’-CCGAACTTGCCCTGTGACAT-5’
Probe: 5’- TGACCGTCCCCCCACGTCACTACT-3’ 
The taqman-TM probes carried a 5’TET reporter label and a 3’TAMRA quencher group 
and were synthesised by PE-Applied Biosystems. DNA-specificity of primers and probes 
was excluded by demonstration of a lack of amplification in samples with human DNA. 
Additionally, omission of reverse transcriptase in the RT-PCR protocol led to failure of 
target gene amplification in the positive controls. The Amplitaq Gold enzyme was activated 
by heating for 10 minutes at 95°C. All genes were amplified by a first step of 15 seconds at 
95°C followed by three minutes at 60°C for 45 cycles. The relatively long cycle times were 
optimised on the basis of a beneficial impact on the detection frequency of low-copy genes. 
Initially 50 cycles were performed but samples never became positive after 40 cycles. 
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Quantitation of target-gene expression
Normalised drug-resistance related gene expression to the internal standard GAPDH is 
given by the following equation(22):
T0/R0= K. (1+E) (CT,r – CT,t)
To: Initial number of target gene copies; Ro: Initial number of standard gene copies; E; 
Efficiency of amplification; CT,t: Threshold cycle of target gene; CT, r: Threshold cycle of 
standard gene; and K: Constant. 
The relation is based on the precondition that efficiency of reference and target gene 
amplification is approximately equal. Serial dilution of 50 ng RPMI dox40 GITC-isolated 
cDNA indeed showed comparable efficiencies for 18S, GAPDH, MDR-1, MRP-1, and LRP 
( slope of log input versus Ct was -3.36, -3.44, -3.39, -3.43, -3.44 respectively). Reference 
gene (GAPDH) is shown to be equally expressed in the cellpopulations of interest (see 
section results). 
Experimental design
All normal bone marrow (NBM) and AML samples were evaluated for a specific target 
and control gene expression in a single PCR series obviating the need for comparison of 
different runs by calculation of run efficiencies. MDR-1 and 18S reactions were performed 
within one tube by the use of a double probe assay. No template controls served as 
negative controls. For MDR-1 and LRP the myeloma RPMI 8226 parental celline was used 
as an additional negative control. 
MDR-1, MRP-1 and LRP expression in the dox 40 subline was used as a positive control. 
All samples were tested as duplicates. For quantitation, the average value of both 
duplicates was used. In the cases that only one of the duplicates showed a positive signal 
the expression of the gene was designated as ‘borderline’ since the binary answer of the 
PCR will reflect a matter of probability in the case of low density of target molecules(23).
Conventional GITC- RNA isolation and cDNA synthesis
RNA from the RPMI 8226 parental and dox 40 celline was extracted from approximately 106 
cells using the guanidinium-thiocyanate acid-phenol-chloroform procedure(24) with minor 
modifications as previously described(21). 50 ng of RNA was used for cDNA synthesis. The 
cDNA synthesis reaction was performed as previously described(21). 
Statistical analysis
Differences in normalised target gene expression between different hematopoietic 
subpopulations were calculated using the student t test with a level of significance of p< 
0.05.
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Results
Performance of 300-cell real time quantitative RT-PCR: experiments in the 
8226 RPMI myeloma cellines 
The number of 300 cells was carefully optimised on the basis of preliminary experiments. 
Lower cell numbers decreased sensitivity of gene detection whereas increase of the cell 
input decreased gene amplification efficiency, possibly caused by PCR inhibition by cell 
lysis products (data not shown).
Efficiency of gene amplification 
Gene amplification in 2.5 ul of cDNA obtained from 300 cells was both linear and efficient 
as assessed by serial dilution of the initial cDNA (figure 1A) and dilution of RPMI dox40 
cells (expressing MDR-1 target) to a background of RPMI parental cells (figure 1B) to 
exclude possible dilution of inhibitory components present in the initial cDNA. Relative 
expression (∆Ct) of target genes to 18S was similar compared to standard (50 ng GITC 
isolated RNA) RT- PCR showing that target gene amplification in 300-cell isolated cDNA is 
representative (table 1).
Figure 1: Efficiency of gene amplification in 300-cell real-time quantitative RT-PCR. A. Serial dilution 
of 300-cel cDNA (2.5 µl) obtained from myeloma RPMI dox 40 celline in lysis/Rt-solution showing high 
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efficiency of PCR reactions over a 1:125 dilution. Efficiency of reference (GAPDH) and target gene (MDR-
1), indicated by the slope of the log dilution curve, are equal (-3.25 and –3.28 respectively). B. Dilutional 
experiment of RPMI dox40 cells (expressing MDR-1 target) to a background of RPMI parental cells with a 
constant 300-cell number input ; 300, 95, 30, 9 and 3 cells RPMI 8226 dox40 were sorted in 0, 205, 270, 
291 and 297 RPMI 8226 parental cells. Efficiency of MDR-1 amplification was –3.25 (R2 0.96). 
Table 1: Quantitation of gene expression in 300-cell real-time quantitative RT-PCR: comparison with 
standard RT-PCR. 
Target 50 ng ∆Ct 300 cell ∆Ct 
18S 10.27 17.87
GAPDH 18.65 8.38 26.29 8.42
MDR-1 19.20 8.93 26.64 8.77
MRP-1 25.65 15.38 33.61 15.74
LRP 23.40 13.07 31.58 13.71
Threshold cycle (Ct) of different target genes in 2.5 µl 300-cell isolated myeloma RPMI dox 40 cDNA versus 
50 ng GITC-isolated cDNA using real-time quantitative PCR. Ct value is mean of in duplicate assessment. 
Comparable delta Ct ( Ct target genes minus Ct 18S) indicates representative gene amplification in 2.5 µl 300-
cell isolated cDNA compared to standard 50 ng GITC isolated cDNA.
Sensitivity and reproducibility of gene quantitation
The low-copy gene porphobilinogen dehydrogenase (PBGD) was invariably detected in 
duplicate in 300 cell cDNA (2.5 µl) at a Ct of 33.0 (mean of four experiments). 
GAPDH could still be detected in duplicate (Ct 35.63) in a 1000-fold dilution of the initial 
2.5 µl cDNA. Cell sorting and RNA-processing caused little variation in quantitative gene 
expression results; the average Ct of independently sorted samples (n=10) was 28.252 
(SD 0.57) for MDR-1 and 19.96 (SD 0.81) for 18S. The mean variation between duplicates 
was 0.21 Ct (SD 0.05) and 0.40 Ct (SD 0.19) respectively. In two completely independent 
experiments the average Ct was 17.56 and 18.21 for 18S, 27.35 and 27.04 for MDR-1 and 
33.21 and 33.23 for PBGD indicating a high interexperimental reproducibility. 
Quantitative gene expression in CD34CD38 subpopulations in human 
normal and leukemic bone marrow
Expression of 18S rRNA and the housekeeping gene GAPDH
The constant input of 300 cells in the samples allows an estimation of the level of 
housekeeping gene expression in different hematopoietic subpopulations by comparison 
of the threshold cycle (Ct). Figure 2 shows the 18S and GAPDH gene expression in human 
CD34+CD38- and CD34+CD38+ cells in human normal (n=6) and leukemic bone marrow 
(n=6). 
40
_____ CHAPTER 2 _____________________________________________________________________________________________________ ___________________________________________________________________ GENE EXPRESSION IN HEMATOPOIETIC STEM CELLS _____ 
41
Figure 2: Expression of housekeeping genes in normal and leukemic CD34+ subpopulations as 
determined by 300-cell real-time quantitative RT-PCR. Mean levels and standard deviation of 18S rRNA and 
GAPDH expression in 300-cell samples of normal and leukemic CD34+CD38- and CD34+CD38+ cellpopulations 
as indicated by the threshold cycle (Ct). 
No significant differences exist in GAPDH expression between the different CD34+CD38- 
and CD34+CD38+ populations in NBM (mean Ct 31.41 ± 1.37 and 29.54 ± 0.63) and AML 
(Ct 31.37 ± 1.23 and 31.65 ± 0.84). The relatively low Ct in the normal CD34+CD38+ 
subpopulation is paralleled by low Ct’s for PBGD and 18S (mean delta Ct’s comparable 
between subpopulations) indicating that this reflects initial amounts or quality of RNA in 
these samples rather than endogenous GAPDH expression. 18S expression varied widely 
within the primitive hematopoietic CD34+CD38- samples in both normal bone marrow (Ct 
18.94-25.63; SD 2.60) and AML (Ct 17.63-27.32; SD 3.36) with a 100-fold and 1000-fold 
variation respectively calculated with the equation shown in figure 1. A significantly higher 
Ct was found for 18S in CD34+CD38+ cells in AML ( mean Ct 23.55; SD 1.91) compared to 
normal bone marrow (mean Ct 19.04; SD1.45, p=0.04). This significantly lower expression 
of 18S in the leukemic CD34+CD38+ cells was confirmed when the expression was 
normalised for GAPDH according to the formula described in the section methods and 
depicted as Xn= k. copies target gene per copy GAPDH (figure 3); 
In AML samples, 18S expression in the CD34+CD38+ population (mean Xn 376 ± 410) was 
lower than in the CD34+CD38+ in normal bone marrow population ( mean Xn 1625 ± 635; 
p= 0.002) and the leukemic CD34+CD38- subpopulation (mean Xn 2263 ± 2731; p=0.07). 
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Figure 3: Normalised 18S rRNA content in CD34+ subpopulations in normal bone marrow and AML as 
determined by real-time quantitative RT-PCR. Expression in CD34+CD38- and CD34+CD38+ cells from paired 
samples in normal bone marrow and AML. Expression (Xn) is normalised for the expression of the standard gene 
GAPDH.
Expression of drug resistance related genes 
We studied the expression of the ABC transporter genes MDR-1 and MRP-1 and the 
lung-resistance related protein (LRP) gene in the normal hematopoietic CD34+CD38- and 
CD34+CD38+ cells using GAPDH as endogenous reference (table 2). MDR-1 was detected 
in all (6/6) CD34+C38- samples but expression was approximately 18-fold lower in the more 
differentiated fraction (1/6 CD34+CD38+ samples positive) Three CD34+CD38+ samples 
showed borderline expression. MRP-1 was detected in all samples (n=4) but expression 
was also invariably lower in CD34+CD38+ cells compared to the CD34+CD38- population 
indicating a approximately 3.8-fold lower expression in the more differentiated fraction. 
Expression of LRP was detected in all (4/4) CD34+CD38- and CD34+CD38+ samples 
without significant differences in mean expression between subpopulations However, a 
lower expression in the CD34+CD38+ cells was noted in 3/4 individuals (Xn CD38- vs 
CD38+ 0.10 vs 0.018, 0.07 vs 0.01 and 0.06 vs 0.009 respectively). 
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Table 2: Quantitative expression of drug resistance related genes in the CD34+CD38- and CD34+CD38+ 
cell populations in human normal bone marrow as determined by 300-cell real-time quantitative RT-PCR.
CD38- CD38+ Difference (P-value)
MDR-1 
Samples positive
Mean Ct ( ± SD)
Mean Xn ( ± SD)
6/6
34.73 ± 1.10
0.09 ± 0.03
1/6
37.09
0.005 18-fold (p<0.0005)
MRP-1
Samples positive
Mean Ct ( ± SD)
Mean Xn ( ± SD)
4/4
32.38 ± 0.93
0.38 ± 0.18
4/4
33.30 ± 1.73
0.10 ± 0.06 3.8-fold (p<0.05)
LRP
Samples positive 
Mean Ct ( ± SD)
Mean Xn ( ± SD)
4/4
34.82 ± 0.70
0.09 ± 0.03
4/4
35.28 ± 2.23
0.05 ± 0.08 1.8-fold (NS)
Relative quantitation (Xn) is defined as the number of target gene copies relative to the number of the standard 
gene (GAPDH) copies. Ct is threshold cycle in 2.5 µl cDNA of 300-cell sample. 
Discussion 
We present the use of a real-time quantitative RT-PCR method for the precise quantitation 
of gene expression in small subsets of human hematopoietic cells.
Combining modified RNA isolation and adjusted PCR-protocols with the sensitivity and 
accuracy of real-time quantitative PCR we were able to detect and to quantitate low-copy 
gene expression without the need of prior cDNA amplification or nested-PCR strategies. 
cDNA amplification is a valuable tool for stem cell gene expression assessment though 
interpretation of quantitative results is critically dependent on representative cDNA 
amplification(9). Furthermore, the hybridisation signal is usually represented by a smear due 
to the presence of truncated cDNA strands of different lengths, compromising sensitivity 
and reliability of gene quantitation by end-point evaluation(12). cDNA amplification is also 
limited to the detection of transcripts with unique 3’ terminal sequences(10). 
Though real-time quantitative RT-PCR has been reported to be applicable to quantitate 
gene expression in single cells(22), in our hands the limit of 300 cells was carefully optimised 
and lowering the input cell number decreased the detection frequency of the low-copy gene 
PBGD. Therefore the method described in this paper cannot be applied to single cells 
without prior cDNA amplification strategies. 
For quantitative analysis of gene expression the expression of housekeeping genes are 
often used as internal standards. The ideal internal standard should be expressed at a 
constant level among different cell populations and individuals and should be unaffected 
by the experimental conditions(25). The stable input of mRNA of 300 cells in each sample 
in our study allows comparison of endogenous gene expression by direct measurement 
of Ct’s. Although GAPDH expression has been reported to vary during the cell cycle(26) 
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and developmental stage(27) no significant differences in expression were found between 
primitive and more committed progenitor populations in normal and leukemic bone 
marrow. 
In contrast, though rRNA is generally considered a suitable and more reliable internal 
control than housekeeping genes(28), we found a striking (100-1000-fold) individual variety 
in 18S rRNA levels in both normal and leukemic primitive CD34+CD38- cell samples. 
Control of rRNA expression has been correlated with differentiation programs(29,30) and 
the metabolic activity in mouse embryonic hematopoietic stem cells(31). Whether the wide 
variety in 18S rRNA in human primitive CD34+CD38- hematopoietic cells reflect differences 
in differentiation within the compartment between individuals is unclear. 
A second important finding is the significantly lower level of 18s rRNA in the leukemic 
CD34+CD38+ blasts compared to both the leukemic CD34+CD38- compartment and the 
CD34+CD38+ subpopulation in normal bone marrow. This finding seems to be in line 
with previous reports on impaired processing of ribosomal precursor RNA leading to a 
failure of rRNA synthesis and relatively small amounts of 18S rRNA in blast cells of acute 
leukemia(32-34). Our results suggests that the putative defect in rRNA synthesis occurs early 
in leukemogenesis on the CD34+ progenitor level. 
The variety in 18S expression, precluding its use as an appropriate reference gene, stresses 
the importance of validating reference genes on expression in specific subpopulations 
when designing quantitative gene expression studies. 
We studied the normalised quantitative expression of the drug-resistance related genes 
MDR-1, MRP-1 and LRP in human primitive CD34+CD38- cells. The expression of MDR-
1 and its protein product P-glycoprotein in hematopoietic stem cells is well known(35) and 
likely responsible for the rhodamine-123 dull phenotype of these cells(18). We found that 
expression of the gene is strongly downregulated in more differentiated progenitors, in 
line with recent findings studying MDR-1 expression in these cells(36). The downregulation 
of MRP-1 and LRP during lineage commitment was less striking compared to MDR-1. 
Expression of these genes persisted in more differentiated CD34+CD38+ progenitors. 
It is tempting to speculate on the function of these genes in human hematopoietic stem 
cells. A role in protection of the hematopoietic stem cell against toxic compounds has 
been shown for P-glycoprotein(16). Similar detoxification functions are conceivable for 
MRP, a membrane bound drug efflux pump, known to have a broad substrate specificity(37), 
and LRP which has been implicated in the transport of diverse substrates from the cell 
nucleus to the cytoplasm(38). Additionally, MDR-1 and MRP-1 might play a role in prolonged 
stem cell survival by protection against apoptosis(39). Finally, it has been speculated that 
ABC transporters extrude molecules required for commitment to differentiation, thereby 
maintaining the quiescent stem cell state(36-40). Further studies addressing the significance 
of these genes in the hematopoietic stem cell and hematopoiesis are clearly warranted. 
The technique described in this study will facilitate these and other experiments addressing 
gene expression in these small cell subpopulations.
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Abstract
Background 
Normal and malignant hematopoietic stem cells are characterised by their capacity to 
actively extrude fluorescent dyes. The contribution of different ATP-binding cassette (ABC) 
transporters to this phenomenon is largely unknown due to the small stem cell numbers 
limiting the use of standard methods to assess functional efflux. 
Methods
We used epifluorescence microscopy (EFM) in combination with single cell image analysis 
to study ABC-transporter mediated efflux in highly purified, viable, CD34+CD38- cells 
sorted on an adhesive biolayer. P-glycoprotein and MRP mediated efflux were quantitated 
using fluorescent substrates (rhodamine-123 and calcein AM) and specific inhibitors 
(verapamil and probenecid, respectively). 
Results
Feasibility, sensitivity and reproducibility of rhodamine-123 efflux quantitation using 
single cell EFM was shown in cell lines and compared to standard flow cytometrical 
assessment. P-glycoprotein mediated transport was higher in CD34+CD38- cells than in 
more differentiated progenitors (mean efflux index 2.24 ± 0.35 and 1.14 ± 0.11 respectively, 
p=0.01) P-glycoprotein mediated transport was the main determinant of the rhodamine dull 
phenotype of these cells. Additionally, significant MRP-mediated efflux was demonstrated 
in CD34+CD38- and CD38+ cells (mean efflux index 1.42 ± 0.19 and 1.28 ± 0.18, 
respectively). 
Conclusion
The described method is a valuable tool for assessment of ABC-transporter mediated efflux 
in highly purified single cells. Both P-glycoprotein and MRP mediated efflux are present in 
human CD34+CD38- hematopoietic stem cells.
Introduction
In human normal hematopoiesis a rare subpopulation of bone marrow cells have stem cell 
characteristics defined as long-term proliferative capacity, self-renewal and engraftment 
potential. Identification and isolation of these cells is based on surface marker expression 
(e.g. CD34+CD38-lin-)(1) or the ability to exclude fluorescent dyes such as rhodamine-
123 and hoechst (rhodamine-123/hoechst “dull”-phenotype)(2-6). Similar to the situation in 
normal hematopoiesis, leukemic cells with stem cell characteristics have been identified 
in acute myeloid leukemia, based on the reduced capacity of these cells to accumulate 
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fluorescent dyes(7,8). The dull-phenotype of stem cell populations has been attributed to 
dye efflux caused by the ATP-binding cassette transporter P-glycoprotein(9,10). Recent data, 
however, on gene expression in mouse and human normal and leukemic CD34+CD38-
stem cell compartments suggest the presence of other ABC-transporters in these primitive 
hematopoietic progenitors(8-12). ABC-transporters (e.g. P-glycoprotein, multidrug-resistance 
proteins (MRP) and breast cancer related protein (BCRP) are involved in the export of a 
broad array of chemotherapeutical agents, a phenomenon referred to as multiple drug 
resistance (MDR). Activity of these transporters could promote survival of normal and 
leukemic stem cells during chemotherapeutic treatment. Therefore, identification and 
characterisation of the ABC-transporter mediated efflux in stem cell populations is of great 
clinical importance. The expression of ABC-transporters can be assessed by determining 
gene or protein expression but discrepancies with chemoresistance and functional drug 
efflux have been reported(13) possibly due to post translational modification of proteins or 
the presence of yet unidentified efflux pumps. Therefore, assessment of functional drug 
efflux is an important tool in determining the significance of ABC-transporters(14). Functional 
tests are based on the accumulation of fluorescent dyes such as rhodamine 123 and 
calcein-AM(15,16), which are substrates for the P-glycoprotein and MRP mediated transport. 
Fluorescence analysis is generally performed by cellular imaging using flow-cytometry(17). 
Limitations of flow-cytometric assessment of drug efflux are the relatively large numbers 
of cells needed to perform the assays (the CD34+CD38- compartment comprises 
approximately 0.01 % of the mononuclear fraction of human normal bone marrow) and the 
problems combining certain fluorescent dye substrates with immunophenotypical markers 
in double-labelling techniques. Additionally, these methods are not suited to continuously 
study efflux kinetics and the effect of efflux modulators at the level of single cells. In an effort 
to overcome these limitations we developed an ABC-transporter-mediated efflux assay 
combining highly purified cell sorting on adhesive protein layers and computerised single 
cell image analysis to allow quantitative and kinetic study of efflux mechanisms in small 
subsets of hematopoietic cells. Using this assay we studied the levels of P-glycoprotein 
and MRP related efflux in normal primitive CD34+CD38- hematopoietic cells compared to 
more differentiated CD34+CD38+ progenitors. 
Material and methods
Cell lines and human CD34+ bone marrow cells
The RPMI 8226 myeloma parental cell line and the doxorubicin resistant subline RPMI 
8226 Dox 40 expressing P-glycoprotein(18) were maintained as a suspension in RPMI 
1640 medium supplemented with 10% (v/v) fetal calf serum, 1% penicillin (100U/mL), 1% 
streptomycin (100µg/mL) and 1% L-glutamine at 37°C in a humidified atmosphere with 5% 
CO2 in the presence of 400nM doxorubicin. Experiments were performed on cells in an 
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exponential growth phase and cultured for 1-2 weeks without doxorubicin. The human T-
cell Jurkat cell line was cultured under the same conditions as the RPMI 8226 myeloma cell 
line without doxorubicin. Bone marrow was obtained from healthy allogeneic bone marrow 
transplantation donors after informed consent. Mononuclear cells were isolated by Ficoll 
1.077 g/mL (Pharmacy Biotech, Uppsala, Sweden). CD34-positive cells were isolated using 
directly conjugated CD34 antibody- coupled immunomagnetic beads (M-450 coated with 
‘561’ a class III epitope anti-CD34, Dynal, Oslo, Norway). Isolation, cryopreservation and 
thawing procedures of the CD34+ cells have been described previously(10). Purity of CD34 
cells was controlled by labelling with CD34-Cy5 monoclonal antibody (Beckton Dickinson, 
BV, Etten- Leur, The Netherlands) using flow cytometry.
Chemicals
Mussel adhesive protein (MAP; bioglue ultra; Swedish BioScience Lab., Floda, Sweden) 
is a formulation of polyphenolic proteins which are the key components of the anchoring 
glue secreted by the marine mussel Mytilus edulis(19). The usefulness of MAP for 
the immobilisation of non-adherent cells for fluorimetric studies has been described 
previously(20). MAP was diluted in PBS and stored at a stock concentration of 1 mg/ml 
(4°C).
Rhodamine-123 (Sigma chemical Co., St. Louis, MO, U.S.A.) was dissolved in distilled 
water and stored in stock concentration 0.1 mg/ml (4°C). Calcein-AM (Molecular probes, 
OR, U.S.A.) was dissolved in DMSO and stored in stock solution 1 mg/ml (4°C). Verapamil 
(Knoll AG, Ludwigshaven, Germany) was stored at room temperature in stock concentration 
2.5mg/ml. Probenecid (Sigma Chemical Co., St. Louis, MO, U.S.A.) was dissolved in 1 
ml phosphate buffered saline (PBS) with 40 µl 1 M NaOH and stored at –20°C in stock 
concentration 5.708 mg/ml. 
Flow-cytometric isolation of CD34+CD38- cells and cell sorting
CD34+ bead selected cells were stained with CD34- CY5 and CD38- phycoerythrin (PE) 
monoclonal antibodies (Beckton Dickinson, BV, Etten-Leur, The Netherlands) at 4°C for 
30 minutes. A Epics Elite flow cytometer ( Coulter, Miami, Florida, U.S.A) was used to sort 
cell populations. Gating on forward and right angle scatter was used to exclude dead cells 
and debris. Cells were excitated with a single Argon ion laser emitting at 548 nm and 647 
nm , running at 15 mW (standard setting). CD34+CD38- cells were defined as the 1% of 
CD34+ cells with the lowest CD38-PE density as shown in figure 1. CD34+CD38+ cells 
were sorted from a gate positioned as indicated in figure1, containing approximately 25% 
of CD34+ cells. CD34+CD38- cells appeared in a consistently restricted light-scattering 
region confirming the lymphoid appearance of these primitive progenitors(21)(figure 1).
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Figure 1: Flow-cytometric analysis of bead-selected CD34+ bone marrow cells stained with CD34-Cy5 and 
CD38-PE. Scatter and histogram (A and B) based on CD38-PE antigen density level. Sort region A defined as 1% 
of the overall CD34+ population with the lowest CD38-PE antigen density. Region B defines the CD34+CD38+ 
subpopulation. The lymphoid character of the primitive progenitors in region A is confirmed by a restricted light-
scattering region (C) compared the heterogeneous light scattering properties of the CD34+CD38+ population 
(D).
Rhodamine-123 and Calceine-AM accumulation and efflux studied using 
direct cell sorting and single cell image analysis
Cell immobilisation and manipulation
Five hundred cells of the cell lines or human CD34 progenitor cells were sorted in 8 µl of 
washing buffer solution containing NaCl 0.9% supplemented with natriumdifosfate (6.6% v/
v), albumin (1% v/v) and glucose (1% v/v) applied on a glass cover slip coated with mussel 
adhesive protein (10 µl/cm2). 
Cells were allowed to adhere for 10 minutes in a perfusion chamber constructed to enable 
cell environment manipulation (incubation and washing steps) within the microscope 
environment (figure 2). The microscope was placed in an incubator to allow all procedures 
to run at 37°C which is essential for physiologic efflux studies.
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Figure 2: Inverted microscope system for analysis of dye efflux placed in a 37°C incubator. Inset: Holder 
of adhesive protein coated cover slip and perfusion chamber. The coated cover slip with the cell population of 
interest is positioned in the middle of the holder and the perfusion chamber is placed on it. Washing steps and 
addition of specific dye efflux modulators are performed through a perfusion system coupled to the perfusion 
chamber.
Uptake and efflux of fluorescent probes
Studies on P-glycoprotein mediated efflux were performed with rhodamine-123 (0.30 µgr/
ml) as a substrate for P-glycoprotein and verapamil (20 µgr/ml) as an inhibitor of efflux. 
Though rhodamine-123 is a MRP substrate as well, it was shown that in short term (60 min) 
drug accumulation assays, rhodamine-123 can be regarded as P-glycoprotein specific(22). 
Moreover, in CD34+ cells verapamil does not seem to inhibit MRP(23). For MRP-mediated 
efflux calcein acetoxymethyl ester (calcein-AM, 10µgr/ml)) was used as a substrate. Since 
P-glycoprotein actively extrudes the calcein-AM but not the fluorescent calcein, which is 
selectively extruded by MRP(16), all experiments on MRP function were performed in the 
presence of verapamil to block P-glycoprotein-mediated efflux of calcein-AM. Probenecid 
(0.20mM), a specific and effective modulator of MRP(24) was used to modulate the calcein 
efflux by MRP. After immobilisation, cells were incubated with either rhodamine-123 or 
calcein-AM dissolved in Iscove’s containing 0.5% v/v heat inactivated fetal calfs serum 
(FCS, Hyclone, Logan, Utah, U.S.A.) with or without efflux modulator during 30 minutes. 
Cells were washed with washing buffer at 37°C, again in the presence or absence of efflux 
modulators, and allowed to efflux the dye for an additional 15 minutes. The time interval of 15 
minutes was based on the observation of efflux kinetics in the CD34+CD38- compartment 
showing the majority of rhodamine-123 efflux taking place within 15 minutes. 
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Fluorescence microscopy 
During efflux, focal planes were adjusted and conventional light microscopy images were 
stored from different fields to identify cells. Fluorescence images were acquired after 15 
minutes of efflux. The images were acquired on a Zeiss Axiovert 35M inverted microscope 
(Thorwood, New York, USA) equipped with a 40x oil (N.A. 1.3) objective, perfusion chamber 
with possibility for using disposable glass cover slips and a cooled 756x580 pixel resolution 
CDD-camera (Variocam, PCO computer optics, Kellheim, Germany) coupled with the pixel 
pipeline in a Macintosh Quadro 800. The microscope was placed in a 37°C controlled 
incubator. Cells were exited with a mercury arc lamp using band pass filter (BP) 440-490 
nm for rhodamine-123 and calcein or BP 510-560 nm for propidium iodide (PI). Emission 
was measured with BP 515-565 and longpass filter 610nm. The perfusion chamber was 
positioned in x, y, and z directions with an EK 86 MTP scanning table (Marzhauser, Wetzlar, 
Germany) controlled by the serial interface of the Macintosh or manually by the operator. 
Calibration of fluorescence signal detection was performed using flowset fluorespheres 
(Coulter Corporation, FI, U.S.A.). Finally, propidium iodide (10 µg/ml, Sigma chemical Co., 
St. Louis, MO, U.S.A.) was added to the washing buffer to confirm cell viability. Cell viability 
typically exceeded 90% of cells. Dead cells were excluded from analysis.
Image analysis
Fluorescence intensity analysis of individual cells was performed on TCL-Image 4.6 
software package (TNO, Delft, The Netherlands). Regions of interest (ROI) were manually 
defined by the operator around cells as well as around empty backgrounds in bright field 
images. The area (A) and fluorescence (F) of each ROI was determined in fluorescence 
images. The fluorescence intensity (FI) of the cell in a ROI was calculated: 
FI= Fcell / A cell – F background /A background 
This formula corrects for differences in cell size between lymphoid-like CD34+CD38- cells 
and the larger CD34+CD38+ cells (fig 1) as well as background illumination. At least 30 
cells (range 30-50) were evaluated per sample. Fluorescence intensity of the overall cell 
population is expressed as mean fluorescence intensity (MFI) and depicted in arbitrary 
fluorescence units (AU). P-glycoprotein and MRP-mediated efflux was quantitated as 
the ratio of mean fluorescence intensity in the presence/absence of a specific inhibitor 
(verapamil and probenecid) and depicted as “efflux index”.
Rhodamine-123 efflux measurement using flow-cytometry
In order to compare single cell image analysis with conventional flow-cytometry, P-
glycoprotein-mediated efflux studies on the RPMI 8226 cell lines were performed using both 
methods. For flow-cytometric efflux assessment, RPMI 8226 parental and Dox 40 cells were 
incubated (2.105 cells/ml) in Iscove’s medium with a rhodamine-123 concentration of 0.3 
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µg/ml (30 min, 37°C) in the presence or absence of 20µg/ml verapamil. After centrifugation, 
cells were resuspended in dye-free Iscove’s medium again in the presence or absence of 
verapamil and incubated at 37°C to allow efflux to take place during 15 minutes. Cellular 
dye content after 15 minutes efflux was measured with the Epics Elite Flow cytometer. 
Cells were excited with a single Argon ion laser emitting at 488 nm, running at 15 mW 
(standard setting). Gating on forward and right angle scatter was used to exclude dead 
cells and debris. Fluorescence intensity of cellular rhodamine was assessed using a 525 
nm BP filter. 
Statistics
For statistical analysis of differences in MFI between subpopulations the t- test and two-
way ANOVA analysis were used as appropriate.
Results
Validation of efflux measurement using single cell image analysis
Sensitivity and linearity of rhodamine-123 fluorescence quantitation
In order to assess the sensitivity and linearity of rhodamine-123 fluorescence detection we 
incubated Jurkat cells, which do not express P-glycoprotein, at increasing concentrations 
(0.01-0.1 µgr/ml) of rhodamine-123 during 30 minutes and quantitated the fluorescence 
intensity (figure 3a). A fluorescence signal was detected in Jurkat cells incubated with the 
lowest (0.01 µgr/ml) concentration of rhodamine-123 and cellular fluorescence intensity 
showed a linear increase with rhodamine-123 concentration (correlation coefficient 
0.99) within a range (2000-25000 AU) similar to that observed in CD34+ hematopoietic 
progenitors (data not shown). 
Demonstration of P-glycoprotein mediated efflux in the 8226 RPMI myeloma cell lines
Rhodamine-123 efflux in the RPMI 8226 Dox 40 and parental cell line was assessed 
using single cell image analysis as well as standard flow cytometry (figure 3b). A lack of P-
glycoprotein mediated efflux was demonstrated by both assays in the RPMI 8226 parental 
cell line (efflux index 0.72 ± 0.14 and 0.86 ± 0.09 respectively). The RPMI 8226 Dox 40 cells 
showed a significant P-glycoprotein mediated efflux using both FCM (index 36.20 ± 0.32) 
and single cell image analysis (index 4.58 ± 1.83). Analysis of P-glycoprotein mediated 
efflux in Dox 40 cells on consecutive days in order to assess the reproducibility of efflux 
measurement using single cell image analysis demonstrated no significant differences in 
fluorescence intensities or efflux indices; The MFI with/without verapamil was 35244 ( ± 
2940) / 10356 ( ± 1250) and 41669 ( ± 8334)/ 9104 ( ± 1802) respectively. This resulted in 
efflux indices of 3.40 ± 0.69 and 4.58 ± 1.83 respectively (differences not significant).
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Figure 3: Validation experiments for single cell efflux measurement. A. Confirmation of linearity and 
sensitivity of rhodamine-123 fluorescence detection with increasing incubation concentrations of rhodamine-123 
in a human T-cell Jurkat cell line. B. Comparison of rhodamine-123 fluorescence with (black bars) and without 
(white bars) verapamil in the human myeloma RPMI 8226 parental (sensitive) and doxorubicin resistant (Dox 40) 
cell line using single cell image analysis (SCIA) and flow cytometry (FCM). 
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P-glycoprotein and MRP mediated efflux in primitive hematopoietic 
progenitors 
P- glycoprotein mediated rhodamine-123 efflux
Rhodamine-123 accumulation and efflux in the absence and presence of verapamil was 
assessed in the CD34+CD38- and CD34+CD38+ subpopulations in four samples (figure 
4). CD34+CD38- progenitors had a rhodamine-123 “dull”phenotype; in the absence 
of verapamil the rhodamine-123 fluorescence intensity was invariably lower in the 
CD34+CD38- subpopulation compared to the CD34+CD38+ population (average MFI 
14.27 vs 25.97 AU respectively). 
Figure 4: P-glycoprotein mediated efflux in CD34+ hematopoietic progenitors. A. Typical example of 
rhodamine-123 fluorescence images in CD38- and CD38+ subpopulations after accumulation and efflux in the 
presence or absence of verapamil. B. Table showing rhodamine-123 fluorescence intensity (MFI) in the presence/
absence of verapamil and P-glycoprotein efflux index in CD34+ subpopulations in four bone marrow samples (# = 
as assessed by two-way ANOVA analysis). C. Rhodamine fluorescence intensity in presence/absence verapamil 
in CD34+ cell populations: average of four samples.
- Verapamil 
CD38- CD38+
CD38- CD38+
Sample MFI ± SEM P-value Efflux MFI ±SEM
1 13.96±0.82 25.19±1.17 <0.0001 1.80±0.19 21.63±0.86 26.13±1.30 0.036 1.21±0.11
2 15.05±0.65 26.04±1.85 <0.0001 1.73±0.20 23.37±1.06 20.87±1.07 0.10 0.89±0.09
3 12.29±1.52 39.79±5.64 <0.0001 3.23±0.86 17.84±0.58 25.05±1.48 0.00003 1.40±0.13
4 15.79±1.15 34.77±3.23 <0.0001 2.20±0.36 41.02±3.19 42.54±3.38 0.75 1.04±0.16
Average 14.27 31.45 < 0.0001# 2.24±0.35 25.97 28.65 0.017# 1.14±0.11
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Addition of verapamil increased the accumulation of rhodamine-123 in CD34+CD38- cells 
significantly in all (4/4) samples (average MFI without/with verapamil 14.27 and 31.45 AU 
respectively, p<0.0001) but only in 2/4 CD34+CD38+ samples (average MFI without/with 
verapamil 25.97 and 28.65 respectively, p=0.017). Interestingly, addition of verapamil 
completely restored rhodamine-123 accumulation to the level of more differentiated 
CD38+ progenitors in all samples, indicating that P-glycoprotein mediated efflux is the 
main determinant of the rhodamine “dull” phenotype of these cells. Consequently, the efflux 
index (defined as the ratio of MFI presence/absence inhibitor) was invariably higher in the 
CD34+CD38- subpopulation compared to CD34+CD38+ cells (mean value 2.24 ± 0.35 vs 
1.14 ± 0.11, p=0.01). 
MRP mediated calcein-AM efflux 
The role of MRP-mediated efflux in CD34+CD38- hematopoietic progenitors using the 
MRP substrate calcein-AM and the MRP inhibitor probenecid was assessed in three bone 
marrow samples (figure 5). 
Figure 5: MRP mediated efflux in CD34+ hematopoietic progenitors. A. Example of calcein fluorescence 
images in CD38- and CD38+ subpopulations after accumulation and efflux in the presence or absence of 
probenecid. B. Table showing calcein fluorescence intensity (MFI) in the presence/absence of probenecid and 
MRP efflux index in CD34+ subpopulations in three bone marrow samples (# = as assessed by two-way ANOVA 
analysis). 
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MRP mediated efflux, as indicated by a significant increase of calceine fluorescence after 
addition of probenecid, was found in 2/3 CD34+CD38- samples (efflux index 1.44 ± 0.12, 
p<0.0001 and 1.73 ± 0.15, p<0.0001, respectively). The lack of MRP related efflux in the 
remaining sample occurred both in the CD34+CD38- and CD34+CD38+ cell population 
and was accompanied by a discordant high calceine fluorescence in these cells compared 
to other samples. Interestingly, this sample displayed the highest P-glycoprotein mediated 
efflux in CD34+CD38- cells. In contrast to P-glycoprotein mediated efflux, no significant 
difference in MRP-mediated efflux was found between CD38- and CD38+ subpopulations 
(average efflux index 1.42 ± 0.19 and 1.28 ± 0.18 respectively).
Discussion 
We used epifluorescence microscopy (EFM) in combination with image analysis to study 
ABC-transporter mediated efflux in highly purified cells from hematopoietic stem cell 
populations. This experimental approach enabled the study of fluorescent dye efflux in 
small numbers of immunophenotypically defined cells. 
Epifluorescence microscopy has previously been shown to allow accurate fluorescence 
measurements in the assessment of efflux and intracellular redistribution properties of 
ABC-transporters in human cells and yeast(25-27). 
However, instrumental and procedure optimisation is required to circumvent limitations 
commonly encountered in EFM(28,29). In our experimental approach, the problem of out of 
focus plain image artefacts was limited since cells were adhered on a bioadhesive layer 
before analysis, reducing out of focus information. To further reduce artefacts, focal planes 
were adjusted for each field before fluorescence images were taken. Background noise and 
shading was corrected for by spatially matched references for each evaluated target cell. 
Finally, photobleaching(30) was prevented by short light exposure times and the selection 
of different fields for consecutive images. No significant differences in mean fluorescence 
intensity between consecutive images were observed (data not shown). 
An important issue is the sensitivity of efflux detection using EFM. In general, fluorescence 
detection is more sensitive using FCM compared to EFM due to higher and more 
directed excitation intensities of argon lasers compared to mercury lamps and the lack of 
fluorescence background in FCM. We compared the sensitivity of efflux detection in EFM to 
flow cytometric analysis. The higher efflux ratio in the RPMI 8226 Dox 40 cell line measured 
by FCM probably reflects the inherently higher sensitivity of FCM. Experimental bias 
induced by the necessary centrifuge washing step, prolonging the duration of efflux in the 
FCM experiment, might play an additional role in these rapidly pumping cells. The studies 
in the Jurkat cell line, however, showed that detection of rhodamine-123 using EFM was 
both sensitive and linear in the fluorescence intensity range observed in the efflux studies 
in hematopoietic cells. In order to further optimise sensitivity of efflux detection in our 
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experimental approach we combined fluorescent dye retention and efflux in the presence 
and absence of inhibitors in a single assay. Combination improves sensitivity compared to 
seperate uptake or efflux studies(17). The relatively short duration of uptake and efflux was 
used for practical (time-limiting) reasons and optimised for CD34+CD38- cells based on our 
own and others(2) observations of rapid efflux in these primitive hematopoietic progenitors. 
Extension of efflux time, however, is likely to further increase sensitivity of efflux detection 
in cells with lower pump activities. 
Using the described method we showed that P-glycoprotein strongly mediates rhodamine-
123 efflux in the primitive CD34+CD38- hematopoietic progenitors compared to more 
differentiated CD34+CD38+ progenitor cells. These findings are in line with previous 
reports on the role of P-glycoprotein in primitive hematopoietic subsets. Chaudhary et al(31) 
found that the population of lymphoid bone marrow cells within the antigenic phenotype 
of pluripotent stem cells (CD34++, HLA-DR low, CD33-) shows the highest level of P-
glycoprotein mediated dye efflux among CD34+ progenitor cells. In these cells a rhodamine 
efflux ratio, comparable (3-4-fold) to our results, was found in a 10 hours efflux assay as 
assessed by FCM. 
Similar results have been reported by Uchida et al(2) demonstrating that within the CD34+ 
subpopulation rhodamine-123 efflux was most rapid in the more primitive Thy-1 subset.
These studies used relatively large subpopulations within the CD34+ population due to flow-
cytometric limitations compared to the current single cell image analysis method, enabling 
us to study a cell population comprising only 1% of the overall CD34+ cell population. In the 
majority of these highly purified cells the blockade of efflux by the P-glycoprotein inhibitor 
verapamil reconstituted the level of rhodamine-123 fluorescence intensity to the level of 
more differentiated CD34+CD38+ cells. This suggest that P-glycoprotein mediated efflux 
is the main determinator of rhodamine-123 accumulation in the majority of these primitive 
progenitor cells rather than cycle status(32,33) or number of mitochondria(34). Down regulation 
of P-glycoprotein mediated efflux observed in CD34+CD38+ cells could be related to cell 
differentiation or proliferation as has been reported previously by our group(35). However, a 
small subpopulation of CD34+CD38- cells (3-4%; data not shown) preserved a rhodamine 
dull phenotype in the presence of verapamil, suggesting the presence of other factors 
responsible for the rhodamine dull phenotype in these cells. This finding seems to 
concur with the observation by Zijlmans et al(36) who reported the presence of a small 
subpopulations of rhodamine dull cells (3-6%) in which rhodamine accumulation was not 
increased after addition of verapamil (Rho-/Rho (VP)- in mouse bone marrow, containing 
cells with long term repopulating ability. The mechanisms underlying the rhodamine dull 
phenotype ( including the possible presence of other rhodamine transporters) and the 
biological significance in terms of stem cell characteristics of this population in human 
normal bone marrow remain to be determined.
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In addition to P-glycoprotein mediated efflux we established the presence of MRP mediated 
efflux in human CD34+CD38- hematopoietic cells. The presence of MRP-mediated efflux 
has been reported previously for normal CD34+ hematopoietic cells(23,37) but to our 
knowledge no studies have been performed to investigate this in the CD34+CD38- stem 
cell compartment. In contrast to P-glycoprotein mediated efflux, MRP mediated efflux seem 
to be rather stable during early hematopoietic differentiation.
Given the role of these efflux mechanisms in protecting cells against cytotoxic agents(38,39), 
these data underscore the possible deleterious effect of the combination of P-glycoprotein 
and MRP blocking agents with chemotherapeutical regimens, used to enhance 
chemosensitivity of cancer cells, on the CD34+CD38- stem cell compartment in normal 
bone marrow.
In conclusion, we developed a method to study ABC-transporter mediated efflux in highly 
purified cells at the single cell level and demonstrated both P-glycoprotein and MRP-
mediated efflux in primitive CD34+CD38- hematopoietic cells. This assay provides a tool to 
study ABC-transporter mediated efflux in (malignant) stem cell populations obtained from a 
variety of sources, for example in clinical samples of AML(40) and other leukemias. 
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Abstract
Acute myeloid leukemia (AML) originates from hematopoietic CD34+38- stem cells. 
Unraveling the mechanisms that confer chemoresistance to these cells is essential to 
provide molecular targets for leukemic stem cell eradication. The multidrug ATP-binding-
cassette transporter ABCB1 is widely studied in AML but its expression and function in 
leukemic CD34+38- cells in comparison to their normal counterparts is unknown.
We demonstrate that ABCB1 is the major drug transporter in CD34+38- cells in bone marrow 
from healthy controls (n=16) as demonstrated by the abrogation of mitoxantrone extrusion 
by ABCB1 modulators (verapamil and PSC833; efflux index 1.99 ± 0.08). Surprisingly, 
ABCB1 mediated drug extrusion was invariably reduced in CD34+38- cells in AML (n=15; 
efflux index 1.21 ± 0.05) which resulted in increased intracellular mitoxantrone accumulation 
in these cells. Active drug extrusion from these cells occurred in the presence of ABCB1 
modulators in the majority of samples, pointing in the direction of redundant drug efflux 
mechanisms. Reduced ABCB1 activity was not observed in CD34+38- cells constituting 
normal hematopoiesis from autologous transplanted patients in long-term remission but 
preceded the development of overt leukemia in refractory anemia, suggesting that it is 
an early leukemic characteristic rather than a characteristic of normal hematopoietic cells 
preceding malignant transformation. In line with this, residual normal CD34+38- cells were 
identified in an AML patient by their conserved ABCB1 mediated mitoxantrone extrusion 
capacity. Together these results indicate that ABCB1 modulation is not an effective strategy 
to circumvent mitoxantrone extrusion from leukemic CD34+38- cells and may preferentially 
target residual normal progenitors in AML. 
Introduction
Cancer is increasingly recognized as a disease originating from the transformation of 
normal stem cells, retaining the capacity for self-renewal(1). This concept for the origin of 
tumorigenesis was confirmed by the postulation of acute myeloid leukemia as a stem cell 
disease(2). Evidence for this concept has come from studies using the NOD-SCID mouse 
model showing that cells with leukemic engraftment and selfrenewal potential in AML are 
found in the CD34+CD38- subpopulation(3). This CD34+CD38- phenotype of leukemia 
initiating cells was observed regardless of the lineage markers expressed by the leukemic 
blasts, percentage of cells expressing the CD34 surface antigen or the FAB subtype(3). A 
similar role for the CD34+CD38- compartment in leukemogenesis has been suggested 
for CML and ALL(4,5). This parallels the hierarchy in normal bone marrow in which a rare 
population of CD34+38- cells have stem cell characteristics(6). These studies stress that 
leukemia-initiating transformation and progression associated genetic events occur at the 
level of these primitive CD34+38- cells. Consequently, incomplete chemotherapeutical 
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eradication of these cells may ultimately result in disease relapse. Therefore elucidation 
of the mechanisms conferring resistance against chemotherapy to these cells is of crucial 
importance(7).
The ABCB1 encoded P-glycoprotein is a highly conserved membrane-bound ATP 
binding cassette transporter which extrudes a wide variety of structurally unrelated 
chemotherapeutical compounds across the cell membrane8), conferring the multidrug 
resistance phenotype in cancer cells. ABCB1, together with another member of the ABC-
transporter family ABCG2 (BCRP), is highly expressed in a wide variety of stem cells 
including normal hematopoietic CD34+38- stem cells(9-11). Its physiological function in these 
cells is believed to be the protection against genetic damage caused by both environmental 
and naturally occurring xenobiotics that are substrates for these transporters. Importantly, 
conserved ABCB1 mediated transport after malignant transformation of normal stem cells 
would represent a formidable obstacle for chemotherapeutical eradication of cancer stem 
cells.
ABCB1 expression and function has been extensively studied in AML. The observation 
that it is frequently expressed and that expression is associated with adverse treatment 
outcome(12) has led to the introduction of ABCB1 modulators to enhance chemotoxicity of 
various chemotherapeutical agents in clinical trials. Trials using PSC-833 (valspodar) as a 
highly potent and specific inhibitor of ABCB1 function have, however, failed to reach their 
intended endpoints of improved complete remission rates and have been complicated by 
increased toxicity(13). 
In interpreting these negative results it is important to know whether the leukemia-initiating 
CD34+38- hematopoietic subpopulation is targeted by ABCB1 modulation. The vast amount 
of studies on ABCB1 expression and function in AML have been performed on general 
blast populations. Its expression and function in leukemic CD34+38- cells and the effect 
of ABCB1 modulators on drug accumulation in these cells is unknown. AML is generally 
considered to be an ABCB1 expressing malignancy reflecting a conserved physiological 
function of CD34+ progenitor cells(14) . This assumption is based on the observation that 
ABCB1 is preferentially expressed in CD34+ blasts in AML(15) and in CD34+ cells in normal 
bone marrow(16), but a direct comparison of ABCB1 expression and function between 
normal and malignant progenitor cells has never been made before. 
The aim of the current study was to investigate ABCB1 expression and the effect of 
ABCB1 modulation on drug accumulation in CD34+38- cells in AML in comparison to their 
counterparts in normal bone marrow. We report that ABCB1 mediated transport is impaired 
in leukemic CD34+38- cells in comparison to their normal counterparts and that additional 
drug transport mechanisms, not inhibited by ABCB1 modulators, confer drug extrusion 
from these cells.
68
_____ CHAPTER 4 _____________________________________________________________________________________________________ _______________________________________________ REDUCED ABCB1 MEDIATED TRANSPORT IN LEUKEMIC PROGENITOR CELLS _____ 
69
Methods
Bone marrow samples 
Bone marrow was obtained after informed consent from healthy bone marrow donors 
and patients with AML at diagnosis. Mononuclear cells were isolated by Ficoll 1.077 
g/ml (Pharmacy Biotech, Uppsala, Sweden). Isolation, cryopreservation and thawing 
procedures of cells have been described previously(17) and were identical for normal and 
leukemic bone marrow samples. 
CD34+CD38- hematopoietic cells
Cells were stained with CD34- CY5 or fluorescein isothiocyanate (FITC) and CD38- 
phycoerythrin (PE) monoclonal antibodies (Becton Dickinson, BV, Etten-Leur, The 
Netherlands) for 30 minutes at 4ºC and washed in Hank’s balanced salt solution (HBSS) 
with 1% v/v heat inactivated fetal calf serum (FCS, Hyclone, Logan, Utah, U.S.A.). A 
Coulter Epics Elite Flow cytometer was used to define cell populations. Gating on forward 
and right angle scatter was used to exclude dead cells and debris. CD34+CD38- cells of 
both normal bone marrow and AML were defined as the cells with CD38-PE fluorescence 
within the first decade of emission as shown in figure 1. CD34+CD38- cells appeared in a 
consistently restricted light-scattering region confirming the lymphoid appearance of these 
primitive progenitors(18). The CD34+CD38+ cells were sorted from a gate positioned in the 
bulk of CD34+ cells separated by a decade from CD34+38- cells as indicated in figure1 and 
showed more heterogeneous light-scattering properties. 
Flow cytometric assessment of ABCB1/P-glycoprotein expression
ABCB1 expression was analyzed using the ABCB1 specific antibody MRK16, recognizing an 
external epitope of the protein, in three-color flow cytometric assays as previously described(12). 
Briefly, cells were blocked with pooled human serum and stained with MRK16 (mouse IgG2a; 
1.0 ug/ 106 cells) and subsequently with biotin goat- anti mouse IgG2a antibody (1.0ug/ 
106 cells; Southern biotech, Birmingham, AB). A 10-minute incubation with goat serum to 
block non-specific binding was followed by staining with fluorescein isothiocyanate (FITC)-
conjugated CD34 and phycoerythrin (PE)-conjugated CD38. MRK16 staining was detected 
with streptavidin conjugated to Texas Red (Red613; Becton Dickinson). Appropriate IgG2a 
isotype controls at the same protein concentration as the relevant antibodies were used as 
controls. ABCB1 protein expression was quantitated as the median fluorescence channel shift 
(MRK16 /Isotype control) in CD34+38-, CD34+38+ and CD34- cell populations. To analyze 
samples, the histogram of MRK16 expression is overlaid on that of the control. Differences in 
fluorescence are assessed using the Kolmogorov-Smirnov (KS) statistic, denoted D, which 
measures the difference between two distribution functions and generates a value ranging 
from -1.0 to 1.0. This method accurately identifies small differences in fluorescence and is 
useful in detection of low level MDR1 expression(12). MRK16 staining intensity is categorized 
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as follows: negative (D < 0.10), dim (0.10 < D < 0.15), moderate (0.15 < D > 0.25) and bright 
(D > 0.25).
Flow cytometric assessment of ABCB1 mediated mitoxantrone transport
Cells were stained with CD34-FITC and CD38-PE membrane markers, washed in HBSS 
1% FCS and pre-incubated with or without verapamil (Knoll AG, Ludwigshaven, Germany 
(20 ug/ml) or PSC-833 (Novartis Pharma AG, Basel; 2 uM) as inhibitors for ABCB1 mediated 
transport for 20 minutes in Iscove’s modified Dulbecco’s medium supplemented with 1% 
FCS. Mitoxantrone (Novantrone, Lederle, Netherlands;10 uM) was added and cells were 
incubated for 2 hrs at 37°C, 5% CO2, with or without verapamil or PSC-833. Subsequently, 
cells were allowed an additional 1-hr efflux in drug free medium with/without inhibitor. 
Cellular mitoxantrone fluorescence was measured on a flow-cytometer (Coulter Elite) 
equipped with an argon laser. Fluorescence was assessed at an excitation wavelength of 
635 nm through a 670-nm band-pass filter in a three-color protocol with CD34-FITC and 
CD38-PE. At least 200 CD34+38- cells were analyzed in each sample. 
ABCB1 mediated transport was assessed by quantitating the effect of ABCB1 inhibition 
on mitoxantrone accumulation and depicted as the ratio of intracellular mitoxantrone 
fluorescence (MFI) in the presence/absence of verapamil or PSC833. 
To assess interexperimental reproducibility, ABCB1 mediated transport in CD34+38- cells 
was assessed in a normal bone marrow sample in completely independent experiments 
performed on separate days (n=7). ABCB1 mediated efflux index was 2.10 ± 0.09 (mean ± 
SEM), indicating good reproducibility of the assay. This sample was subsequently included 
in other experiments as a control. Preliminary experiments demonstrated similar ABCB1 
mediated efflux in cryopreserved samples when compared with fresh cells in normal bone 
marrow and AML, in line with a previous report addressing this issue(19). 
Single cell image analysis for assessment of ABCB1 mediated transport of 
rhodamine-123 in CD34+38- cells
We developed an assay to study ABCB1 mediated transport of the xenobiotic compound 
rhodamine- 123 in immunophenotypically defined stem cells, sorted on adhesive biolayers. 
This assay has been comprehensively described elsewhere(20).
The mean rhodamine-123 fluorescence intensity (MFI) of CD34+38- and CD34+38+ cells 
was calculated using TCL-image 4.6 software package (TNO, Delft, the Netherlands) and 
depicted in arbitrary fluorescence units (AU). ABCB1 mediated transport was quantitated 
as the ratio of mean fluorescence intensity in the presence/absence of verapamil and 
depicted as “efflux index”. Propidium iodide (10 µg/ml, Sigma chemical Co., St. Louis, MO, 
U.S.A.) was added to confirm cell viability which typically exceeded 90% of cells. Dead 
cells were excluded from analysis.
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Fluorescence in situ hybridization (FISH)
CD34+38- cells were sorted and lysed in 15 ul KCl (75 uM) on a glass cover slip. Cells were 
fixed in methanol:acetic acid and stored at 4°C until analysis. FISH was performed using 
the LSI AML1/ETO Dual Color, Dual Fusion t(8;21) Probe or the LSI EGR1 (5q31) Dual 
Color Probe (Vysis, Downers Grove, IL, U.S.A.) according to manufacturer’s instructions. 
One hundred cells were analyzed microscopically for t(8;21) or chromosome 5 (5q31) 
cytogenetic abnormalities, as appropriate.
Adapted real-time quantitative RT-PCR for assessment of CBFB-MYH11 
gene expression in CD34+38- cells
A linear real-time quantitative RT-PCR approach has been developed for quantitation 
of gene expression in low-frequency hematopoietic stem cells and was described 
comprehensively elsewhere(11) . 
Primer and probe sequences were:
GAPDH:
GAPDH control reagents (Applied Biosystems; part number 402869)
CBFB-MYH11 (Type D) fusion gene:
Forward primer: 5’-CATTAGCACAACAGGCCTTTGA-3’
Reverse primer: 5’- CCTCGTTAAGCATCCCTGTGA-3’
Probe: TET-ATAGAGACAGGTCTCATCG
Normalized gene expression to the internal standard GAPDH is given by the following 
equation:
T0/R0 (Xn) = K. (1+E) (CT,r – CT,t)
To: Initial number of target gene copies; Ro: Initial number of standard gene copies; E; 
Efficiency of amplification; CT,t: Threshold cycle of target gene; CT, r: Threshold cycle of 
standard gene; and K: Constant. 
Statistical analysis
Differences in ABCB1 gene expression and function between different normal and leukemic 
cell populations were calculated using the students t-test with a level of significance of p< 
0.05.
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Results
ABCB1 is the major determinant of mitoxantrone extrusion in CD34+38- 
cells in normal bone marrow
CD34+38- hematopoietic cells were flow-cytometrically defined as described in the section 
methods (figure 1). 
Figure 1: Definition of CD34+38- hematopoietic cells in normal bone marrow and acute myeloid leukemia 
(for color reproduction: see appendix). Representative example of normal bone marrow (NBM) and acute 
myeloid leukemia (AML). CD34+38- cells were defined flow-cytrometrically as the CD34-FITC+ cells (indicated in 
blue) with CD38-PE expression within the first decade of fluorescence emission (indicated in red) and compared with 
CD34+38+ cells (indicated as blue gated) with exclusion of a decade between CD38- and CD38+ cells. CD34- cells 
are shown in gray. CD34+38- cells exhibited restricted light-scattering characteristics (SSC) confirming the lymphoid 
appearance of these cells (inset). The median frequency of CD34+38- cells was 0.1 % of mononuclear cells (MNC) 
(range 0.1%-0.3%) in NBM and 0.2 % of MNC (range 0.1%- 10%) in AML. No difference existed in average CD38 
density between normal and leukemic CD34+38- cells (MFI 0.57 ± 0.05 SD, range 0.40-0.70 and MFI 0.53 ± 0.12 
SD, range 0.30-0.70).
ABCB1 protein expression was assessed in hematopoietic cell populations using the 
monoclonal antibody MRK-16. ABCB1 was differentially expressed in CD34+38- cells in 
comparison to more differentiated cell populations (figure 2). A decrease in ABCB1 protein 
expression in CD34+38+ and CD34- cells was observed in all samples examined.
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Figure 2: ABCB1 is differentially expressed in CD34+38- cells in both normal bone marrow and acute 
myeloid leukemia. P-glycoprotein expression was assessed flow-cytometrically using the MRK16 monoclonal 
antibody and valued using the Kolmogorov-Smirnov (KS) statistic, denoted D, as described in the section 
methods. MRK16 staining intensity is categorized as follows: negative (d < 0.10), dim (0.10 < D < 0.15), moderate 
(0.15 < D > 0.25) and bright (D > 0.25). P-glycoprotein was preferentially expressed in CD34+38- cells in 
comparison to more differentiated CD34+38+ progenitors in all normal (n=10; black dots) and leukemic (n=10; 
white dots) samples examined. No difference existed in levels of expression in CD34+38- cells between NBM and 
AML (Average D-value 0.16 ± 0.03 and 0.16 ± 0.04 respectively). 
We next studied ABCB1 mediated transport using mitoxantrone as a substrate.
Mitoxantrone was used as a substrate because of its favorable fluorescence emission 
characteristics in multi-parameter flowcytometry and its importance as a drug frequently 
used for remission induction and consolidation in AML. 
After two hours exposure to mitoxantrone followed by an hour efflux in drug free medium, 
CD34+38- cells in normal bone marrow were mitoxantrone “dull” compared to CD34+38+ 
cells (MFI 3.08 ± 0.23 vs. 7.29 ± 0.50, p<0.001; n=16). Inhibition of ABCB1 mediated 
transport by verapamil significantly increased mitoxantrone fluorescence in CD34+38- cells 
(figure 3A). In line with expression profiles, ABCB1 mediated efflux was invariably higher 
in CD34+38- cells (mean efflux index 1.99 ± 0.08, range 1.64-2.92) compared to more 
differentiated CD34+38+ (1.45 ± 0.06) cells. 
The phenomenon of verapamil-sensitive drug efflux has also been attributed to ABCG2/
BCRP mediated transport, though at higher concentrations of verapamil than used in our 
experiments(21). To demonstrate that the observed mitoxantrone efflux in CD34+38- cells is 
mediated by ABCB1 rather than other transporters, additional experiments were performed. 
First, similar results were found when the ABCB1 specific inhibitor PSC-833 was used in a 
subgroup of samples (n=4); (mean EI ± SEM 2.03 ± 0.12 and 1.38 ± 0.09 for CD34+38- and 
CD34+38+ cells, respectively; Figure 3A). 
Secondly, using single cell image analysis, we assessed ABCB1 mediated transport in 
single CD34+38- cells using rhodamine-123 as a substrate which is not a substrate for 
BCRP(22) (figure 3B); Rhodamine-123 accumulation was significantly lower in CD34+CD38- 
cells compared to CD34+CD38+ cells in normal bone marrow (p<0.001), similar to the 
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mitoxantrone “dull” phenotype of CD34+38- cells. Blocking of ABCB1 mediated transport 
by verapamil increased rhodamine-123 fluorescence significantly. ABCB1 mediated efflux 
was found in all examined (n=5) CD34+CD38- samples (mean efflux index 3.74 ± 1.81). 
Figure 3: ABCB1 is the major mitoxantrone and rhodamine-123 transporter in hematopoietic CD34+38- 
cells in human normal bone marrow  (for color reproduction: see appendix). A1 Representative example of 
flow-cytometric assessment of ABCB1 mediated mitoxantrone transport in CD34+38- cells in NBM. CD34+38- 
cells display low intracellular mitoxantrone fluorescence in comparison to CD34+38+ cells (inset) which can be 
increased significantly by blockage of ABCB1 mediated transport by verapamil/PSC833. A2 Average mitoxantrone 
fluorescence (n=16) (depicted as mean fluorescence intensity (MFI) in CD34+ cells in the absence (shaded bars) 
or presence (black bars) of verapamil. B1 Representative example of the effect of ABCB1 inhibition by verapamil 
on rhodamine-123 fluorescence in CD34+38- cells assessed by single cell image analysis. B2. Average values ± 
S.D. of rhodamine-123 fluorescence (n=5)(depicted as arbitrary units) in the absence (shaded bars) or presence 
(black bars) of verapamil. Rhodamine-123 accumulation was significantly lower in CD34+CD38- cells compared 
to CD34+CD38+ cells (rhodamine-123 fluorescence 2820 ± 501 AU vs. 9369 ± 2367 AU). Blockage of ABCB1 
mediated transport significantly increases rhodamine-123 accumulation in CD34+38- cells.
Thirdly, experiments with the BCRP/ABCG2 specific inhibitor KO143 in these CD34+38- 
hematopoietic cells demonstrated only a minor contribution of these transporters to the 
mitoxantrone dull phenotype of these cells, as we described recently(23).
To obtain further insight in the relative contribution of ABCB1 mediated mitoxantrone 
extrusion to the mitoxantrone “dull” appearance ot these cells, serial measurements of 
mitoxantrone fluorescence were performed in a subpanel of samples (n=7) both after 2 
hours exposure with mitoxantrone and after an additional hour of efflux in drug free medium 
in the presence and absence of verapamil (figure 4A). Inhibition of ABCB1 by verapamil 
completely abrogated mitoxantrone efflux during an hour efflux in drug-free medium in 
CD34+38- cells (MFI 6.74 ± 0.34 vs. 6.74 ± 0.49 respectively). 
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Figure 4: ABCB1 modulation abrogates mitoxantrone extrusion from normal but not leukemic CD34+38- 
cells. To assess whether mitoxantrone efflux occurs in CD34+38- cells in the presence of ABCB1 modulation 
(verapamil=VERA), serial measurements were performed of mitoxantrone fluorescence after 2 hrs of exposure 
to mitoxantrone (MITO) and after an additional hour of efflux in drug free medium (DFM), both in the presence 
and absence of ABCB1 modulation. Inhibition of ABCB1 by verapamil completely abrogates mitoxantrone efflux 
during the additional hour of efflux in DFM in CD34+38- cells from normal bone marrow (MFI 6.74 ± 0.34 vs. 6.74 
± 0.49 respectively; figure 4A) but not in AML (MFI 6.90 ± 0.55 vs. 6.26 ± 0.62 respectively, difference using T-
test for paired samples p=0.006; Figure 4B) (average value mitoxantrone ± SEM represented by bar, individual 
samples represented by symbols). When cells were put on ice during the additional hour of efflux, no decrease in 
mitoxantrone fluorescence was observed.
Together, these results demonstrate that ABCB1 mediated transport is the major 
determinant of the mitoxantrone dull phenotype of CD34+CD38- cells in human normal 
bone marrow.
Impaired ABCB1 mediated transport is a biological commonality in 
CD34+38- hematopoietic cells in AML 
Conserved ABCB1 mediated drug extrusion from CD34+38- cells after malignant 
transformation would be an important obstacle for chemotherapeutical eradication of 
these cells in AML. We therefore investigated ABCB1 expression and function of this cell 
population in AML in comparison to their counterparts in normal bone marrow. 
Investigations were performed on a panel of bone marrow samples of 20 untreated AML 
patients (table 1). 
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Table 1: Patient characteristics.
N 20
Sex
M
F
9
11
Age (median/range) 50(15-71)
% CD34 31 (1-91)
FAB
M1
M2
M4
M5
6
8
3
3
Cytogenetics
Normal
t(8;21)
(6;11)
45XO
Complex
9
4 (+2 complex)
2
1
4
The FAB M3 subtype was not included in this study because controversy exist about the 
origin of leukemic stem cells in this subtype, which may not be CD34+38- cells(3). The 
panel consisted predominantly of CD34+ leukemias with a median percentage of CD34+ 
cells of 31% (range 1-91). CD34+38- cells in AML were immunophenotypically defined as 
indicated in figure 1. These cells showed comparable scatter characteristics and CD38 
expression in comparison to their counterparts in normal bone marrow. FISH analyses in 
AML patients who carried a cytogenetic abnormality and from whom sufficient cells were 
available for analysis demonstrated a predominantly leukemic character of CD34+38- cells 
in these samples (n=5; table 2). 
Table 2: CD34+38- cells in AML are predominately of leukemic origin.
Pat. nr.
Cytogenetic 
aberrancy
% cytogenetic aberrant 
CD34+38- cells ABCB1 efflux-index
Rhodamine-123
3.74 (1.76-5.66)A
Mitoxantrone
1.99 (1.64-2.94)A
1. -5,-7,-15,-17,t(2:3) 56% 0.84 1.32
2. t(8;21) 90% NA 0.92
3. t(8;21) 95% 0.81 1.15
4. t(8;21) 90% 1.39 NA
5. t(8;21) 100% NA 1.28
The incidence of cytogenetic aberant cells in the CD34+38- cell population as assessed by FISH and ABCB1 
mediated transport in these cells. NA= material not available for analysis.
A Values normal bone marrow: mean (range).
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ABCB1/Pglycoprotein expression in CD34+CD38- cells in AML as assessed by the MRK-
16 monoclonal antibody was comparable to expression of their counterparts in normal 
bone marrow (figure 2). Similar to the expression in normal bone marrow, decreased 
protein expression in CD34+38+ and CD34- subsets was observed in all samples. 
Next, we studied the effect of ABCB1 modulation on drug accumulation in CD34+38- cells 
in AML (figure 5); 
Figure 5: ABCB1 transport is impaired in hematopoietic CD34+38- cells in acute myeloid leukemia 
(for color reproduction: see appendix). A1. Representative example demonstrating increased intracellular 
mitoxantrone accumulation in comparison to CD34+38- cells from normal bone marrow due to impaired 
ABCB1 mediated transport in CD34+38- cells illustrated by a lack of effect of verapamil/PSC833 on intracellular 
mitoxantrone fluorescence. A2. Average mitoxantrone fluorescence (depicted as mean fluorescence intensity 
(MFI) in CD34+ cells in the absence (shaded bars) or presence (black bars) of verapamil. B1. Representative 
example of impaired ABCB1 mediated rhodamine-123 extrusion from CD34+38- cells, illustrated by the lack 
of effect of ABCB1 inhibition by verapamil on intracellular rhodamine-123 fluorescence assessed by single cell 
image analysis. B2. Average values ± S.D. Rhodamine-123 fluorescence was significantly lower in CD34+CD38- 
cells compared to CD34+CD38+ cells (3106 ± 267 AU vs. 4594 ± 373 AU) but blockage of ABCB1 by verapamil 
has no effect on rhodamine-123 fluorescence. 
Intracellular mitoxantrone accumulation in CD34+38- cells in AML upon exposure and 
subsequent efflux in drug free medium was significantly higher in comparison to their 
normal counterparts (MFI 4.54 ± 0.44 vs. 3.08 ± 0.23 ; p<0.001; figure 5A). This increased 
mitoxantrone accumulation was due to reduced ABCB1 mediated extrusion from these 
cells; blockage of ABCB1 mediated transport by verapamil increased mitoxantrone 
fluorescence in CD34+38- cells to a much lower extent than in normal bone marrow (MFI 
4.54 ± 0.44 vs. 5.42 ± 0.52 in the absence vs. presence of verapamil respectively; p=0.009; 
figure 5A). 
ABCB1 mediated efflux, defined as the fluorescence ratio with modulator divided by drug 
fluorescence without modulator, was invariably impaired in CD34+38- cells in AML (n=15) 
compared to these cells in normal bone marrow (mean efflux index 1.21 ± 0.05 (0.93-1.51); 
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p<0.0001; figure 6, panel A). Impairment of ABCB1 function was not restricted to CD34+38- 
cells in AML; impaired ABCB1 function in comparison to normal counterparts was also 
found for CD34+38+ cells (mean EI 1.17 ± 0.03, range 1.05-1.31; p<0.001). 
Figure 6: Impaired ABCB1 mediated drug transport in CD34+38- cells in AML is a biological commonality 
that is the result of early leukemic alterations rather than a characteristic of normal CD34+38- cells 
predisposing to malignant transformation. A. ABCB1 mediated mitoxantrone transport in hematopoietic 
CD34+38- cells from normal bone marrow (NBM) and AML samples depicted as an efflux index (EI) of 
mitoxantrone fluorescence in the presence/absence of verapamil. Each sample is represented by a black dot. 
Average ABCB1 efflux index ± SEM is depicted on top. MM = CD34+38- cells from multiple myeloma. 
B. ABCB1 mediated transport in autologous transplanted cells constituting normal hematopoiesis in AML 
(AUT-AML) is significantly higher than in AML at diagnosis and similar to ABCB1 transport after autologous 
transplantation in MM (AUTO-MM) indicating that impaired ABCB1 function is not a characteristic of normal 
CD34+38- cells predisposing to malignant transformation in AML. ALLO-AML= long-term remission after 
allogeneic transplantation. C. Patients suffering from refractory anemia (RA) that have normal ABCB1 mediated 
mitoxantrone transport show no malignant progression whereas patients that developed AML after RA (RA-AML) 
have impaired ABCB1 mediated transport in CD34+38- cells at the moment of RA diagnosis.
To confirm that impaired verapamil-inhibitable transport in CD34+38- cells in AML is indeed 
due to impaired ABCB1 mediated transport, additional experiments were performed. First, 
similar results were found when PSC-833 was used as an inhibitor (n=4, average efflux 
index in CD34+38- cells 1.23 ± 0.16; figure 5A). 
Additionally, impaired ABCB1 mediated transport in CD34+38- cells in AML was confirmed 
using rhodamine-123 as a substrate in single cells (figure 5B). CD34+CD38- cells in AML 
(n=8) were rhodamine-123 dull compared to the more differentiated CD34+CD38+ cells. 
Addition of verapamil did not increase rhodamine-123 fluorescence in CD34+38- cells. The 
mean efflux index was 0.99 ± 0.07 (figure 7). 
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Figure 7: Impaired ABCB1 mediated rhodamine-123 transport in CD34+38- cells is a biological 
commonality in AML. ABCB1 mediated rhodamine-123 transport in hematopoietic CD34+38- cells from normal 
bone marrow (NBM) and AML samples depicted as an efflux index (EI) of rhodamine-123 fluorescence in the 
presence/absence of verapamil. Each sample is represented by a black dot.
Finally, analysis of mitoxantrone efflux mediated by the ATP-binding cassette transporters 
ABCG2 (BCRP), performed in a series of normal and leukemic bone marrow samples 
including those described in this paper, using the ABCG2-specific fumitremorgin C analog 
KO143 as inhibitor, demonstrated no difference between normal and leukemic CD34+38- 
cells(23). 
To unravel whether additional mechanisms confer drug transport from these cells, serial 
measurements of mitoxantrone fluorescence were performed in a subpanel of AML 
samples (n=10) both after 2 hours exposure with mitoxantrone and after an additional 
hour of efflux in drug free medium in the presence and absence of ABCB1 blockage by 
verapamil (figure 4B). A significant decrease in mitoxantrone fluorescence was observed 
during an hour efflux in drug free medium in the presence of verapamil (MFI 6.90 ± 0.55 vs. 
6.26 ± 0.62 respectively, difference using T-test for paired samples p=0.006) in the majority 
of patients, pointing in the direction of additional drug extrusion mechanisms. No decrease 
in mitoxantrone fluorescence was observed when cells were put on ice during the efflux in 
drug free medium. 
These results indicate that ABCB1 mediated mitoxantrone transport is reduced in CD34+38- 
cells in AML in comparison to their counterparts in normal bone marrow. 
Modulation of ABCB1 alone does not abrogate drug efflux from these cells due to the 
activity of promiscuous, non verapamil- inhibitable transport mechanisms. 
Impairment of ABCB1 mediated transport is an early leukemic characteristic 
of CD34+38- hematopoietic cells in AML
The observation that impaired ABCB1 mediated transport is a biological commonality in 
AML and not observed in normal bone marrow opened the possibility that impaired function 
of the major xenobiotic transporter in normal hematopietic stem cells predisposes to the 
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malignant transformation of these cells. Alternatively, impaired ABCB1 function could be 
an early characteristic induced by leukemia-associated genetic events in hematopoietic 
CD34+38- cells. To address this question we studied ABCB1 mediated transport in AML 
patients in which normal hematopoiesis was restored after bone marrow transplantation. 
Long term survivors following autologous bone marrow transplantation were compared 
with long term survivors following allogeneic transplantation. Patient and CD34+38- cell 
characteristics are shown in table 3.
Table 3: Autologous vs allogeneic transplanted patients: Patient and CD34+38- cell characteristics.
Autologous BMT (n=11) Allogeneic BMT (n=9)
Age 38 (19-55) 34 (26-56)
Sex M 6 2
F 5 7
FAB M1 1 0
M2 4 6
M4 3 1
M5 2 2
M6 1 0
Cytogenetics Normal 6 4
T (8;21) 2 3
T (9;11) 1 0
T (16;16) 1 0
Complex 1 2
CD34+38- cells CD38 (MFI) 5.72 ± 0.84(SD) 4.83 ± 0.42(SD)
Incidence (%MNC) 0.21 ± 0.27(SD) 0.40 ± 0.15(SD)
ABCB1 transport assessment 
(months after BMT)
38 (12-80) 37 (12-140)
Survival (months after BMT) 74 (38-139) 158 (59-254)
BMT=Bone marrow transplantation.
ABCB1 mediated efflux was assessed when hematopoiesis was morphologically normal. 
Patients following allogeneic transplantation had complete donor hematopoiesis as 
assessed by XY chromosome karyotyping or single nucleotide polymorphism analysis at 
the time of evaluation. Polyclonality of hematopoiesis in autologous transplanted female 
patients was confirmed using the HUMARA-assay (data not shown). All patients are still 
alive without recurrence of disease after a median follow-up of 74 and 158 months in 
autologous and allogeneic transplanted patients respectively. 
ABCB1 mediated mitoxantrone transport in allogeneic transplanted CD34+38- cells was 
similar to that observed in normal bone marrow (mean efflux index 1.94 ± 0.06, 1.76-2.29; 
figure 6, panel B and figure 8). ABCB1 mediated transport in autologous transplanted 
CD34+38- cells was significantly higher than in CD34+38- cells in AML at diagnosis (EI 1.53 
± 0.02 vs. 1.21 ± 0.05, p<0.001), although lower than in allogeneic transplanted cells. 
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Figure 8: Representative examples of ABCB1 mediated mitoxantrone efflux in CD34+38- cells from 
autologous and allogeneic transplanted cells constituting normal hematopoiesis in long-term remission, 
refractory anemia (RA), refractory anemia progressing towards AML (RA-AML)  (for color reproduction: 
see appendix). 
To address whether the lower ABCB1 activity in CD34+38- cells in autologous transplanted 
patients in comparison to normal CD34+38- cells was transplantation-related or a 
preleukemic characteristic of these cells, as a control, ABCB1 mediated transport was 
assessed in CD34+38- hematopoietic stem cells in multiple myeloma (MM). MM is a 
plasma cell malignancy that is derived from differentiated clonogenic B-cells rather than 
multipotential CD34+38- cells and is therefore regarded as a malignancy not originating 
from hematopoietic stem cells. ABCB1 mediated transport in CD34+38- cells from 
bone marrow obtained from patients with MM (n=5) was similar to that in normal bone 
marrow (Efflux index 2.18 ± 0.08; figure 6, panel A) and significantly higher than in AML 
(p<0.001). Autologous transplanted cells from 2 patients with multiple myeloma (MM) that 
demonstrated normal ABCB1 mediated transport in their CD34+38- cells at diagnosis 
displayed reduced ABCB1 activity similar to the activity observed in CD34+38- cells from 
autologous transplanted AML patients (figure 6, panel B), indicating that the reduction in 
function in autologous transplants in AML in comparison to allogeneic transplanted cells 
is treatment-related rather than a pre-leukemic characteristic. Together, these findings 
argue against the possibility that impaired ABCB1 mediated transport is a characteristic of 
normal, polyclonal, CD34+38- cells predisposing to malignant transformation in AML. 
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Impaired ABCB1 mediated transport is an early characteristic of hematopoietic 
CD34+38- cells in patients with refractory anemia developing acute myeloid leukemia
To gain further insight into the timing and significance of impaired ABCB1 mediated 
transport in leukemogenesis, we studied bone marrow of patients suffering from refractory 
anemia (RA) and patients with refractory anemia with ring sideroblasts (RARS). RA 
and RARS are preleukemic syndromes representing subgroups of the myelodysplastic 
syndrome (MDS) characterized by the absence of leukemic blasts in the bone marrow 
(<5%) and peripheral blood (<1%)(24). Malignant transformation to AML occurs in 10-20% of 
patients with RA/RARS(25)). We selected RA/RARS patients who received supportive care 
only (no chemotherapy or bone marrow transplantation) with a follow-up of at least 2 years. 
Eleven patients were identified who matched these criteria and from whom bone marrow at 
diagnosis was available for analysis (table 4). 
Table 4: ABCB1 mediated mitoxantrone transport in CD34+38- cells at diagnosis related to malignant 
transformation in RA/RARS patients.
Nr. Sex Age Diagnosis
ABCB1 mediated 
transport (EI) AML Latency period Survival Status
1. F 68 RARS 1.88 no 87 -
2. M 66 RA 1.86 no 89 -
3. M 59 RA 2.42 no 39 -
4. M 56 RARS 2.23 no 79 Alive
5. F 50 RA 1.86 no 46 Alive
6. M 54 RA 2.09 no 31 Alive
7. F 68 RA 2.00 no 58 -
8. M 25 RA 1.80 no 172 Alive
2.02 ± 0.08A
9. M 44 RA 1.24 yes 32 34 -
10. M 76 RA 1.30 yes 24 26 -
11. F 55 RA 1.53 yes 48 56 -
1.36 ± 0.07A
RA=refractory anemia. RARS=refractory anemia with ringed sideroblasts. A average ± S.E.M.
ABCB1 mediated mitoxantrone transport in CD34+38- cells was assessed in all patients 
(table 4; figure 6; panel C and figure 8). CD34+38- cells in 8/11 patients displayed normal 
(defined as efflux index values within the range found in normal bone marrow) ABCB1 
mediated transport (mean efflux index 2.02 ± 0.08, range 1.80-2.42). None (0/8) of these 
patients developed AML with a median follow-up of 58 months. Impaired ABCB1 mediated 
efflux at diagnosis was found in CD34+38- cells in 3/11 patients (1.36 ± 0.09, range 1.24-
1.53). These 3 patients developed AML after a latency period of 2-4 years. Together these 
data demonstrate that impaired ABCB1 mediated transport in hematopoietic progenitors 
is an early leukemic event, preceding the development of clinically overt AML in patients 
suffering from refractory anemia.
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ABCB1 mediated drug transport identifies a subpopulation of residual normal CD34+38- 
hematopoietic stem cells in a patient with CBFB-MYH11 positive AML
The finding that impairment of ABCB1 function is not a characteristic of normal 
hematopoietic stem cells preceding malignant transformation but rather an early leukemic 
event implies that in AML residual normal CD34+38- hematopoietic cells may be identified 
by their conserved ABCB1 mediated transport capacity.
Indeed, during additional monitoring, one patient was identified with a clearly discernable 
CD34+38- mitoxantrone dull population caused by ABCB1 mediated drug efflux within the 
range observed in normal bone marrow (figure 9). 
Figure 9: ABCB1 mediated mitoxantrone transport identifies a subpopulation that harbors residual 
normal CD34+38- cells in a patient with CBFB-MYH11 AML (for color reproduction: see appendix). A patient 
was identified in which mitoxantrone discriminated a population of CD34+38- mitoxantrone dull cells. The dull 
phenotype was determined by strong ABCB1 mediated efflux (CD34+38- ABCB1 efflux ++), within the range 
observed in CD34+38- cells observed in normal bone marrow (EI=2.50). The CBFB-MYH11 (type D) transcript 
could be detected at the level of the positive control ( blast population from CBFB-MYH11 positive patient; Xn 
= 5.1. 10-3 copies CBFB-MYH11/Copy GAPDH) in the CD34+38- mitoxantrone bright population. CBFB-MYH11 
transcripts were not detected in the CD34+38- ABCB1 efflux ++ population.
Because the intracellular presence of mitoxantrone precluded the use of FISH, we used 
real-time quantitative RT-PCR to quantify the number of CBFB-MYH11 transcripts in these 
CD34+38- subpopulations. The number of transcripts in the CD34+38- cell population was 
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similar to that in the positive control (blast population from CBFB-MYH11, type D positive 
patient) (Xn 4.3 .10-3 vs. 3.5 .10-3 copies CBFB-MYH11/copy GAPDH, respectively), 
whereas no transcripts were detected in the CD34+38- ABCB1 efflux ++ subpopulation. 
This sample provides proof of principle that ABCB1 mediated drug efflux may indeed 
identify a subpopulation of CD34+38- cells that harbor residual normal cells at least in a 
subgroup of AML patients. 
Discussion
In this report we demonstrate that ABCB1 mediated drug transport is impaired in leukemic 
CD34+38- progenitor cells in comparison to their normal counterparts in AML. This 
finding was initially unanticipated since AML is generally considered to be an ABCB1 
over-expressing malignancy with levels of expression reflecting the expression in normal 
bone marrow(14). This assumption, however, is based on the observation that ABCB1 is 
preferentially expressed in CD34+ blasts in AML(15) similar to preferential expression of 
ABCB1 in these cells in normal bone marrow(16), thus reflecting patterns of expression 
rather than direct comparison of ABCB1 expression and function of normal and malignant 
cell subpopulations. Expression data in our study confirm the preferential expression of 
ABCB1 in CD34+ cells in AML(15) at levels comparable to those observed in normal bone 
marrow. ABCB1 transport capacity, however, was markedly reduced both in CD34+38- and 
in CD34+38+ cells in AML.
The molecular determinants behind impaired ABCB1 mediated transport in hematopoietic 
cells in AML remain to be elucidated. The finding in this study that reduced ABCB1 function 
in CD34+38- hematopoietic cells is an early leukemic event preceding the development 
of clinically overt leukemia in patients suffering from refractory anemia, rather than a 
preleukemic characteristic of normal hematopoietic cells argues against polymorphisms 
in the ABCB1 gene(26) as an explanation. ABCB1 downregulation has been reported as 
a downstream event of oncoproteins central in leukemogenesis such as AML1-ETO(27) 
and TEL-AML1(28). Additionally, down-regulation of ABCB1 by the PML-RARa leukemic 
oncoprotein in the preleukemic phase of the disease(29) has recently been described in 
transgenic mice. Although ABCB1 protein expression in this study was similar in CD34+38- 
cells from normal bone marrow and AML, this does not always reflect gene expression, 
possibly through lack of sensitivity of protein expression detection. Consequently, 
downregulation of ABCB1 expression by oncoproteins cannot be excluded as a possible 
mechanism behind the reduced transport capacity. To address this issue we are currently 
profiling gene expression in normal and leukemic CD34+38- hematopoietic cells.
Alternatively, factors governed by the cellular environment such as disruption of cellular 
ATP- metabolism, membrane integrity or cell cycle regulation(30) could be involved in 
reduced ABCB1 function in leukemic progenitor cells.
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The finding in this study that reduced ABCB1 mediated transport in CD34+38- cells is 
a biological commonality and an early leukemic event preceding the development of 
clinically overt AML in the pre-leukemic disorder refractory anemia, raises questions about 
its biological significance in leukemogenesis. It is tempting to hypothesize that impaired 
xenobiotic transport in hematopoietic cells that are the target for leukemic transformation 
attributes to increased susceptibility for progression-associated genetic events induced by 
naturally occurring genotoxic xenobiotics required for malignant transformation. Interestingly, 
a decrease in ABCB1 function in CD34+ hematopoietic cells has been described in aplastic 
anemia (AA), another hematopoietic disorder associated with xenobiotic exposure(31). AA 
is associated with an increased risk for the development of clonal hematopoietic disorders 
with about 25% of patients developing acute leukemia(32). Additionally, polymorphisms in 
the ABCB1 gene, associated with reduced expression and function of ABCB1, have been 
related to the occurrence of acute leukemia(33) and other tumors(34). 
It has to be noted however that leukemia initiating capacity using NOD-SCID models 
is found in only about 1/1000 CD34+38- cells in AML and therefore our results do not 
necessarily apply to these repopulating cells. Studies investigating the leukemia engrafting 
capacity of CD34+38- ABCB1 efflux++ and efflux- subpopulations are warranted to 
definitely address whether reduced ABCB1 function is required to confer the leukemic stem 
cell phenotype to hematopoietic CD34+38- hematopoietic cells. The low frequency of cells 
in the cell samples we examined and the use of mitoxantrone precluded these experiments 
in the current study.
Regardless the underlying mechanism and biological significance, the finding that ABCB1 
mediated transport is impaired in CD34+38- cells in AML has important clinical implications; 
The recognition of AML as a disease originating from these cells dictates a paradigm 
shift in the treatment towards the eradication of this crucial stem cell population in AML. 
Unraveling the mechanisms underlying chemoresistance in these cells is therefore of great 
importance. Our results indicate that ABCB1 plays a limited role in mitoxantrone extrusion 
from leukemic CD34+38- cells. In this study we used mitoxantrone as a drug because of 
its favorable emission characteristics in multiparameter flow cytometry. It remains to be 
determined whether the ABCB1 extrusion capacity for other drugs, such as daunorubicin 
and idarubicin is reduced in leukemic CD34+38- cells as well. The observation that 
rhodamin-123 extrusion capacity is reduced, however, suggests that reduced function may 
comprise multiple (drug) substrates. The relatively mitoxantrone and rhodamine-123 dull 
phenotype of CD34+38- cells in AML in comparison to more differentiated CD34+38+ cells 
in the absence of ABCB1 mediated transport in our experiments, points to the direction 
of additional redundant mitoxantrone transporters in these cells. We have recently 
documented ABCG2/BCRP as one of these additional drug transporters in leukemic 
CD34+38- cells(23). Modulation of additional transporters is likely to be required to increase 
mitoxantrone accumulation and to enhance mitoxantrone induced eradication of leukemic 
stem cells in AML. 
86
_____ CHAPTER 4 _____________________________________________________________________________________________________ _______________________________________________ REDUCED ABCB1 MEDIATED TRANSPORT IN LEUKEMIC PROGENITOR CELLS _____ 
87
Additionally, the current study demonstrates that residual normal CD34+38- cells are 
likely to harbor within the ABCB1 efflux ++ subpopulation. This seems congruent with 
the report(35) that the capacity to efflux hoechst 33342 (side population) identifies a 
subpopulation of CD34+38- residual normal cells in AML, whereas CD34+38- hoechst 
bright cells were leukemic. Although these authors could not relate hoechst 33342 
efflux with ABCB1 protein expression in the overall side population of cells, this was not 
investigated in the CD34+38- subset. The current report demonstrates that differences 
in ABCB1 mediated efflux discriminates normal from leukemic CD34+38- cells. We can 
however not completely exclude the possibility that yet unidentified transporters that efflux 
rhodamine-123 and mitoxantrone and are blocked by verapamil and PSC 833 are involved. 
The hoechst transporter ABCG2 is not involved because we recently demonstrated that its 
transport capacity is conserved in CD34+38- cells in AML in comparison to their normal 
counterparts(23). 
Translated to the use of ABCB1 modulation in AML, the finding that residual normal 
CD34+38- cells in AML exhibit high ABCB1 mediated drug efflux, suggests that this 
approach may preferentially target residual normal hematopoietic cells whereas leukemic 
CD34+38- cells escape its effect through the action of redundant mechanisms. These 
laboratory findings could provide an alternative explanation for the poor results of ABCB1 
modulation by PSC 833 on long-term disease outcome in clinical trials(13,36). The early 
reports of improved clinical outcome in a clinical trial using cyclosporin as a ABCB1 
modulator(37) may actually reflect this assumption since cyclosporin is a more promiscuous 
ABC-transporter inhibitor with effects on both ABCB1 and ABCG2(12). 
These data prompt further research to elucidate the transport mechanisms involved in the 
extrusion of drugs from leukemic CD34+38- cells to provide novel targets for the eradication 
of this crucial cell population within the AML hierarchy. 
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Abstract
Purpose
Acute myeloid leukemia (AML) is considered a stem cell disease. Incomplete 
chemotherapeutical eradication of leukemic CD34+38- stem cells is likely to result in 
disease relapse. The purpose of this study was to investigate the role of the Breast Cancer 
resistance Protein (BCRP/ABCG2) in drug resistance of leukemic stem cells and the effect 
of its modulation on stem cell eradication in AML.
Experimental design
BCRP expression (measured flow-cytometrically using the BXP21 monoclonal antibody) 
and the effect of its modulation (using the novel fumitremorgin C analog KO143) on 
intracellular mitoxantrone accumulation and in vitro chemosensitivity were assessed in 
leukemic CD34+38- cells. 
Results
BCRP was preferentially expressed in leukemic CD34+38- cells and blockage of BCRP 
mediated drug extrusion by the novel fumitremorgin C analog KO143 resulted in increased 
intracellular mitoxantrone accumulation in these cells in the majority of patients. This 
increase, however, was much lower than in the mitoxantrone resistant breast cancer cell 
line MCF7-MR and significant drug extrusion occurred in the presence of BCRP blockage 
due to the presence of additional drug transport mechanisms, among which P-glycoprotein 
and Multiple Drug Resistance Protein (MRP). In line with these findings, selective blockage 
of BCRP by KO143 did not enhance in vitro chemosensitivity of leukemic CD34+38- cells. 
Conclusions
These results demonstrate that drug extrusion from leukemic stem cells is mediated by the 
promiscuous action of BCRP and additional transporters. Broad-spectrum inhibition, rather 
than modulation of single mechanisms, is therefore likely to be required to circumvent drug 
resistance and eradicate leukemic stem cells in AML. 
Introduction
Cancer is increasingly recognized as a disease originating from the transformation of 
normal stem cells, retaining the capacity for self-renewal(1). This emerging concept for 
the origin of tumorigenesis was stimulated by the postulation of acute myeloid leukemia 
as a stem cell disease. Cells with leukemic stem cell characteristics, defined as leukemic 
engraftment potential and self renewal capacity, in acute myeloid leukemia are found in 
the CD34+CD38- cell population. The involvement of CD34+38- cells in leukemogenesis 
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is suggested by the presence of cytogenetically aberrant cells in the CD34+CD38- 
compartment as demonstrated by FISH and PCR for leukemia specific translocations(2,3). 
Additionally, leukemic cells with long-term proliferative ability both in vitro and in vivo have 
been identified as CD34+CD38-(4). Studies using the NOD-SCID mouse model have shown 
that cells with leukemic engraftment and self renewal potential in AML are found in the 
CD34+CD38- subpopulation(5,6) and not in more differentiated CD34+CD38+ cells. These 
studies strongly argue that leukemia initiating transformation and progression associated 
genetic events occur at the level of these primitive cell populations. Importantly, incomplete 
chemotherapeutical eradication of cancer stem cells is likely to result in disease relapse. 
Elucidation of the mechanisms conferring resistance to these cells is therefore essential to 
provide novel targets for stem cell eradication in AML.
The ATP-binding cassette protein family is a large family of highly conserved membrane 
proteins transporting a wide variety of substrates across the cell membrane(7) . Several 
members, among which MDR1 (ABCB1) and BCRP (ABCG2) extrude a variety of 
structurally unrelated chemotherapeutical compounds, thereby conferring a multi-drug 
resistance phenotype to cancer cells.
BCRP (ABCG2) is a 655-aa member of the ABCG subfamily of ABC- membrane transporters 
first described in drug resistant cell lines(8-10). BCRP is a half transporter functioning as a 
dimer and confers multidrug resistance to topotecan, mitoxantrone, doxorubicin and 
related compounds by ATP dependent drug extrusion(9,11). BCRP is expressed in placental 
syncytiotrophoblasts, intestinal epithelium, liver canicular membrane(12) suggesting 
a physiological role in detoxification. Recently, BCRP has been shown to be highly 
expressed in a wide variety of stem cells(13) including immature human hematopoietic 
progenitors(14). BCRP is proposed to protect these long-lived cells from naturally occurring 
toxic substrates(15).
KO143 is a novel fumitrimorgin C (FTC) analogue which has recently been shown to be 
an extremely potent BCRP inhibitor(16) . KO143 is a specific inhibitor of BCRP and much 
more potent than currently known inhibitors of BCRP such as FTC(17) and GF120918(18). 
Importantly, KO 143 is non toxic at effective in vitro and in vivo concentrations which makes 
it one of the most promising compounds for development of clinical modulators of BCRP 
mediated efflux. The purpose of the current study was to investigate the role of BCRP in 
drug resistance of leukemic CD34+38- stem cells and the effect of its modulation on stem 
cell eradication in AML.
Methods
Bone marrow samples and CD34+38- hematopoietic cells
Bone marrow was obtained after informed consent from healthy allogeneic bone marrow 
donors and patients with AML at diagnosis. Patient characteristics are shown in table 1. 
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Table 1: Patient characteristics.
N 22
Sex
M
F
12
10
Age (median/range) 52 (20-68)
% CD34 40 (3-88)
FAB
M1
M2
M4
M5
5
12
1
4
Cytogenetics
Normal
t(8;21)
t(11;19)
+8
Complex
12
4
1
2
3
Mononuclear cells were isolated by density gradient centrifugation using Ficoll 1.077 
g/mL (Pharmacia Biotech, Uppsala, Sweden). Isolation, cryopreservation and thawing 
procedures of cells have been described previously(19) and were identical for normal 
and leukemic bone marrow samples. After thawing, cells were stained with fluoresceïne 
isothiocyanate (FITC) or CY5 labeled CD34 and CD38- phycoerythrin (PE) monoclonal 
antibodies (Becton Dickinson, BV, Etten-Leur, The Netherlands) for 30 minutes at 4ºC and 
washed in HBSS with 1% v/v heat inactivated fetal calf’s serum (FCS, Hyclone, Logan, 
Utah, U.S.A.). A Coulter Epics Elite Flow cytometer was used to define cell populations. 
Gating on forward and right angle scatter was used to exclude dead cells and debris. 
CD34+CD38- cells of both normal bone marrow and AML were defined as the cells with 
CD38-PE fluorescence within the first decade of emission. CD34+CD38- cells appeared 
in a consistently restricted light-scattering region confirming the lymphoid appearance of 
these primitive progenitors(20). The CD34+CD38+ cells were sorted from a gate positioned 
in the bulk of CD34+ cells and showed more heterogeneous light-scattering properties.
BCRP cell line
The human breast cancer cell line MCF7-MR (gift from R.Scheper, Free University 
Hospital, Amsterdam, the Netherlands) is resistant to mitoxantrone and overexpresses 
BCRP but mot MRP and MDR1 (P-glycoprotein)(21). MCF7-MR cells were cultured in RPMI 
1640 medium supplemented with 10 % FCS in the presence of 80 nM mitoxantrone. 
BCRP expression 
BCRP was detected with the BXP21 monoclonal antibody (gift from R. Scheper, Free 
University Hospital, Amsterdam, the Netherlands) which recognizes an internal epitope 
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of the protein(12) and has been shown to specifically bind BCRP, displaying no cross 
reactivity with other proteins(12). In AML patient samples BXP21 was more sensitive than 
another BCRP specific moab BXP 34(22). BXP21 was used in a three color flow cytometric 
assay, which, in preliminary experiments prooved to be much more sensitive than 
immunocytochemical assessment using immunofluorescence-microscopy, as previously 
recognized for other ATP-binding cassette transporters(23). First cells (1×106) were fixed 
and permeabilised (“Fix & Perm”, Caltag Lab., Burlingame, CA, U.S.A., according to 
manufacturer’s instructions) and subsequently washed in HBSS 1% FCS. Following 
fixation, cells were blocked with pooled human serum for 10 minutes and incubated with 
BXP21 (2.5 ug/ml) or isotype control IgG2a in the same concentration for 60 min at 4C. 
BXP21 was detected by fluorescein (FITC)-conjugated goat anti mouse F(ab)2 fragments 
(5.0 ug/ml) for 30 minutes. A 10 minute incubation with goat serum to block non-specific 
binding was followed by staining with CY5-conjugated CD34 and phycoerythrin (PE)-
conjugated CD38. BCRP appropriate isotype control at the same protein concentration as 
the relevant antibody was used as control. BCRP protein expression was quantitated as 
the median fluorescence channel shift (BXP21/Isotype control). 
ABCG2 gene expression
RNA was isolated from subfractions (105 cells) of G-CSF mobilzed CD34+ hematopoietic 
cells using cDNA synthesis and real time quantitative RT-PCR was performed as described 
previously(24) . ÁBCG2 target gene expression was quantitated relatively to housekeeping 
genes glyceraldehyde-3-phosphate- dehydrogenase (GAPDH) and hydroxymethylbilane 
synthase (HMBS) as described previously(24). We earlier showed that GAPDH is an 
appropriate gene for standardisation of target gene expression in human CD34+38- and 
CD34+38+ hematopoietic cell populations(24).
Primer and probe sequences for gene amplification:
ABCG2: Taqman gene expression assay (Apllied Biosystems) no HS 00184979 GAPDH: 
Taqman gene expression assay (Apllied Biosystems) no HS 99999905
HMBS: Taqman gene expression assay (Apllied Biosystems) no HS00609297
BCRP mediated mitoxantrone efflux
BCRP function was tested using mitoxantrone as a substrate and the fumitremorgin C 
analog KO143 as an inhibitor for BCRP; Mitoxantrone, rather than an anthracyclin was 
used as a substrate because mitoxantrone appears to be a more sensitive substrate to 
detect BCRP mediated efflux as suggested by resistance profiles in cell line models(8,11). 
The novel fumitremorgin C analog KO143 (0.1 uM) was used as a specific inhibitor for 
BCRP mediated efflux. KO143 was shown to be the most potent inhibitor currently available 
and, importantly, is BCRP-specific (without inhibition of MDR1 or MRP) at the concentration 
used in our assay(16). Flow cytometric measurement of FTC-sensitive mitoxantrone efflux 
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has been shown to be a sensitive and specific method for measuring the function of BCRP 
in both selected and unselected cell lines(25)
Cells were stained with CD34-FITC and CD38-PE membrane markers, washed in HBSS 1% 
FCS and pre-incubated with or without BCRP inhibitor for 20 minutes in Iscove’s modified 
Dulbecco’s medium supplemented with 1% FCS. Mitoxantrone (10 uM) was added and 
cells were incubated for 2 hrs at 37C, 5% CO2, with or without inhibitor. Subsequently, 
cells were washed in ice cold HBSS 1% FCS and kept on ice until flow-cytometric analysis 
or allowed an additional 1 hr efflux in drug free medium with or without inhibitor to further 
enhance sensitivity of the assay. Cellular mitoxantrone fluorescence was measured on a 
FACS-elite cytometer equipped with an argon laser. Fluorescence was assessed at an 
excitation wavelength of 635 nm through a 670 nm band-pass filter in a three color protocol 
with CD34-FITC and CD38-PE (figure 1B). At least 200 CD34+38- cells were analyzed in 
each sample.
BCRP mediated efflux was quantitated as the ratio of mitoxantrone fluorescence (MFI) 
in the presence/absence of KO143 and assessed in CD34+CD38-, CD34+CD38+ and 
CD34- cells as defined. Interexperimental variability was assessed by performing triplicate, 
independently performed, experiments in a panel of four different normal bone marrow 
samples. BCRP mediated efflux, assessed in 200 CD34+38- cells and indicated as an 
efflux index was 1.05 ± 0.03 (mean ± SEM), 0.88 ± 0.06, 1.11 ± 0.02 and 1.09 ± 0.03 
in these samples. Based on the average SEM (0.036) observed in these preliminary 
experiments, a cut-off level of EI 1.05 was used to define significant BCRP mediated efflux 
in individual samples. 
P-glycoprotein and multiple drug resistance protein (MRP) mediated drug 
efflux
Flow cytometric assessment of P-glycoprotein and MRP mediated mitoxantrone efflux was 
performed as described above using verapamil (Knoll AG, Ludwigshaven, Germany (20 
ugr/ml) and probenecid (0.5 mM) as inhibitors for P-glycoprotein and MRP, respectively. 
Fluorescence in situ hybridization (FISH)
CD34+38- cells were sorted and lysed in 15 ul KCL (75 uM) on a glass cover slip. Cells were 
fixed in methanol:acetic acid and stored at 4°C until analysis. FISH was performed using 
the LSI AML1/ETO Dual Color, Dual Fusion t (8;21) Probe or the LSI EGR1 (5q31) Dual 
Color Probe (Vysis, Downers Grove, IL, U.S.A.) according to manufacturer’s instructions. 
One hundred cells were analyzed microscopically for t(8;21) or chromosome 5 (5q31) 
cytogenetic abnormalities, as appropriate.
96-well chemosensitivity assay
CD34+38- cells were sorted in 96-well, round bottom, plates (200 cells/well) containing 
Iscove’s medium supplemented with 10% FCS with/without mitoxantrone (1.0 uM) and 
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with/without KO 143 in different concentrations (0.1, 1.0 and 10.0 uM). Plates were 
incubated at 37°C, 5% CO2 for 48 hours. All experiments were performed in quadruplicate. 
Cell apoptosis was assessed at 24 hrs and 48 hrs using propidium iodide (PI) as a cell 
death marker. Cell images were acquired on a Zeiss Axiovert 35M inverted microscope 
(Thorwood, New York, USA) equipped with a 40x oil (N.A. 1.3) objective and a cooled 
756x580 pixel resolution CDD-camera (Variocam, PCO computer optics, Kellheim, 
Germany) coupled with the pixel pipeline in a Macintosh Quadro 800. Cells were excited 
with a mercury arc lamp using band pass filter 510-560 nm for propidium iodide (PI). 
Emission was measured with a longpass filter 610nm. 
Statistical analysis
The Student’s T-test was used to calculate significant differences. Correlations were 
calculated using correlation coefficients. Data are presented as mean ± standard error of 
the mean (SEM). P values < 0.05 were considered significant. 
Results
BCRP expression and BCRP mediated mitoxantrone efflux in MCF7-MR 
cells 
BCRP expression in the MCF7-MR cell line, indicated as BXP21/IgG2a isotype control, 
using the current protocol was 44.7 ± 4.5 (mean ± SD of three experiments; figure 1a). 
BCRP-mediated efflux was examined using KO143 as a specific inhibitor of BCRP. KO143 
has been shown to be specific for BCRP at concentrations of 0.1-1.0 uM, not inhibiting 
MDR1 (P-glycoprotein) or MRP1 at these concentrations(16). The effect of KO143 on 
cellular mitoxantrone (10 uM) fluorescence in MCF7-MR cells, measured after 2 hours 
accumulation with/without inhibitor, is shown in figure 1b. 
Mitoxantrone fluorescence (MFI) of MF7-MR cells after 2 hrs accumulation without 
mitoxantrone and in the presence of mitoxantrone without/with KO143 were 0.4 ± 0.1 (SD), 
9.1 ± 0.3 and 28.5 ± 6.7, respectively (n=3). The mean BCRP mediated mitoxantrone 
efflux, indicated as a fluorescence shift index was 3.13 ± 0.62. Mitoxantrone efflux during 
an additional hour in drug-free medium was completely blocked by KO143, illustrating 
the potency of KO143 as a BCRP inhibitor and increasing sensitivity of BCRP efflux 
assessment in the MCF7-cell line (mean efflux index 5.70 ± 0.35, figure 1B2). Importantly, 
these data confirm that KO143 at the concentration used in our assays (0.1 uM) completely 
blocks BCRP mediated mitoxantrone efflux, as demonstrated earlier(16).
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Figure 1: BCRP expression and BCRP mediated mitoxantrone efflux in MCF7-MR cells. A. Flow cytometric 
assessment of BCRP expression using secondary FITC labeled F(ab)2 fragments against monoclonal antibody 
BXP21 (dotted line) or isotype control. B. Mitoxantrone fluorescence (on y-axis) in the presence (dotted line) or 
absence of the BCRP specific inhibitor KO143 (0.1 uM) after 2 hr accumulation (B1) and an additional hour of 
efflux in drug free medium (B2).
BCRP is preferentially expressed and functionally active in primitive 
CD34+38- hematopoietic cells in human normal bone marrow 
In order to compare BCRP expression and function in normal and malignant hematopoietic 
stem cells, first, BCRP expression was assessed in hematopoietic subpopulations in seven 
normal bone marrow samples (figures 2 and 3). 
BCRP expression was higher in CD34+38- cells (mean BXP21/IgG2a index 7.95 ± 1.32 
compared to more differentiated CD34+38+ progenitors (6.81 ± 0.98; p= 0.05, using 
student’s T-test for paired samples) and sharply decreased during further differentiation in 
CD34- cells ( 3.36 ± 0.62; p<0.001)(figure 3A). 
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Figure 2: Flow-cytometric assessment of BCRP expression and BCRP mediated mitoxantrone efflux 
in CD34+38- hematopoietic in normal bone marrow and AML (for color reproduction: see appendix). 
A.Definition of CD34+38- hematopoietic cells in human normal bone marrow (NBM) and AML. CD34+38- cells 
were defined flow-cytrometrically as the CD34 expressing cells (indicated in blue) with CD38 expression within 
the first decade of fluorescence emission (indicated in red) and compared with CD34+38+ cells (indicated as 
blue gated) with an exclusion of a decade between CD38- and CD38+. CD34- cells are shown in grey. CD34+38- 
cells were found invariably in both normal bone marrow (A1) and both CD34+ (> 10% CD34+ cells in bone 
marrow by definition, A2) and CD34- leukemias (A3). The median frequency of CD34+38- cells was 0.1 % of 
mononuclear cells in normal bone marrow (range 0.1%-0.3%) and 0.2 % in acute myeloid leukemia (range 0.1%- 
10%). B. Cellular mitoxantrone fluorescence in different cell populations after 2 hrs incubation with mitoxantrone 
(10 uM) in the absence of BCRP inhibitor. CD34+38- cells have a mitoxantrone “dull” phenotype. C. BCRP 
protein expression in CD34+38- cells as determined by the BXP-21 antibody (dotted line) vs isotype control. 
D. Mitoxantrone fluorescence in CD34+38- cells in the presence (dotted line) or absence of the BCRP specific 
inhibitor KO143 (0.1 uM)
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Figure 3: BCRP is preferentially expressed and functionally active in CD34+38- hematopoietic cells in 
human normal bone marrow. A. BCRP expression indicated as BXP21/IgG2a isotype control. Mean values 
are indicated as bars and individual samples are represented by lines. BCRP expression is higher in CD34+38- 
cells compared to more differentiated CD34+38+ progenitors and CD34- cells (7.95 ± 1.32, 6.81 ± 0.98; p= 0.05 
and 3.36 ± 0.62; p<0.001, respectively). B. BCRP mediated mitoxantrone efflux indicated as efflux index (EI) in 
different hematopoietic subpopulations. 
To provide additional evidence that BCRP is preferentially expressed in CD34+38- 
hematopoietic cells in comparison to committed progenitors and differentiated cells, ABCG2 
gene expression was assessed in these cell populations using real-time quantitative RT-
PCR. Since bone marrow samples yielded insufficient cell numbers to reliably perform 
real-time quantitative RT-PCR on the relatively low-copy transcript ABCG2, we used 
GCS-F mobilized peripheral blood CD34+ cells obtained from two normal controls. ABCG2 
expression was assessed relatively to house keeping genes as described previously(24) in 
CD34+38-, CD34+38+ and differentiated cells (monocytes) (figure 4).
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Figure 4: ABCG2 is highly expressed in normal hematopoietic stem cells. ABCG2 expression was assessed 
in different subfractions from GCSF-mobilized peripheral blood in two normal donors and quantitated relative to 
the housekeeping genes HMBS and GAPDH (indicated on the y-axis as copy’s ABCG2/ copy HMBS/GAPDH)
These results confirm, in an independent assay, that primitive hematopoietic stem cells 
express high levels of ABCG2, in line with previous reports(14,26). 
Next, we investigated BCRP mediated efflux in CD34+38-, CD34+38+ and CD34- 
hematopoietic subpopulations, using mitoxantrone as a substrate; cellular mitoxantrone 
fluorescence (MFI) after 2 hrs mitoxantrone accumulation was low in CD34+38- cells, 
compared to more differentiated CD34+38+ progenitors and CD34- cells (4.4 ± 0.29, 9.29 
± 0.83 and 7.63 ± 0.55 respectively). BCRP mediated mitoxantrone efflux contributed to 
the mitoxantrone “dull” appearance of primitive CD34+38- cells as evidenced by the ability 
of KO143 to increase fluorescence intensity; Significant BCRP mediated efflux, defined 
as a mitoxantrone fluorescence (MFI) index with/without KO143 (0.1 uM) > 1.05 (see 
section “methods”), was found in CD34+38- cells in 5/7 (71%) samples. In 2/7 samples no 
BCRP mediated efflux was found in either hematopoietic subpopulation. In those samples 
displaying BCRP mediated efflux, this was invariably and significantly higher in CD34+38- 
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cells compared to CD34+38+ and CD34- cells (mean efflux index 1.22 ± 0.08, 1.13 ± 0.04; 
p=0.03 and 1.11 ± 0.03; p=0.03, respectively; figures 2 and 3B). 
These data show that BCRP is preferentially expressed and functionally active in primitive 
CD34+38- hematopoietic cells compared to more differentiated cells in human normal 
bone marrow.
BCRP expression and function is conserved in primitive leukemic CD34+38- 
hematopoietic cells in AML
BCRP is preferentially expressed and functionally active in CD34+38- hematopoietic 
cells in AML 
BCRP expression was assessed in different hematopoietic subpopulations in 22 de novo 
AML samples (figure 2 and 5). 
Figure 5: BCRP is preferentially expressed and mediates mitoxantrone efflux in CD34+38- hematopoietic 
cells in AML. BCRP expression A. indicated as BXP21/IgG2a isotype control and BCRP mediated mitoxantrone 
efflux B. indicated as efflux index (EI) in different hematopoietic subpopulations. Mean values are indicated as 
bars and individual samples represented by lines.
Expression was higher in CD34+38- cells compared to more differentiated CD34+38+ and 
CD34- cell populations in 19/22 samples investigated. Mean BCRP expression was 9.00 ± 
1.01 (range 1.59-21.4), 6.53 ± 0.68 (range 2.84-14.89); p<0.001 and 5.75 ± 0.58 (range 1.66-
10.13); p<0.001, respectively. BCRP expression in CD34+38- cells in AML was not significantly 
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different from the expression in these cells in normal bone marrow (p=0.30). These results 
indicate that BCRP is preferentially expressed in primitive CD34+38- cells in the majority of 
AML samples, similar to the expression profile in normal bone marrow. We next investigated 
whether the preferential expression of BCRP in leukemic CD34+38- cells was reflected by 
increased BCRP mediated transport in these cells; In AML, similar to the situation in normal 
bone marrow, CD34+38- hematopoietic cells accumulated the lowest amount of mitoxantrone 
relative to more differentiated CD34+38+ and CD34- cell populations (MFI 6.6 ± 0.49, 10.0 ± 
0.66, 10.34 ± 0.74, respectively). To determine the contribution of BCRP mediated efflux to 
the mitoxantrone “dull” phenotype of leukemic CD34+38- cells, BCRP mediated mitoxantrone 
efflux was assessed in 22 leukemic bone marrow samples using KO143 (0.1 uM) as an 
inhibitor; In the majority of samples (14/22=64%), BCRP mediated efflux was detected in 
CD34+38- cells. The remaining 8 samples displayed no BCRP mediated efflux in either cell 
population. In the samples displaying BCRP mediated efflux, efflux was significantly higher 
in CD34+38- cells compared to CD34+38+ and CD34- cells (Efflux index 1.20 ± 0.03, 1.08 ± 
0.02; p=0.003 and 1.06 ± 0.002; p=0.001, respectively, Figure 5B). The differences remain 
significant when the overall population (n=22) is considered (Efflux index 1.11 ± 0.04, 1.03 ± 
0.02; p=0.005 and 1.02 ± 0.02; p=0.003, respectively). No significant differences were found 
when BCRP mediated efflux in different subpopulations in AML was compared with these 
populations in normal bone marrow. No correlation existed between BCRP expression or 
BCRP-mediated mitoxantrone efflux and mitoxantrone accumulation in leukemic CD34+38- 
cells (r –0.22 and –0.27, respectively). 
BCRP is expressed and mediates mitoxantrone efflux in leukemic CD34+38- 
hematopoietic cells
The CD34+38- cell population in AML harbors residual normal CD34+38- cells(27). To 
exclude the possibility that the expression and function of BCRP is present in residual 
normal rather than leukemic cells within the CD34+38- cell compartment in AML, we 
performed FISH analysis on leukemia associated cytogenetic aberrations in these cells 
(n=5); Table 2 shows that either BCRP expression or efflux is present in CD34+38- cells 
with predominantly or exclusively leukemic cells within this compartment (sample 2-5). 
Table 2: BCRP is expressed and mediates mitoxantrone efflux in leukemic CD34+38- cells.
Patient Cytogenetics % 34+38- aberrant cells BCRP BCRP-mediated transport
1. -5q31 56 4.95 0.94
2. t(8;21) 90 1.59 1.22
3. t(8;21) 90 NA 1.10
4. t(8;21) 100 3.19 1.03
5. t(8;21) 95 8.52 1.18
BCRP expression (BXP21/IgG2a) and BCRP mediated mitoxantrone efflux (indicated as efflux index) related to 
percentage of cytogenetically aberrant cells in the CD34+38- cell population in AML. 
NA= no material available for analysis.
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Together, these results demonstrate that BCRP is preferentially expressed and functionally 
active in primitive leukemic hematopoietic CD34+38- cells in the majority of patients. This 
phenotype reflects a conserved physiological function, similar to the situation in normal 
bone marrow. 
Additional transporters are involved in drug efflux in leukemic CD34+38- hematopoietic cells
The relatively small effect of BCRP blockage by KO143 on cellular mitoxantrone 
concentration and the lack of correlation between BCRP expression or BCRP mediated 
drug efflux and mitoxantrone fluorescence in leukemic CD34+38- cells suggest that BCRP 
is not the major determinant of the intracellular drug concentration in these cells. To assess 
the contribution of other transporters to mitoxantrone efflux in leukemic CD34+38- cells, 
we investigated whether mitoxantrone efflux took place in CD34+38- cells in the presence 
of BCRP blockage. For this purpose cells were incubated with mitoxantrone (10 uM) with 
KO143 (0.1 uM) for 2 hrs and subsequently allowed to efflux mitoxantrone in drug free 
medium for an additional hour in the presence of KO143 (0.1 uM). In all AML samples 
(n=10) mitoxantrone fluorescence (MFI) in CD34+38- cells decreased during the additional 
hour of efflux with a MFI decrease of 20% ± 12% (mean ± SD). When cells were put 
on ice after mitoxantrone accumulation to block active transport, no decrease in cellular 
mitoxantrone was observed. The observation that KO143 in BCRP blocking concentration 
can not completely abrogate drug efflux in CD34+38- cells indicates that additional 
transporters are mediating mitoxantrone efflux in these cells. 
To assess the role of other ATP-binding cassette transporters in drug extrusion from 
leukemic stem cells, P-glycoprotein (ABCB1/MDR1) and MRP (ABCC2) mediated 
mitoxantrone efflux was assessed in these 10 samples displaying drug efflux in the 
presence of BCRP inhibition (table 3). 
Table 3: Additional drug efflux mechanisms are involved in mitoxantrone efflux from leukemic stem cells. 
Pat. Nr. BCRP (ABCG2) P-glycoprotein (ABCB1) MRP (ABCC2)
1 1.27 1.25 1.51
2 ns ns ns
3 ns 1.15 ns
4 1.22 ns ns
5 1.10 1.13 ns
6 1.10 ns 1.12
7 ns 1.15 na
8 1.08 ns 1.10
9 1.08 1.19 1.28
10 ns 1.12 ns
mean ± SEM 1.14 ± 0.03 1.17 ± 0.02 1.25 ± 0.09
P-glycoprotein and MRP mediated mitoxantrone efflux, indicated as efflux index, in leukemic CD34+38- cells. 
ns= not significant (defined as efflux index < 1.05). na= no material available for analysis
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CD34+38- cells in 8/10 samples displayed either significant P-glycoprotein or MRP 
mediated transport or both. The combined effect of P-glycoprotein and MRP inhibition on 
mitoxantrone accumulation exceeded the effect of BCRP blockage in all these samples. 
Additionally, the observation that drug efflux occurs in the presence of BCRP blockage 
in a sample with only BCRP mediated efflux (sample 4) and a sample in which no ABC-
transporter activity could be demonstrated (sample 2) suggests the presence of yet 
unidentified drug extrusion mechanisms.
Together these results indicate that BCRP is not the predominant drug efflux mechanism 
in leukemic CD34+38- stem cells and that other mechanisms, among which P-glycoprotein 
and MRP, play a role in drug efflux from leukemic stem cells. 
Modulation of BCRP by the fumitremorgin C analog KO143 does not enhance drug 
induced apoptosis in leukemic CD34+38- cells 
Because inhibition of BCRP with KO143 (0.1 uM) increases mitoxantrone concentration 
only moderately in primitive CD34+38- leukemic cells compared to the drug resistant MCF-
7 cell line and other drug transporters are active in these leukemic cells, we raised the 
question whether selective modulation of BCRP could enhance chemosensitivity of these 
cells. To investigate this, a 96-well cytotoxicity assay was employed on sorted CD34+38- 
cells in 5 AML samples that displayed BCRP-mediated drug efflux (median efflux index 
1.25 (1.21-1.37)(figure 6). 
Mitoxantrone (1.0 uM) significantly induced apoptosis in leukemic CD34+38- cells at 48 
hrs of incubation in all samples (relative increase in apoptotic cells compared to drug free 
medium 1.66 ± 0.23; p=0.007)(Figure 6). KO143 at concentrations that completely block 
BCRP mediated efflux (0.1-1.0 uM; as demonstrated in the MCF7-MR cell line) did not 
significantly increase drug induced apoptosis (relative increase 1.81 ± 0.32 and 1.87 ± 0.37 
respectively). Enhanced apoptosis when KO143 was used at high concentration (10 uM) 
(average increase 2.57 ± 0.58, (figure 6), likely reflected intrinsic toxicity of the compound 
rather than modulation of drug efflux mechanisms as demonstrated by increased apoptosis 
in controls lacking mitoxantrone and the observation that KO143 at 10 uM did not further 
increase intracellular mitoxantrone concentration in drug accumulation assays (data not 
shown). 
These results argue that specific modulation of BCRP, though functionally active in these 
samples, does not significantly enhance drug induced apoptosis in leukemic CD34+38- 
cells.
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Figure 6: Specific inhibition of BCRP does not increase mitoxantrone induced apoptosis in primitive 
leukemic CD34+38- hematopoietic cells. Effect of KO143 on mitoxantrone induced apoptosis in leukemic 
CD34+38- cells. A. Typical example of microscope images of leukemic CD34+38- cells of a patient in the 
presence/absence of mitoxantrone and KO143. Apoptotic (PI-positive) cells are depicted in black (negative 
images). DFM=drug free medium, MITO= mitoxantrone alone, + KO143= mitoxantrone in the presence of 
KO143 at different concentrations. B. Mitoxantrone induced cell death depicted as relative increase in apoptotic 
cells in sorted CD34+38- cells in the presence/ absence of KO143. Values represent the mean ± S.E.M. of five 
patients. The white bars represent control experiments with KO143 at different concentrations in the absence 
of mitoxantrone. No significant increase in mitoxantrone induced apoptosis is seen when KO143 is added in 
BCRP specific concentrations (0.1-1.0 uM). Enhanced apoptosis when KO143 was used at high concentration 
(10 uM) reflects intrinsic toxicity of the compound as demonstrated by increased apoptosis in controls lacking 
mitoxantrone.
Discussion
Incomplete eradication of cancer stem cells is likely to result in disease relapse. Elucidation 
of the mechanisms conferring chemoresistance to these cells is therefore of major 
importance. In this report we demonstrate that the ATP-binding cassette transporter BCRP/
ABCG2 is preferentially expressed in the leukemic CD34+38- stem cell subpopulation and 
contributes to mitoxantrone efflux in these cells. 
Recently, several studies have addressed the expression of BCRP in leukemic blasts in 
AML(22,26). Abott et al(26) found relatively low levels of BCRP gene expression compared 
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to drug resistant BCRP clones in newly diagnosed adult AML patients. Flow cytometry 
revealed very small subpopulations of BCRP expressing cells, suggesting that BCRP 
expression may be limited to a small cell subpopulation. Similar findings have been 
reported by Sargent et al(28), who demonstrated, using imunocytochemistry with the BXP-
34 antibody, that BCRP is expressed in a minority of leukemic cells in AML. Although the 
results of these studies suggested the possibility of high BCRP expression in a small 
subpopulation of cells, until now the subpopulations of BCRP expressing cells in AML 
had not been identified. We here demonstrate that BCRP is preferentially expressed in a 
subpopulation of primitive CD34+38- leukemic cells, which have previously been shown 
to comprise leukemic stem cells. BCRP expression and efflux in leukemic CD34+38- cells 
was not different from expression and function in normal CD34+38- cells. This shows that 
the high BCRP expression in leukemic CD34+38- cells reflects a conserved physiological 
function of BCRP in primitive hematopoietic cells rather than being a leukemia- associated 
phenotype; BCRP has previously been shown to be highly expressed in a wide variety 
of human normal stem cells(13), including hematopoietic stem cell populations(14) and is 
believed to protect these long-lived cells against genetic damage induced by naturally 
occurring xenobiotic toxins(15). 
Incomplete chemotherapeutical eradication of leukemia-initiating CD34+38- cells due to 
intrinsic chemoresistance, is likely to result in disease relapse in acute myeloid leukemia. 
The preferential expression in the majority of newly diagnosed AML patients suggested 
that BCRP might be a target for stem cell eradication in AML. To test this hypothesis, we 
assessed the effect of BCRP modulation on the chemosensitivity of leukemic CD34+38- 
cells. Importantly, selective blockage of BCRP by KO143, the most potent BCRP inhibitor 
currently available(16) and capable of completely blocking BCRP as confirmed in the MCF7-
MR cell line, did not increase mitoxantrone induced apoptosis to leukemic CD34+38- cells. 
This lack of a chemosensitizing effect of BCRP modulation by KO143 was anticipated by 
several observations in this study; First BCRP expression and BCRP mediated efflux were 
not correlated with intracellular mitoxantrone accumulation in CD34+38- cells, suggesting 
that other determinants are involved in the mitoxantrone “dull” phenotype. Secondly, 
BCRP expression and the effect of KO143 on mitoxantrone accumulation was moderate 
in leukemic CD34+38- cells compared to the drug resistant MCF7-MR cell line in which 
BCRP confers resistance to mitoxantrone. Finally, we observed substantial drug efflux in 
leukemic CD34+38- cells in the presence of BCRP inhibition, demonstrating that other 
drug transporters, among which P-glycoprotein and MRP, are active in these cells. The 
presence of these promiscuous drug extrusion mechanisms might provide an explanation 
for the poor correlation between BCRP expression and function reported in literature(22, 29) 
and the observation in this study that KO143 increased mitoxantrone accumulation in only 
64% of samples expressing BCRP. 
Together, these findings argue that selective modulation of BCRP is not sufficient to 
circumvent resistance of leukemic CD34+38- cells. Alternatively, we cannot completely 
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exclude the possibility that KO143 does not completely inhibit BCRP in leukemic cells. The 
report that KO143 is the most potent BCRP inhibitor known thus far, tested in a panel of 
cell lines and our finding that it completely blocks efflux in the MCF7-MR cell line argues 
against this possibility.
Simultaneous modulation of several transporters, among which BCRP, could be required 
to sufficiently increase drug accumulation and eradicate CD34+38- stem cells in AML. The 
recent report of improved clinical outcome in a trial using cyclosporin as a P-glycoprotein 
inhibitor in AML(30), in contrast to the earlier, consistently poor, results of selective 
P-glycoprotein modulation on long-term disease outcome, could be in line with this 
assumption since cyclosporin is a more promiscuous ABC-transporter inhibitor with effects 
on both P-glycoprotein and BCRP(31). Together, these data warrant further research into 
the usefulness and feasibility of broad-spectrum ABC-transporter inhibitors to eradicate 
leukemic stem cells in AML.
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Abstract
Introduction
Acute myeloid leukemia (AML) is considered a disease originating from hematopoietic 
CD34+38- stem cells. Incomplete chemotherapeutical eradication of leukemic CD34+38- 
stem cells is likely to result in disease relapse. Elucidation of the mechanisms conferring 
resistance to these cells is therefore essential to provide novel targets for stem cell 
eradication in AML. 
Methods
We studied gene expression of 45 ABC-transporters (the complete ABCA, B, C, D and G 
family) in human hematopoietic CD34+38- cells in comparison to committed CD34+38+ 
progenitors in normal G-CSF mobilized or bone marrow cells (n=11) and their malignant 
counterparts in AML (n=11). Gene expression was assessed with a novel real-time 
quantitative RT-PCR approach using microfluidic low-density arrays.
Results
In normal CD34+38- cells 36 transporters were expressed of which 24 displayed significant 
differential expression in comparison to committed progenitors. In addition to known stem 
cell transporters (ABCB1, ABCG2 and ABCC1) these differentially expressed genes 
included many members not previously associated with stem cell biology. ABC transporter 
gene expression profile of CD34+38- cells was largely conserved in AML and included 
expression of all 13 members currently associated with drug extrusion and resistance.
Conclusions
These data suggest an important role for previously unrecognized ABC-transporters 
in hematopoietic stem cell biology. Additionally, the identification of many, previously 
unidentified, drug transporters in leukemic stem cells prompts further research to test their 
role in drug resistance and value as potential new targets to enhance chemotherapeutical 
eradication of leukemic stem cells in AML
Introduction
AML is considered a disease originating from hematopoietic CD34+38- stem cells. In AML, 
cells with leukemic stem cell characteristics, defined as leukemic engraftment potential and 
self-renewal capacity, are found in the CD34+CD38- cell population, similar to the hierarchy 
in normal bone marrow. The involvement of CD34+38- cells in leukemogenesis is suggested 
by the presence of cytogenetically aberrant cells in the CD34+CD38- compartment as 
demonstrated by FISH and PCR for leukemia specific translocations(1 2). Additionally, 
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leukemic cells with long-term proliferative ability both in vitro and in vivo have been identified 
as CD34+CD38-(3). Studies using the NOD-SCID mouse model have shown that cells with 
leukemic engraftment and self renewal potential in AML are found in the CD34+CD38- 
subpopulation (4,5) and not in more differentiated CD34+CD38+ cells. These studies strongly 
argue that leukemia initiating transformation and progression associated genetic events 
occur at the level of these primitive cell populations. Incomplete chemotherapeutical 
eradication of leukemic stem cells is likely to result in disease relapse. Elucidation of the 
mechanisms conferring resistance to these cells is therefore essential to provide novel 
targets for stem cell eradication in AML.
Normal hematopoietic (CD34+38-) stem cells (HSC) are characterized by their ability to 
extrude a variety of fluorescent compounds such as Hoechst and rhodamine123, resulting 
in a fluorescent-dye “dull” phenotype of these cells. The molecular basis of this phenotype 
is the expression of the ATP-binding cassette (ABC) transmembrane transporters 
ABCB1(6-9) and ABCG2(10,11), that efflux the fluorescent dyes. ABC-transporters represent 
the largest family of transmembrane proteins involved in the transmembrane transport of 
a huge variety of substrates including sugars, peptides, inorganic anions, amino-acids, 
oligopeptides, polysaccharides and proteins vitamins and metallic ions(12,13) The human 
superfamily of ABC transporters currently consists of 48 members. The genes can be 
divided into subfamilies based on similarity in gene structure resulting in seven mammalian 
ABC gene subfamilies (ABCA, B, C, D, E, F and G family).
The physiological function of ABC transporters in human stem cell biology is largely 
unknown. A role for ABC-transporters in the protection from genetic damage by naturally 
occurring xenobiotics that are substrates for the transporter have been suggested for 
hematopoietic stem cells(14,15) and has recently been substantiated by the observation of 
increased cytotoxicity to normal bone marrow in ABCB1(7) and ABCG2/BCRP knock-out 
mice(16). 
Recently, an increasing number of ABC transporters has been associated with extrusion 
of xenobiotic compounds and chemotherapeutical agents(17) and thus may be important 
for stem cell protection. The expression of the vast majority of ABC transporters on 
hematopoietic CD34+38- stem cells, however, is currently unknown.
Identification of such drug transporters may be particularly relevant for the treatment of 
hematological malignancies originating from hematopoietic CD34+38- stem cells such 
as AML since conserved expression of ABC transporters involved in drug resistance 
after malignant transformation of CD34+38- hematopoietic stem cells would represent 
an important mechanism of drug resistance to these cells(18). We recently demonstrated 
conserved expression and function of ABCG2 in CD34+38- cells in AML but observed 
significant mitoxantrone extrusion from these cells in the presence of ABCG2 inhibition(19), 
suggesting the presence of additional drug transporters in these cells.
In the current study we profiled the expression of 45 ABC transporters (the complete 
subfamilies A, B, C, D and G) in CD34+38- hematopoietic stem cells and committed 
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CD34+38+ progenitors from normal bone marrow and AML using real-time RT-PCR. 
Using this approach we demonstrate the differential expression of a large number of 
ABC transporters in hematopoietic stem cells suggesting an important biological function 
of these molecules in hematopoietic stem cell biology. These transporters include many 
transporters associated with drug transport of which the expression is conserved in the 
CD34+38- leukemic stem cell population in AML.
Methods
Isolation of CD34+38- and CD34+38+ hematopoietic cells
Bone marrow or granulocyte-colony stimulating factor (G-CSF) mobilized peripheral blood 
was obtained after informed consent from healthy bone marrow donors and patients with 
AML at diagnosis. Mononuclear cells were isolated by Ficoll 1.077 g/ml (Pharmacy Biotech, 
Uppsala, Sweden). Isolation, cryopreservation and thawing procedures of cells have 
been described previously(15) and were identical for normal and leukemic bone marrow 
samples. 
Cells were stained with CD34- CY5 or fluorescein isothiocyanate (FITC) and CD38- 
phycoerythrin (PE) monoclonal antibodies (Becton Dickinson, BV, Etten-Leur, The 
Netherlands) for 30 minutes at 4ºC and washed in Hank’s balanced salt solution (HBSS) 
with 1% v/v heat inactivated fetal calf serum (FCS, Hyclone, Logan, Utah, U.S.A.). A 
Coulter Epics Elite Flow cytometer was used to define cell populations. Gating on forward 
and right angle scatter was used to exclude dead cells and debris. CD34+CD38- cells of 
both normal bone marrow and AML were defined as the cells with CD38-PE fluorescence 
within the first decade of emission as shown in figure 1. CD34+CD38- cells appeared in a 
consistently restricted light-scattering region confirming the lymphoid appearance of these 
primitive progenitors(20). The CD34+CD38+ cells were sorted from a gate positioned in the 
bulk of CD34+ cells separated by a decade from CD34+38- cells as indicated in figure1 and 
showed more heterogeneous light-scattering properties. 
RNA isolation
Sorted cells were centrifuged at 1500 rpm for 5 minutes, and supernatant was removed 
completely. Total RNA was extracted using a Zymo research Mini RNA isolation II kit (Zymo 
research, USA) according to the manufacturer’s protocol. Reverse transcriptase PCR was 
performed using 5x 1st strand buffer (Life Technologies), DTT (10mM, Life Technologies), dN6 
(5mg/ml, Amersham Pharmacia Biotech), dNTP (0.625 mM, Amersham Pharmacia Biotech), 
Rnasin (20 U, Promega) and M-MLV reverse transcriptase (200 U, Life Technologies) in a 
total volume of 20 µl. The reaction mixture was incubated at 20°C for 10 minutes, at 42°C 
for 60 minutes followed by heat inactivation of the enzyme at 95°C for 10 minutes. Before 
storage at -80°C the cDNA was diluted in distilled water to a final volume of 100µl.
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Real-time RT-PCR
Design low-density array-microfluidic card
By using pre-configured Taqman low-density array-micro fluidic cards (Applied Biosystems, 
USA), 45 ABC transporters in combination with 3 housekeeping genes were quantified 
simultaneously by real time RT-PCR in single samples. Primer sets for real rime RT-PCR 
were designed by Applied Biosystems (http://myscience.appliedbiosystems.com/index.jsp) 
and spotted on the micro fluidic card. For quantification of each sample a 2x Taqman 
Universal mastermix and 50µl cDNA template was added to a total volume of 100 µl. PCR 
was performed in an Applied Biosystems 7900 HT Fast Real-time PCR sequence detector 
by 40 cycles of 30 seconds at 95°C and 1 minute at 60°C.
Quantitation of gene expression
Normalized drug-resistance related gene expression to the internal standard glyceraldehyde-
3-phosphate- dehydrogenase (GAPDH) is given by the following equation(21,22):
T0/R0= K. (1+E) (CT,r – CT,t)
To: Initial number of target gene copies; Ro: Initial number of standard gene copies; E; 
Efficiency of amplification; CT,t: Threshold cycle of target gene; CT, r: Threshold cycle of 
standard gene; and K: Constant. 
ABC transporter gene expression was quantitated relatively to housekeeping genes 
GAPDH, hydroxymethylbilane synthase (HMBS) and porphobilinogen dehydrogenase 
(PBGD). We earlier showed that GAPDH is an appropriate gene for standardization of 
target gene expression in human CD34+38- and CD34+38+ hematopoietic cell populations 
from normal bone marrow and AML(21)
Statistical analysis
Differences in normalized target gene expression between different hematopoietic 
subpopulations were calculated using the Student’s t-test with a level of significance op 
p<0.05.
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Results
ATP-binding cassette transporter gene expression in normal hematopoietic 
CD34+38- cells
Normalized levels of ABC transporter gene expression in CD34+38- cells
We assessed gene expression of 45 ABC-transporters by real-time RT-PCR using low-
density array microfluidic cards in normal CD34+38- cells of G-CSF-mobilized peripheral 
blood (n=8) or bone marrow (n=3) from allogeneic stem cell donors. CD34+38- cells were 
purified as described in the section “methods”. CD34+38- cDNA input varied between 
samples due to variability in number of cells available for sorting (average threshold 
cycle (Ct) GAPDH 24.18 ± 0.56 SEM; range 20.97-26.30). We have previously shown 
that GAPDH is an appropriate reference gene for normalizing target gene expression in 
CD34+38- hematopoietic cells with similar levels of expression in committed CD34+38+ 
progenitors in both normal bone marrow and AML(21). Normalized CD38 gene expression 
was 0.13 ± 0.02 copy CD38/copy GAPDH (mean ± SEM) and 0.39± 0.09 copy CD38/copy 
GAPDH for CD34+38- and CD34+38+ populations respectively, indicating a median 2.88 ± 
0.37-fold higher expression in CD34+38+ cells. 
Normalized levels of ABC transporter gene expression in comparison to GAPDH are shown 
in figure 1. Similar results were found when HMBS or PBGD were used as reference genes 
(data not shown). The expression of 36 ABC-transporters was detected in CD34+38- 
cells (figure 1). 24 ABC transporters were detected in all (11/11) samples. The lower 
frequency of expression in the other 12 ABC transporters is likely to reflect the relatively 
low expression level of these genes in addition to the lower amount of cDNA input in some 
samples, precluding the detection of these low-copy genes, rather than biological binary of 
expression. This is supported by the finding that genes with the highest level of expression 
were detected invariably in all samples and that low frequency ABC transporters are the 
genes with relative low expression levels (figure 1). This is further corroborated by the 
finding that in the sample with the highest input (Ct GAPDH 20.97) 34 transporters were 
detected (exceptions are ABCD2 and ABCC8). 
Levels of ABC transporter gene expression were generally low in comparison to GAPDH 
expression (mean expression level 0.059 ± 0.009 copies/copy GAPDH - 6.19.10-(5) copies/
copy GAPDH for highest (ABCC1) and lowest (ABCA8) expressed genes respectively). 
Highest levels of expression were found for ABCC1, ABCA2, ABCB2, ABCB7, ABCD4 
and ABCB1 respectively, confirming the relatively high expression of known stem cell 
transporters ABCB1/ MDR1 and ABCC1/MRP1. 
ABC-transporter gene expression levels were not significantly different in G-CSF mobilized 
CD34+38- cells in comparison to their counterparts in normal bone marrow (data not 
shown) with the exception of ABCB8 (copies ABCB8/copy GAPDH 0.014 ± 0.002 SEM 
vs. 0.003± 0.0004 respectively; p< 0.001) and ABCB5 that was detected in all G-CSF 
mobilized samples (8/8) but not in normal bone marrow (0/3). 
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Figure 1: ABC transporter gene expression in normal hematopoietic CD34+38- cells. Gene expression of 45 
ABC transporters was assessed in CD34+38- hematopoietic cells from G-CSF-mobilized peripheral blood or bone 
marrow (n=11) from allogeneic stem cell donors. Levels of gene expression are depicted as natural logarithmic 
values normalized for the expression of the housekeeping gene GAPDH. Mean values of gene expression of 
positive samples (± SEM) are represented by bars. On the X-axis frequency of expression (number of samples in 
which gene expression was detectable) is shown. 
ABC transporter gene expression in CD34+38- cells in comparison to committed 
CD34+38+ progenitors
Cellular decisions concerning differentiation are reflected in altered patterns of gene 
expression and therefore differential expression of genes in hematopoietic stem cells 
in comparison to committed progenitors may be more relevant for understanding the 
molecular events underlying normal and malignant hematopoiesis than absolute levels 
of gene expression. For this reason we compared ABC transporter gene expression in 
CD34+38- hematopoietic cells to the expression in committed CD34+38+ progenitors 
(figure 2).
All 36 ABC transporter genes that were detected in CD34+38- cells were preferentially 
expressed in CD34+38- cells in comparison to CD34+38+ committed progenitors, although 
expression of none of these genes was restricted to hematopoietic CD34+38- stem cells. 
This differential expression reached statistical significance, using student t-test for paired 
samples; p≤0.05) in 24 ABC transporter genes (figure 2). Among these significantly 
differential expressed genes were the anticipated transporters previously associated with 
hematopoietic stem cells ABCB1 (median 5.0-fold difference; p<0.001), ABCC1 (1.66-
fold; p=0.003) and ABCG2 (1.97- fold; p=0.005). Additionally, many ABC transporters not 
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previously associated with hematopoietic stem cell biology were identified that displayed 
significant differential expression in CD34+38- cells. In ranking order of differential 
expression: 1. ABCA13 (33.4-fold; p=0.05) 2. ABCA9 (30.1-fold; p=0.04), 3. ABCB5 (21.36-
fold; p=0.02), 4. ABCC6 (16.6-fold ; p=0.05), 5. ABCA10 (13.2-fold ; p=0.01), 6. ABCA6 
(9.0-fold ; p=0.004), 7.ABCA5 (5.4-fold ; p< 0.001) 8. ABCB4 (5.0-fold ; p=0.03), 9. ABCB1 
(5.0-fold p<0.01), 10. ABCG1 (4.5-fold ; p=0.01). 
In conclusion these results demonstrate that hematopoietic stem cells display differential 
expression of a large number of ABC-transporters, including many members not previously 
associated with stem cell biology. 
Figure 2: Differential expression of ABC-transporters in hematopoietic CD34+38- stem cells in 
comparison to committed CD34+38+ progenitors. Difference in levels of gene expression between CD34+38- 
and CD34+38+ cells is depicted at the y-axis as median X-fold difference in samples that expressed the ABC 
transporter in CD34+38- cells. Transporters for which differential expression reached statistical significance 
(paired analysis using student t-test for all samples; p<0.05) are indicated with an asterix. 
ABC transporter gene expression in CD34+38- hematopoietic progenitors in 
AML
The differential expression of many ABC transporter genes among which many genes 
associated with the extrusion of chemotherapeutical compounds and drug resistance 
prompted us to investigate the expression of these transporters in the leukemia- initiating 
CD34+38- cell population in AML. We and others have previously shown that these cells 
are predominantly of leukemic origin in the majority of samples(19,23).
ABC transporter gene expression was assessed by real-time PCR in CD34+38- cells from 
11 AML patients at diagnosis. Patient characteristics are listed in table 1. FAB M3 was not 
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included in this study because this subtype is not considered a disease originating from 
CD34+38- stem cells as evidenced by the failure of CD34+38- cells to engraft leukemia 
in the NOD-SCID model(5) . Samples were selected with a relatively high percentage of 
CD34+ cells in order to enable the sorting of sufficient CD34+38- cells for the quantitation 
of low-copy genes.
Table 1: Patient characteristics.
Patients 11
Age (median; range) 55 (10-72)
Sex
M
F
4
7
FAB subtype
Mo
M1
M2
M4
M5
2
3
2
2
2
CD34 % (median, range) 82 (19-90)
CD34+38- cells isolated from AML patients were comparable to normal CD34+38- cell 
samples regarding CD38 expression both on protein level (average MFI 9.6 ±2.24 and 8.4 
± 1.34 respectively, difference not significant) and CD38 gene expression (median 0.11 
± 0.06 copy CD38/copy GAPDH and 0.13 ± 0.02 copy CD38/copy GAPDH respectively; 
difference not significant). CD34+38- cDNA input was similar for AML and normal samples 
(average Ct GAPDH 23.47 ± 0.69 and 24.18 ±0.56 respectively). 
In CD34+38- cells in AML 40 ABC-transporter genes were expressed (figure 3). All genes 
expressed in normal CD34+38- cells were detected in CD34+38- cells in AML with the 
exception of ABCA8 that was detected in CD34+38- cells of 1/11 normal samples but not in 
CD34+38- cells in AML. Additionally 5 ABC transporters were detected with low frequency 
in AML but not in normal CD34+38- cells (ABCA4, ABCC7, ABCC9, ABCC11, and ABCG4). 
A significant difference in frequency of expression between normal and leukemic CD34+38- 
cells was found for ABCA13 (10/11 vs. 3/11 respectively; p< 0.001) and ABCB5 (8/11 vs. 
1/11 respectively p<0.001). 
Levels of expression of ABC transporters did not differ significantly between CD34+38- 
cells in AML and their normal counterparts for the majority of ABC transporters that 
were expressed in both normal and leukemic samples (31/35). Significant lower levels 
of expression in CD34+38- cells in AML were found for ABCA3 (mean 0.002 ± 0.001 
copy/copy GAPDH vs. 0.012 ±0.003; p=0.004), ABCA5 (0.005 ± 0.002 vs., 0.012 ± 0.003; 
p<0.001),ABCB1 (0.01 ± 0.002 vs. 0.03 ± 0.005; p<0.001) and ABCB7 (0.03 ± 0.006 vs. 
0.04 ± 0.006; p=0.04). 
ABC transporter gene expression profiles for individual AML samples are included in the in 
supplementary data.
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Figure 3: ABC transporter gene expression in CD34+38- cells in AML. Gene expression of 45 ABC 
transporters was assessed in CD34+38- hematopoietic cells from AML patients (n=11) at diagnosis. Levels of 
gene expression are depicted as natural logarithmic values normalized for the expression of the housekeeping 
gene GAPDH. Mean values of gene expression of positive samples (± SEM) are represented by bars. On the 
X-axis frequency of expression (number of samples in which gene expression was detectable) is shown. ABC 
transporters with significant different frequency or level of expression in comparison to normal CD34+38- cells are 
indicated with an asterix.
Similar to the expression pattern in normal CD34+38- cells, significant differential 
expression in comparison to CD34+38+ cells was found for most (27/40) ABC transporter 
genes detected in CD34+38- cells in AML. (figure 4) Together these results demonstrate that 
ABC transporter gene expression levels in hematopoietic stem cells and their differential 
expression in comparison to CD34+38+ cells is largely conserved in AML. 
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Figure 4: Differential expression of ABC-transporters in CD34+38- cells in comparison to CD34+38+ 
progenitors in AML Difference in levels of gene expression between CD34+38- and CD34+38+ cells is depicted 
at the y-axis as median X-fold difference in samples that expressed the ABC transporter in CD34+38- cells. 
Transporters for which differential expression reached statistical significance (paired analysis using student t-test 
for all samples; p<0.05) are indicated with an asterix. 
Expression of ABC transporter genes involved in drug resistance in CD34+38 
hematopoietic cells in AML
Failure to eradicate CD34+38- leukemic stem cells in AML is likely to result in disease 
relapse. Therefore elucidation of the mechanisms that confer chemoresistance to these 
cells is of crucial importance. Currently, 13 members of the ABC transporter family are 
associated with extrusion of chemotherapeutical compounds and drug resistance(24). 
Table 2 shows the expression of these genes in CD34+38- cells in AML. In addition to 
expected expression of ABCB1, ABCC1 and ABCG2, all other drug transport related ABC 
transporter genes were expressed in CD34+38- cells in AML at varying frequency. Six 
drug transport related genes were found in CD34+38- cells of all patients examined and a 
significant differential expression in CD34+38- cells in comparison to CD34+38+ cells was 
documented in 10/13 ABC transporters detected. 
These results demonstrate that the ABC transporter profile of leukemic CD34+38- cells 
includes many members implicated in drug extrusion and resistance in addition to the 
known stem cell ABC transporters ABCB1, ABCG2 and ABCC1. 
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Table 2: Expression of ABC transporter genes associated with extrusion of chemotherapeutical 
compounds in CD34+38- cells in AML
Gene
Frequency of 
expression (%) 
Level of expression
(copy/copy GAPDH)
Differential expression 
In comparison to 
CD34+38+cells
(median X-fold; p-value)
Chemotherapeutical 
compounds 
ABCA2 11/11 0.044± 0.014 3.51-fold; p=0.001 estramustine
ABCB1 11/11 0.011±0.002 4.19-fold; p< 0.001 anthracyclins, etoposide, 
imatinib, taxanes, 
mitoxantrone, vinca 
alkaloids
ABCB4 6/11 0.0004±0.0001 5.14-fold; p=0.022 paclitaxel, vinblastine
ABCB11 1/11 6.4.10-6 0.34-fold paclitaxel
ABCC1 11/11 0.027 ± 0.017 2.45-fold; p=0.014 anthracyclins, etoposide, 
methotrexate, 
ABCC2 10/11 0.0017 ±0.0012 5.01-fold; p=0.027 cisplatin, doxorubicin, 
etoposide, methotrexate, 
mitoxantrone, vinca 
alkaloids
ABCC3 3/11 0.0015±0.0006 56.47-fold; p=0.079 cisplatin, doxorubicin, 
etoposide, methotrexate, 
vinca alkaloids
ABCC4 11/11 0.0058 ± 0.0057 3.26-fold; p=0.046 methotrexate, thiopurines
ABCC5 11/11 0.011 ± 0.003 3.36-fold; p=0.007 6-mercaptopurine, 
6-thioguanine
ABCC6 8/11 0.0005 ± 0.0003 3.71-fold; p=0.048 anthracyclins, etoposide, 
teniposide
ABCC10 11/11 0.0041 ± 0.0018 3.35-fold; p=0.005 docetaxel, paclitaxel, vinca 
alkaloids
ABCC11 1/11 0.0002 ± 0.0002 751.94-fold purine and pyrimidine 
nucleotide analogs
ABCG2 6/11 0.0004 ± 0.0003 10.75-fold; p= 0.051 mitoxantrone, 
methotrexate, topetocan, 
SN-38, imatinib, 
flavopiridol, anthracyclins
Differential expression is depicted as the median value of the X-fold difference between CD34+38- and 
CD34+38+ cells in patients in which the gene is expressed in CD34+38- cells 
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Discussion
In this report we describe the ABC transporter gene expression profiling of normal 
CD34+38- hematopoietic cells using real-time RT-PCR on low-density micro-arrays. Using 
this approach we describe the differential expression of many, previously unrecognized 
ABC transporters on normal hematopoietic cells and conservation of expression pattern 
and levels after malignant transformation in AML.
Besides the known stem cell transporters ABCB1(6,25) and ABCG2(10,26), a number of 
other differentially expressed transcripts were anticipated based on reports from mouse 
hematopoietic stem cell gene profiling using high density affymetrix arrays. Ramalho et 
al(27), investigating mouse side population cells in comparison to the bone marrow main 
population using Affymetrix U74Av2 Showed that ABCG1, ABCG2, ABCB1, ABCB2, 
ABCB3, ABCB8, ABCD3, ABCF3 were differentially expressed in this hematopoietic 
stem cell population. All these genes that displayed differential expression in mouse SP 
cells were significantly differential expressed in normal CD34+38- cells in comparison to 
committed progenitors in our study. Similarly, gene profiling in fetal Sca+AA4.1+Kit+Lin- 
liver hematopoietic cells versus stem cell-depleted AA4.1- cells(28) identified 14 differentially 
expressed ABC transporters (ABCA1, ABCA2, ABCA5, ABCA7, ABCA13, ABCB1, ABCB2, 
ABCB9, ABCC1, ABCC4, ABCF3, ABCG1, ABCG3, ABCF2), all of which, when included, 
are differentially expressed in human CD34+38- cells in our study. (ABCG3 does not have 
a human ortholog).
Finally, Langmann et all(30) investigated ABC transporter gene expression using real time 
RT-PCR in a panel of human tissues including whole bone marrow (mixed RNA sample 
83 donors). Most ABC transporters were detected in bone marrow with exception of 
ABCA4, ABCB5, ABCB11, ABCC7, ABCC8, ABCC11, ABCC12, ABCG4, ABCG5 and 
ABCG8. Interestingly, of the 10 members not detected in whole bone marrow, in 7 
transporters we were not able to detect expression in CD34+38- cells indicating high 
concordance between these data sets. Two transporters in which no expression could 
be detected in the Langmann study (ABCB11 and ABCC8), showed expression in only 
the minority of samples in our study. The only exception was ABCB5 that was detected in 
8/11 samples in our study. Interestingly, however, ABCB5 was detected only in all G-CSF 
mobilized CD34+38- samples but not in NBM suggesting that expression of ABCB5 is 
G-CSF mobilization-related or a specific characteristic of peripheral blood hematopoietic 
stem cells. Interestingly, ABCB5 has been implicated in cell fusion of progenitor cells(31), 
opening the possibility that it is a specific characteristic of mobilized cells enabling them to 
participate in fusion events in peripheral tissues. 
Together these comparisons with reported expression of ABC transporter in hematopoietic 
stem cell populations show high concordance with the results from our study indicating 
great reliability of the “gold standard” real-time RT-PCR gene quantitation method used. 
In addition to the anticipated differentially expressed genes however, we identified a large 
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number of previously unrecognized ABC transporter genes that displayed differential 
expression in hematopoietic stem cells. 
The sensitivity of real-time PCR in comparison to cDNA and oligonucleotide arrays(32), 
especially in quantifying low-copy genes, likely explains the identification of these genes in 
the current study. It is noteworthy that many of the differentially expressed ABC transporter 
genes, not previously recognized, in CD34+38- cells are indeed low-copy genes when 
compared to the expression of the housekeeping gene GAPDH and are not detected above 
background in cDNA arrays. Additionally, the lack of necessity for mRNA amplification, the 
limited number of ABC transporters represented in some cDNA arrays and differences in 
cell populations studied (CD34+38- versus the more heterogeneous side-population and 
CD34+38+ versus whole bone marrow in other studies) could explain the identification of 
novel differentially expressed transcripts in hematopoietic cells in this study.
The identification of many previously unrecognized ABC transporters with differential 
expression in hematopoietic stem cells raises questions about the physiological function 
in these cells. In addition to protection of these long-lived cells to naturally occurring 
xenobiotics, a role in stem cell biology for ABC transporters has been suggested based 
on studies in Dictyostelium demonstrating that a rhodamine-123 cellular efflux pump with 
the properties of a ABC-transporter prevents differentiation of prespore cells(33) through 
efflux of a differentiation inducing factor.The results presented in this study suggested 
that hematopoietic stem cells may escape the effect of differentiation factors present in 
the bone marrow through extrusion of these factors by ABC transporters. However, no 
such role has been demonstrated for the ABC-transporters currently identified on human 
(hematopoietic) stem cells. It remains to be determined whether novel transporters identified 
in this study serve such function in human hematopoietic cells. Interestingly, among the 
ranking order 10 most differentially expressed ABC transporters 5 members of the ABCA 
family are listed (ABCA5, ABCA6, ABCA9, ABCA10 and ABCA13). Interestingly, four of 
these genes (ABCA5, A6, A9 and A10) are arranged in a cluster on chromosome 17q24 
representing a phylogenetically distinct subgroup within the ABCA gene subfamily(34,35). 
Though the substrates and function of these ABCA transporters are currently unknown, 
recent studies have led to the concept that some of these transporters may serve critical 
physiological functions in the transmembrane transport of endogenous lipid substrates 
such as phospholipids and essential fatty-acids, substrates involved in the regulation of 
differentiation of hematopoietic cells. (reviewed in(36)). Additionally, ABCA13 has recently 
been shown to have a putative promoter sequence containing multiple binding sites for 
hematopoietic stem cell transcription factors suggesting a key role in hematopoiesis(37). 
Clearly, further research is warranted to elucidate the role of these ABCA transporters in 
stem cell biology and is currently ongoing at our laboratory.
Regardless their role in stem cell biology, conserved expression of ABC transporters 
involved in drug extrusion after malignant transformation of hematopoietic stem cell in 
AML, as demonstrated in this study, could greatly impede sensitivity of these cells to 
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chemotherapeutical eradication. In this study we demonstrated expression of all 13 ABC 
transporter members currently associated with drug resistance(24). However, given the 
high structure similarity of ABC transporters it is conceivable that additional members 
will be associated with drug resistance. A recent study examining ABC-transporter gene 
expression in drug-selected cancer cell lines demonstrated over expression of a number of 
transporters thus far not recognized as associated with drug resistance (ABCA4, ABCA7, 
ABCB2, ABCB3, ABCB6, ABCB8, ABCB9, ABCC6, ABCG1)(17) suggesting that these 
transporters are involved in drug resistance as well. Interestingly, all these additional 
transporters are expressed in a differential fashion in CD34+38- hematopoietic stem cells 
in AML as well. Obviously, care has to be taken in extrapolating these gene expression 
data to clinical drug resistance since gene expression will not necessarily reflect protein 
expression and function but our data suggest that drug efflux mediated drug resistance 
of leukemic stem cells is conferred by many members of the ABC family of membrane 
transporters with possibly promiscuous action on different chemotherapeutical compounds. 
Modulation of additional transporters is therefore likely to be required to increase drug 
accumulation and induce chemotherapeutical eradication of leukemic stem cells in AML. 
These data have too be taken into account when interpreting the largely poor results of 
ABCB1 modulation on long-term disease outcome in clinical trials(38,39). 
Additionally, the similar patterns of ABC-transporter expression in normal and leukemic 
hematopoietic stem cells predict that modulation of these transporters in AML as a 
therapeutic strategy to target leukemic stem cells will target residual normal hematopoietic 
stem cells as well and is therefore likely to encounter increased bone marrow toxicity. 
Nevertheless, the identification of previously unrecognized ABC transporters in leukemic 
stem cells offer the basis for future studies investigating the role of these ABC transporters 
in resistance of leukemic stem cells and their usefulness as therapeutical targets to 
eradicate this crucial cell population in AML.
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Appendix: ABC transporter profiles of CD34+38- cells from 11 patients with AML at diagnosis. Graphs 
represent relative expression (copies target gene/copy GAPDH; upper graphs) and expression in comparison to 
committed CD34+38+ cells (fold-difference; lower graph).
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Abstract
This study was undertaken to assess the significance of lung-resistance related protein 
(LRP) expression in plasma cells from untreated multiple myeloma (MM) patients and 
to determine whether LRP was associated with a poor response and survival in patients 
treated with different dose regimens of melphalan. Seventy untreated patients received 
conventional oral dose melphalan (0.25 mg/kg, day 1 to 4) combined with prednisone (MP) 
or intravenous intermediate IDM; 70 mg/m2) or high- (140 mg/m2) dose Melphalan (HDM). 
LRP expression was assessed with immunocytochemistry using the LRP-56 monoclonal 
antibody. LRP expression was found in 47% of patients. In the MP treated patients, LRP 
expression was a significant prognostic factor regarding response induction (P < .05), event 
free survival (P < .003), and overall survival (P < .001). In the intensified dose melphalan 
treated patients LRP did not have a prognostic value. The response rates of LRP-positive 
patients to MP and IDM/HDM were 18% versus 81%, respectively (P < .0001). We conclude 
that LRP is frequently expressed in untreated MM patients and is an independent predictor 
for response and survival in patients treated with MP. Pretreatment assessment of LRP 
identifies a subpopulation of patients with a poor probability of response to conventional 
dose melphalan. Dose intensification of melphalan is likely to overcome LRP-mediated 
resistance.
Introduction
Alkylating agents and corticosteroids are still the mainstay of therapy for patients with 
multiple myeloma (MM).(1,2) However, only approximately 50% to 60% of patients respond 
to oral melphalan and prednisone in conventional dose resulting in a median response 
duration of 1 to 2 years and a median survival of about 3 to 4 years. Dose-intensification 
studies have shown a dose-response relationship for melphalan(3-5) in MM; therefore, high-
dose melphalan has been used to improve response rates and survival.
Melphalan, like other alkylating agents, exerts its cytotoxic effect through the covalent 
linkage of alkyl groups to DNA. Resistance against alkylating agents includes both cellular 
and extracellular factors. In cell line studies resistance to melphalan has been attributed 
to a decreased drug uptake caused by alterations in either the number or the affinity of 
membrane-bound proteins.(6) An alternative explanation may be an increased cellular 
detoxifcation by glutathione S-transferases.(7) So far, studies in hematological malignancies 
such as MM have failed to show a role of these laboratory findings in clinical specimens.(8) 
Multiple drug resistance (MDR) has been identifed as an important path of drug resistance 
in MM. MDR is the phenomenon of cancer cells developing cross-resistance to a 
variety of structurally unrelated chemotherapeutic compounds such as vinca-alkaloids, 
anthracyclines, and epipodophyllotoxins.(9) MDR is associated with the expression of 
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the drug transport mediating proteins P-glycoprotein (PgP) and the multidrug resistance-
related protein (MRP).(10) The increasing evidence of additional mechanisms of MDR led 
recently to the identifcation of a novel protein associated with MDR, originally termed the 
lung-resistance protein (LRP).
The LRP gene has recently been cloned and identifed as the human p110 major vault 
protein.(11) Vaults are novel cellular organelles first described by Kedersha and Rome in 
1986,(12) which are thought to mediate intracellular transport of a wide variety of substrates. 
LRP has been found to be widely distributed in human normal tissues and in tumors, 
closely reflecting the susceptibility to chemotherapy of different tumor types.(13) Importantly, 
recent studies in myeloma and other human cancer cell lines relate LRP expression to 
resistance against the alkylating agent melphalan(14,15) (and W.S. Dalton et al, personal 
communication, July 1997).
In the current study we have assessed LRP expression in myeloma patients, and based 
on these results we introduce this MDR-related protein as a putative important marker of 
clinical resistance to the alkylating agent melphalan resulting in an adverse prognosis. 
Moreover, we describe the overcoming of LRP-related resistance against melphalan by 
dose intensification.
Patients and methods
The study was performed on nonselected, sequentially stored frozen cytocentrifuge 
slides prepared from Ficoll-Hypaque-purifed bone marrow aspirates obtained from all MM 
patients with newly diagnosed disease who were treated with melphalan-based regimens 
between January 1987 and November 1995.
Additionally, bone marrow aspirates of three normal donors for allogeneic bone marrow 
transplantation (BMT) and the aspirates of five patients with monoclonal gammopathy of 
undetermined significance (MGUS) were studies for LRP expression.
Patients
Seventy unselected patients treated at the Departments of Haematology of the University 
Hospital Utrecht or the University Hospital Rotterdam Dijkzigt were studied. Clinical staging 
was defined according to the criteria proposed by Salmon and Durie.(16) Median age of 
patients treated with conventional-dose oral melphalan and prednisone was 67 years. 
Patients treated with intravenous (IV) intermediate or high-dose melphalan were median 
52 years. The performance status was determined according to the criteria of the Eastern 
Cooperative Oncology Group (ECOG): 0, normal; 1, ambulant with symptoms; 2, bedrest 
less than 50% of the day; 3, bedrest greater than 50% of the day; 4, bedrest all day. The 
patient characteristics are summarized in Table 1.
132
_____ CHAPTER 7 _____________________________________________________________________________________________________ ________________________________________________________________________________________ LRP IN MULTIPLE MYELOMA _____ 
133
Table 1: Patient Characteristics.
ALL IDM/HDM* MP†
No. patients 70 32 38
Age
  Median
  Range
61
34-86
52
35-65
67
35-85
Sex (male:female) 44:26 18:14 26:12
M-component
  IgG
  IgA
  IgD
  LCD
44
16
1
9
22
  7
  3
22
  9
  1
  6
k:λ 41:29 19:13 22:16
Stage:
  II-A
  III-A
  III-B
13
50
  7
  5
25
  2
  8
25
  5
Performance status (ECOG)
  0
  1
  2
  3
  4
  9
22
21
13
  5
  4
  9
  9
  7
  3
  5
13
12
  6
  2
Abbreviation: LCD, light chain disease.
*Patients treated with 2 courses of intravenous intermediate dose melphalan, 70 mg/m2 with an interval of 6 
weeks (n = 20) or a single IV high-dose melphalan, 140 mg/m2 (n = 12).
†Patients treated with intermittent oral melphalan 0.25 mg/kg/d and prednisone 2 mg/kg/d.
Chemotherapy regimens and response evaluation
Patients received melphalan as first-line treatment, either in combination with prednisone 
(MP, 38 patients) or as monotherapy in intermediate dose (IDM, 20 patients) or high dose 
(HDM, 12 patients). Patients under 65 years of age were candidates for IDM or HDM, 
unless they refused intensive treatment. Patients refusing intensive treatment and patients 
over 65 years received MP. Performance status was no selection criterium for treatment 
modality. The intermittent MP regimen consisted of oral melphalan 0.25 mg/kg/d and 
prednisone 2 mg/kg/d administered for 4 days. Courses were repeated every 6 weeks.
IDM (melphalan 70 mg/m2) was administered by rapid IV infusion. Two courses of IDM 
were given with an interval of 6 weeks.(17) The HDM regimen (140 mg/m2) consisted of a 
single dose. Response was determined by standard criteria for myeloma response.(18) A 
partial response was defined as a reduction of at least 50% in serum M protein or urinary 
light chain concentration with no progression of lytic bone lesions, without increase of bone 
pain or anemia. A complete response (CR) was defined as complete disappearance of 
myeloma proteins from serum and urine and normalization of the bone marrow. Response 
in patients treated with MP was determined after 4 courses, or earlier when progression 
was obvious. When a partial response (≥50% reduction in M protein) was achieved, 
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therapy was continued for at least 1 year. Patients with a minimal response (between 25% 
and 50% reduction in M protein) received another four courses. Patients unresponsive 
after four courses (less than 25% reduction in M-protein concentration) and patients with 
a minimal response after four courses but no further improvement of response after eight 
courses, continued with secondline chemotherapy, usually a combination of vincristine, 
adriamycin, and dexamethasone (VAD). Patients treated with IDM or HDM were evaluated 
2 months after the second IDM or single-dose HDM, respectively. Nonresponding patients 
were also treated with VAD.
Immunocytochemical staining of LRP
LRP expression was determined by an alkaline phosphatase immunocytochemical 
detection method(19) using the specific murine monoclonal antibody (MoAb) LRP-56 (IgG2b) 
that was obtained after immunization of mice with the non-Pgp multidrug-resistant human 
nonsmall lung cancer cell line SW-1573/2R120.(14) Bone marrow cells were separated 
by Ficoll-Hypaque, washed twice with minimal essential medium (MEM; GIBCO, Grand 
Island, NY) and stored at -20°C until use. Cytocentrifuged slides were airdried overnight 
and fixed in acetone for 10 minutes.
After preincubation for 20 minutes with 10% rabbit serum in phosphate-buffered 
saline plus 1% bovine serum albumin (PBS/BSA; Sigma Chemical Co, St Louis, MO), 
cytospins were incubated with LRP-56 (diluted 1:500 in 1% BSA) or with idiotype 
matched control (nonspecific mouse IgG-1; Cappel: Organon Teknica 50327/36345) 
for 1.5 hours. Next, rabbit anti-mouse immunoglobulin (RAM; Dakopatts Z 259, DAKO 
Corp, Glastrup, Denmark) diluted 1:25 for 1 hour was added followed by incubation with 
alkaline phosphatase substrate (APAAP; Dakopatts D 651, DAKO), diluted 1:50 for 1 
hour. Incubations with RAM and APAAP were repeated for 0.5 hour. The color reaction 
was produced using a Neufuchsin (Merck 4041; Merck, Darmstadt, Germany) substrate 
incubating for 40 minutes. All incubations were performed at room temperature. Between 
incubation steps, slides were washed thoroughly in PBS for 10 minutes. Finally, cytospins 
were counterstained in diluted hematoxilin and washed with tap water. Simultaneously, the 
LRP-positive fibrosarcoma HT1080 DR4 control cell line(20) was stained as control for the 
immunocytochemical assay.
All slides were examined and scored independently by two observers, blinded to the 
clinical data. Plasma cells were identified on morphological criteria. At least 250 plasma 
cells were evaluated. A sample was considered to be LRP-positive if ≥10% of the plasma 
cells stained with the LRP-56 antibody and the idiotype matched controls were indeed 
negative. These criteria were based on previous experience with LRP-56 staining in 155 
cancer specimens, which indicated that a 10% cut-off value may distinguish two groups of 
LRP-expressing tumors.(13,21)
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Determination of prognostic factors
The serum B2-microglobulin level was determined by means of a competitive enzyme 
immunoassay (Phadezym; Pharmacia, Uppsala, Sweden). The plasma cell labeling index 
(LI) was measured by the incorporation of bromodeoxyuridine as described previously.(22) 
Serum levels of lactate dehydrogenase (LDH) were measured according to standard 
methods.
Statistical analysis
Data analysis was performed using the SPSS statistical software package (SPSS Inc, 
Chicago, IL).
Prognostic parameters such as age were determined at diagnosis and were retrospectively 
assessed for their relationship with LRP expression. The response rates were compared 
between LRP and prognostic factors expression groups. Qualitative variables were 
analyzed using the chi-squared test. Multivariate analysis was performed using step-
wise discriminant analysis. Overall survival was measured in months from the moment of 
diagnosis, providing 95% confidence intervals. Actuarial survival curves were estimated 
using the Kaplan-Meier method,(23) and differences in survival between subgroups were 
compared with the log-rank test (Mantel-Cox).(24) Also, the hazard rates for each variable 
were calculated with the Cox-regression model using enter and remove limits of 0.05 and 
0.1. Hypotheses were evaluated at a significance level of 0.05. Two-sided statistical tests 
were used in all analyses.
Results
Frequency and pattern of LRP expression
LRP was expressed in 47% (33/70) of bone marrow samples of patients with newly 
diagnosed myeloma. In the MP-treated population 47% (17/38) of patients were LRP 
positive as compared with 50% (16/32) in the IDM/HDM-treated population. The staining 
of the LRP-56 MoAb in the LRP-positive myeloma cells was invariably cytoplasmatic 
in the perinuclear region, in a granular fashion (Figure 1). The intensity of the staining 
was generally strong, but variance in staining intensity was too small to justify objective 
classification between aspirates. LRP expression in positive bone marrow samples was 
heterogeneous, typically showing LRP-56 immunoreactivity in the majority of myeloma 
cells (median 50%, range 10 to 90). There were no samples with LRP expression in less 
than 10% of the plasma cells. LRP was not expressed in plasma cells of normal donors (0/
3) or patients with MGUS (0/5). In the majority of MM patients, LRP expression was found 
in granulocytic marrow components, irrespective of expression on plasma cells.
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Figure 1: Alkaline phosphatase immunocytohistochemical staining using the MoAb LRP-56 of 
cytocentrifuged bone marrow cells containing >95% plasma cells of a patient with multiple myeloma. 
Cytospins were counterstained in diluted hemotoxiline. LRP immunoreactivity in a granular fashion in the 
cytoplasm is present in almost all plasma cells (A). Isotype control is negative (B).
Correlation with established prognostic factors
Using previously defined cut-off levels we studied the distribution of the plasma cell LI%, 
serum B2-microglobulin level, and serum LDH in relation to plasma cell LRP expression. 
The cut-off level for LI was ≥2%,(25) for B2-microglobulin ≥4 µg/mL,(26) and for LDH ≥300 
U/L.(26) LRP expression was associated with high LDH levels at diagnosis (X2, P = .05). 
LRP did not correlate with serum B2-microglobulin (P = .1), plasma cell LI% (P = .07), or 
age (P = .9).
LRP expression and response to melphalan chemotherapy
The response to chemotherapy consisting of MP or IDM/HDM is summarized in Table 
2; in 38 patients treated with standard MP the overall response rate was 37% (14/38). 
There were no complete remissions obtained with MP. In this group, LRP expression was 
associated with a poor response to induction treatment. Fifty-two percent (11/21) of the 
LRP-negative patients achieved a remission as compared with 18% (3/17) of the patients 
with LRP-positive myeloma at diagnosis (X2, P = .027). By univariate analysis, bone 
marrow plasma cell LI, serum B2-microglobulin, and serum LDH did not have a significant 
prognostic value regarding the response to MP therapy (Table 2).
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A remission was achieved in 84% (27/32) of the patients treated with intensified dose 
melphalan, including 8 patients who achieved a CR (25%). No significant difference 
was found between the response rate in the LRP-negative patients (88%, 14/16) and 
the LRP positive population (81%, 13/16; P = .285). The subgroups of LRP-positive and 
LRP-negative IDM/HDMtreated patients showed no statistically significant differences in 
distribution of LDH, LI%, B2-microglobulin, or age. A comparison of responses between 
the two regimens in LRP-positive patients showed a significant higher response rate with 
IDM/ HDM as compared with MP (81% v 18%, P <.0001). In LRP-negative patients a better 
response rate with IDM/HDM (88% v 52%, P = .006) was also observed.
Expression of LRP and survival
Kaplan-Meier survival curves of LRP-positive and LRP-negative patients are presented in 
Figures 2 through 4. An inverse correlation was found between LRP expression and survival 
duration. In the complete group, the median survival of LRP-positive patients was 28 
months (95%-Cl: 23 to 33), whereas the median survival duration of LRP negative patients 
was 54 months (Cl: 26 to 82; P <.002; hazard ratio [HR] = 2.9 (1.4-5.7); Table 2, Fig 2). This 
difference was likely caused by the 38 MP-treated patients who had a median survival 40 
months in LRP-negative (95%-Cl: 41 to 69) and 22 months in LRP-positive patients (95%-
Cl: 18 to 26; P = .0006, HR = 4.1 (1.7-9.8); Table 2, Fig 3). In the IDM/HDM-treated patients 
no significant difference in survival between LRP-positive and LRP-negative patients was 
observed (median survival 69 months [95%-Cl 14 to 124]) in LRP-negative patients and not 
reached in LRP-positive patients (P = .365, HR = 1.7 [0.5-5.9; Table 2, Fig 4]).
By univariate analysis LRP (P <.002) was the strongest adverse prognostic marker 
for survival in the whole population followed by bone marrow plasma LI, serum B2-
microglobulin, and serum LDH (Table 2). In MP-treated patients high serum LDH (P = 
.0001) and LRP expression (P <.0006) both had an adverse effect on survival (Table 2).
Multivariate analysis showed that in the whole population (50 cases available for analysis) 
only LRP expression was an independent prognostic factor (P = .03). In the subgroup 
of MP-treated patients (25 cases available) LRP (P = .03) and serum LDH (P = .0001) 
remained statistically significant for survival. In the patients treated with IDM/HDM none of 
the prognostic factors affected survival. Age had no prognostic significance for survival by 
either univariate or multivariate analysis.
In the subgroup of responding patients we performed statistical analysis regarding event-
free survival (EFS). Within the responding MP-treated patients, the EFS was remarkable 
shorter in LRP-positive patients. Three LRP-positive patients treated with MP relapsed 
after 6, 7, and 15 months, respectively (median 7 months, 95%-Cl: 5 to 9), whereas the 
EFS of LRP-negative MP-treated patients was median 24 months (n = 11, 95%-Cl; 16 to 
32; P <.003). EFS of IDM/HDMtreated LRP-positive patients was median 22 months (n 
= 14, 95%-Cl: 14 to 30) versus 24 months (n = 13, 95%-Cl: 15 to 33; P = .182) for LRP-
negative patients.
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Figure 2: Patients treated with melphalan, either at conventional dose and combined with prednisone or 
administered as an intensified (70/140 mg/m2 IV). Probability of survival from the start of treatment.
Figure 3: Patients treated with conventional melphalan and prednisone. Probability of survival from the 
start of treatment.
Figure 4: Patients treated with IV intensified melphalan (70/140 mg/m2 IV). Probability of survival from the 
start of treatment.
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Discussion
Our findings indicate that LRP is widely expressed in untreated MM and that it is 
associated with a low probability of response and a shorter survival in patients treated with 
a conventional MP regimen. LRP positivity was found in 47% of the patients with newly 
diagnosed MM. This figure is consistent with data indicating the widespread expression 
of LRP in untreated human malignancies.(13) Multivariate analysis showed that LRP was 
an adverse prognostic marker that was independent for serum B2-microglobulin, bone 
marrow plasma cell LI, serum LDH, and age. Interestingly, LRP-related resistance to 
MP may initially be overcome by dose intensification of melphalan as suggested by the 
outcome of patients treated with IDM and HDM.
These observations add proof to the recent in vitro and clinical studies identifying LRP 
as an independent predictor for chemoresistance against melphalan. Studies undertaken 
to assess the in vitro sensitivity of the RPMI, 8226 human myeloma cell line to several 
cytotoxic drugs showed that by exposure to melphalan an MDR subline emerged, termed 
8226 LR5, which is resistant to melphalan and highly upregulates LRP expression in 
absence of other MDR proteins (showing a drug accumulation defect). Also exposure to 
mitoxantrone resulted in a highly LRP-positive cell population (8226 MR40), which showed 
additional resistance to melphalan, again in absence of other MDR-related proteins (W.S. 
Dalton et al, personal communication, July 1997).
Moreover, in human cancer cell lines derived from 8 cancer types, using 
immunocytohistochemical detection methods, a significant correlation between LRP 
expression in these cancer types and in vitro sensitivity to melphalan was found. No 
correlation was found between the expression of other MDRrelated proteins and melphalan 
sensitivity.(15) These in vitro results are in line with our clinical finding of an association 
between LRP expression on myeloma cells in untreated patients and lack of response to 
oral melphalan chemotherapy in these patients.
Further evidence for the relationship of LRP with chemoresistance to both classical and 
MDR-related drugs is provided by several recent clinical studies. In patients with adult 
myeloid leukemia(27) and patients with FIGO stage III/IV ovarian cancer,(21) LRP expression 
of malignant cells was significantly correlated with inferior response to chemotherapy, 
including cisplatin and alkylating agents, and with shorter overall survival.
The precise mechanism of LRP-related chemoresistance, however, is still unsolved. To 
date the biological function of LRP as a major constituent of the human vault protein is 
unknown. A small fraction of vaults are localized to the nuclear membrane and nuclear pore 
complexes, raising the possibility that vaults mediate the bidirectional transport of a variety 
of substrates between the nucleus and the cytoplasm.(28) In support of this view, entrapment 
of drugs in exocytotic vesicles and decreased nuclear to cytoplasmic drug ratios were 
reported in LRP-overexpressing multidrug resistant cells.(29,30) Interestingly, melphalan and 
cisplatin exert their main cytotoxic effect in the cell nucleus having very similar modes of 
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action on nucleic acids. This makes it tempting to hypothesize that vaults are involved in 
the nucleo-cytoplasmic exchange of these drugs.
Our findings cannot exclude that LRP is a pleiotropic marker of resistance coexpressed 
with other (MDR-related) drug resistance genes. In this study we did not assess the 
expression of other MDR-related proteins, ie, Pgp and MRP. Therefore, no conclusion can 
be drawn on the individual roles of each resistance protein in these MM samples. However, 
we and others found that PgP is expressed in very low frequency (<5%) in untreated MM 
and has no prognostic value at that stage.(31,32) In contrast, PgP is highly expressed in 
VAD-refractory MM,(31,33) whereas MRP is not expressed above background values in the 
majority of MM samples.(34) Moreover, in in vitro experiments and clinical studies MDR and 
MRP did not confer resistance to melphalan.(15,21)
Obviously other nonclassical MDR transport mechanisms of resistance must be involved in 
MM, which may explain why resistance occurs in LRP-negative patients.
An alternate conclusion from the adverse prognostic value of LRP in patients treated with 
the MP regimen could be an inverse relation between LRP expression and the sensitivity of 
myeloma cells to corticosteroids. Previous studies have shown that steroid dose intensity 
is one of the most important predictors of treatment outcome. Considering this, the use 
of prednisone in patients receiving oral melphalan is an important difference between the 
treatment groups. However, recent in vitro studies in acute lymphocytic leukemia using 
flow cytometry and a methylthiotetrazole (MTT) assay have shown a lack of relation 
between LRP expression and resistance to prednisolone (M.L. den Boer et al, Department 
of Paediatrics, Free University Hospital, Amsterdam, The Netherlands, personal 
communication, January 1997). In addition to a potential role in chemoresistance LRP may 
be associated with a biologically more aggressive state of MM. This is not only suggested 
by the fact that EFS of LRP-positive patients tended to be shorter but also by the relation 
between LRP and elevated LDH levels in untreated disease. LRP did not correlate with 
serum B2-microglobulin, LI, or age. High LDH levels in untreated MM have been related to 
high tumor mass, unusual clinical features like extraosseous masses, and hypodiploidy or 
low RNA content of plasma cells, possibly reflecting a late stage of myeloma transformation 
and a poor clinical outcome.(26) Also in our study MP-treated patients with elevated LDH 
levels survived significantly shorter. More detailed studies on the relation of LRP with 
clinipathological and cytogenetic parameters in MM are therefore warranted.
Our findings are clinically important because LRP-related resistance to the MP regimen 
may be circumvented by dose intensification of melphalan. LRP-positive patients had a 
significant better response to IDM/HDM as compared with MP. The dose-response relation 
for melphalan has been widely documented, and dose escalation has been clinically applied 
in recent years.(3-5) In general, previously untreated patients have superior response rates 
to intensive regimens as compared with MP, and remissions are of good quality.(5) Our 
results indicate that assessment of the LRP status might identify a patient population that 
can initially benefit from dose intensification and in which this regimen could be considered 
as a first-line treatment above the MP regimen.
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In conclusion, in this study we assessed the expression of LRP in untreated myeloma and 
introduce this novel drug resistance-related protein as a prognostic factor for response 
to the MP regimen and survival. Moreover, we report that LRP-associated resistance to 
melphalan may be circumvented by dose intensification, creating the possibility to select 
patients who benefit from these regimens. Further studies on the expression of LRP and 
other mechanisms of drug resistance seem warranted to confirm these results and to clarify 
the functional characterization and the biological role of LRP in myeloma and other tumor 
types.
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Abstract
The Breast Cancer Resistance Protein (BCRP/ABCG2) is an ATP-binding-cassette 
transporter involved in the transport of drugs used in the treatment of multiple myeloma 
(MM). Its expression, function and clinical significance in MM, however, are unknown. We 
report that BCRP is preferentially expressed and functionally active in normal plasma cells 
but that its function is significantly impaired in plasma cells in newly diagnosed MM. The 
data presented argue against a role for BCRP in primary drug resistance in MM and the 
utilisation as a molecular target as such but warrant research into its (patho)physiological 
role in normal and malignant plasma cells.
Introduction
Multiple drug resistance (MDR) is a major obstacle for response to chemotherapy in patients 
with multiple myeloma (MM). MDR in MM has been associated with drug efflux by the ATP-
binding cassette (ABC) transporter P-glycoprotein (ABCB1) and expression of the lung 
resistance-related protein (LRP)(1). Studies in the multidrug resistant 8226 myeloma cell line 
have demonstrated additional mechanisms involved in the MDR phenotype of malignant 
plasma cells including an additional energy-dependent drug efflux pump(2), identified as 
the breast cancer resistance protein (BCRP/ABCG2)(3). BCRP is a 655-aa member of the 
ABCG subfamily of ABC- membrane transporters encoded by the BCRP gene and confers 
multidrug resistance to topotecan, mitoxantrone, doxorubicin and other anthracyclins 
by ATP dependent drug extrusion. Recent findings suggest that BCRP may also play a 
role in the transport of steroids(4), one of the main drugs in anti-myeloma treatment. The 
expression of BCRP in myeloma cell lines and its involvement in transporting anthracyclins 
steroids suggest that BCRP could be involved in drug resistance against these agents in 
MM. This prompted us to investigate BCRP expression, function and role in resistance to 
vincristine, adriamycin and dexamethasone (VAD) chemotherapy in de novo MM. 
Methods
Bone marrow samples and plasma cells
Bone marrow was obtained after informed consent from healthy allogeneic bone marrow 
donors and MM patients at diagnosis. Patient characteristics are shown in table 1. 
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Table 1: Patient characteristics, BCRP expression, BCRP mediated mitoxantrone transport and response 
to VAD treatment. 
Nr Age Sex Stage Ig
BCRP
(BXP21/IgG)
BCRP efflux 
(EI)
MDR1 efflux 
(EI)
Initial 
treatment Response
1. 59 M III-a IgG-k 3.68 1.13 0.97 VAD CR
2. 50 M III-a IgA-l 7.79 0.98 1.35 VAD PR
3. 64 F II-a IgA-l 7.29 0.92 1.01 VAD PR
4. 59 M III-a IgG-k 7.31 1.03 1.51 VAD PD
5. 58 M III-a IgA-k 7.71 1.09 1.24 VAD CR
6. 61 F III-a BJ-k 4.58 1.29 1.25 VAD PR
7. 43 F III-a IgA-l 2.85 1.06 1.12 VAD CR
8. 39 M II-a IgG-k 3.88 1.07 1.25 VAD SD
9. 58 M III-b IgG-k 2.40 1.01 1.13 VAD PR
10 63 M II-a IgA-k 3.79 1.01 1.05 VAD SD
CR=complete remission; PR=partial remission; SD=stable disease; PD=progressive disease
All patients received vincristine, adriamycin and dexamethasone (VAD) chemotherapy as 
initial treatment. Response was evaluated after 3 courses according to the criteria of the 
Eastern Cooperative Oncology Group (ECOG). Isolation, cryopreservation and thawing 
procedures of cells have been described previously(5). Plasma cells were identified as 
CD38hi, side scatterhi cells (figure1). 
Figure 1: BCRP mediated mitoxantrone efflux in normal and malignant plasma cells. Typical examples of 
CD34-FITC and CD38-PE labeled bone marrow mononuclear cells in normal bone marrow (NBM) and multiple 
myeloma (MM). Plasma cells (PC) were defined as CD38hi, side scatterhi cells. Inhibition of BCRP by the 
fumitremorgin C analog KO143 significantly increases mitoxantrone fluorescence in normal but not in malignant 
plasma cells, indicating deficient drug efflux in the latter. (NI=no inhibitor)
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Plasma cell nature was confirmed with the specific monoclonal antibody VS38c (data 
not shown) and the number was correlated with the number of plasma cells identified 
morphologically on cytospins in MM patients. 
BCRP expression and function
BCRP was detected as described previously(5) using the BXP21 monoclonal antibody (2.5 
ug/ml) in a three-color flowcytometric assay using fluorescein (FITC)-conjugated goat 
anti mouse F(ab)2 fragments (5.0 ug/ml), CY5-conjugated CD34 and phycoerythrin (PE)-
conjugated CD38 and quantified as the median fluorescence channel shift (BXP21/Isotype 
control). CD34 was included in all flowcytometric analyses to allow comparison of BCRP 
expression and function in plasma cells with CD34 cell populations and to allow CD34+ and 
CD34- cells to serve as internal controls.
BCRP function was tested flow-cytometrically using mitoxantrone as a substrate and the 
fumitremorgin C (FTC) analog KO143 as an inhibitor for BCRP as described previously (5) ; 
KO143 (0.1 uM) is the most potent inhibitor currently available and, importantly, is BCRP-
specific (without inhibition of MDR1 or MRP). BCRP mediated efflux was quantified as 
the mitoxantrone fluorescence (MFI) shift in the presence/absence of KO143 (depicted as 
efflux index) and assessed in CD38hi/ SSchi, CD34+ and CD34- cells as defined (figure 1). 
At least 2000 events were evaluated in each cell population. 
P-glycoprotein (MDR1/ABCB1) mediated drug efflux
Flow cytometric assessment of P-glycoprotein mediated mitoxantrone efflux was performed 
as described above using verapamil (Knoll AG, Ludwigshaven, Germany (20 ug/ml) as 
inhibitor for P-glycoprotein mediated efflux instead of KO143. 
Statistical analysis
Differences in expression and function between cell populations and normal and malignant 
plasma cells were calculated using the student t-test with a level of significance of p ≤ 0.05.
Results
BCRP is preferentially expressed and functionally active in normal plasma 
cells
BCRP was expressed in plasma cells in all normal bone marrow samples examined (n=10) 
(figure 2A). The average BCRP expression (BXP21/ Isotype control) was 5.58 ± 0.70 
(S.E.M) (range 3.10 -10.24). Expression was significantly higher in plasma cells compared 
to other CD34- cells (mean BXP21/Isotype control 2.92 ± 0.52, p=0.002; range 1.60-
6.08) in all samples examined and was similar to the expression in CD34+ hematopoietic 
progenitors (mean 6.18 ± 0.77, p=0.13; range 4.04-10.93). 
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BCRP mediated efflux was significantly higher in plasma cells (mean efflux index 1.20 ± 
0.06 SEM, range 0.9-1.53) than in both CD34- cells (mean efflux index 1.03 ± 0.04, range 
0.75-1.11; p< 0.001) and CD34+ hematopoietic cells (mean efflux index 1.07 ± 0.04, range 
0.89-1.37; p< 0.001) in all samples examined (figure 2B). 
The contribution of BCRP to mitoxantrone efflux in plasma cells was similar to P-glycoprotein 
mediated efflux (efflux index 1.22 ± 0.05, range 1.01-1.56; NS) (figure 2C). Together these 
results indicate that BCRP is preferentially expressed and functionally active in human 
normal plasma cells and mediates mitoxantrone efflux in these cells in cooperation with 
P-glycoprotein mediated transport.
BCRP mediated drug transport is impaired in plasma cells in multiple 
myeloma
The preferential expression and activity of BCRP in normal plasma cells and its possible 
implications for primary drug resistance in MM, prompted us to investigate BCRP 
expression and function in in malignant plasma cells in MM at diagnosis. BCRP was 
detected on plasma cells in all MM samples examined (n=10) (figure 2A). 
Expression was similar to the expression in normal plasma cells (mean BXP-21/ isotype 
control 5.13 ± 0.68, range 2.40-7.79; NS). BCRP mediated mitoxantrone efflux, however, 
was significantly impaired in malignant plasma cells compared to their normal counterparts 
(mean efflux index 1.06 ± 0.03, range 0.92-1.29; p=0.02) (figure 1 and 2B). BCRP mediated 
efflux in CD34- and CD34+ cells in MM did not significantly differ from normal bone marrow 
and therefore provided a suitable internal control for BCRP efflux assessment in MM 
samples. Together these results indicate that BCRP mediated drug efflux, which is an 
intrinsic characteristic of normal plasma cells, is impaired in malignant plasma cells in the 
majority of MM patients. 
P-glycoprotein mediated efflux, in contrast, was unaltered in malignant plasma cells 
compared to plasma cells in normal bone marrow (mean efflux index 1.19 ± 0.05, range 
0.97-1.51; difference ns) (figure 2C), indicating that intrinsic P-glycoprotein mediated efflux 
is the more important determinant of mitoxantrone accumulation in malignant plasma 
cells. 
In line with the deficient function of the protein, no correlation was found between BCRP 
expression and response to initial VAD treatment (table1); 3/4 patients with high BCRP 
expression (arbitrarily defined as BXP-21/Isotype ≥ 5.0) responded to treatment compared 
to 4/6 patients with low BCRP expression. Additionally, responses were achieved in the 
two patients that displayed significant BCRP mediated efflux in their plasma cells, arguing 
against an important role for BCRP in clinical resistance to VAD treatment in MM patients.
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Figure 2: BCRP mediated drug efflux is impaired in malignant plasma cells. BCRP expression (A), BCRP 
mediated drug efflux (B) and P-glycoprotein mediated drug efflux (C) in human normal and malignant plasma 
cells. Average values (±SEM) are given for cell populations in normal bone marrow (grey bars) and multiple 
myeloma (open bars). Individual samples are represented by dots. Efflux indices (EI) ≤ 1.00 are indicated on 
the x-axis. Significant differences (p<0.05) in comparison to normal plasma cells (grey bars in far left corner) are 
indicated with an asterix.
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Discussion
In this report we demonstrate that the ATP-binding cassette transporter ABCG2/BCRP 
is preferentially expressed and functionally active in human normal plasma cells. BCRP 
expression in bone marrow cells is thought to be restricted to a small population of 
hematopoietic stem cells(6). Strikingly, BCRP mediated efflux in plasma cells exceeded the 
rate of transport observed in highly purified CD34+38- stem cells(5) , raising questions about 
the physiological function of the protein in these highly specialized cells. Intriguingly, cells 
with constitutive BCRP expression such as epithelial cells of the digestive tract, biliary ducts 
and the mammary gland, are all sites at which apico-luminal transport of immunoglobulins 
takes place. Together these data warrant further research into the role of BCRP in plasma 
cells and its possible involvement in immunoglobulin secretion.
BCRP mediated drug transport was found to be impaired in plasma cells in MM. Interestingly, 
deficient transport function in malignant plasma cells has been described before and been 
attributed to dysfunction of P-glycoprotein(7). These authors investigated P-glycoprotein 
function using cyclosporin A as an inhibitor. Cyclosporin A has later been shown to be a 
more promiscuous inhibitor with effects both on P-glycoprotein and BCRP. The findings 
described in this paper suggest that impaired function of BCRP likely accounts at least 
partly for the deficient transporter function in plasma cells observed by these authors. 
The mechanisms behind impaired BCRP mediated drug efflux in malignant plasma cells 
remain to be elucidated; MM is characterised by genetic instability in plasma cells and it 
is conceivable that mutations in the BCRP gene, that have been shown to alter substrate 
specificity, are responsible for impaired mitoxantrone transport. Alternatively, impaired 
BCRP mediated drug transport in malignant plasma cells could reflect competitive 
engagement of the protein in other processes in these cells. Involvement in secretion of 
autocrine factors such as interleukins, which is frequently observed in MM, and has been 
described for ATP-binding-cassette transporters(8), could explain impaired drug efflux by 
BCRP. The possibility of alternate functions of BCRP in malignant plasma cells, related to 
disease pathogenesis, prompts further research.
Regardless the underlying mechanism, impaired BCRP mediated drug transport is likely 
to undermine its role in drug resistance in MM; This is supported by the lack of relation 
between BCRP expression and response to initial VAD chemotherapy in this study. Though 
the number of patients was small, the combined in vitro and clinical data argue against a 
role for BCRP in drug resistance in de novo MM and the utilisation of BCRP modulators to 
circumvent it. 
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Summary
Acute myeloid leukemia (AML) is considered a disease originating from hematopoietic 
CD34+38- stem cells. The recognition of AML and other forms of cancer as stem cell 
diseases propagates a paradigm shift in the treatment of leukemia away from targeting the 
blast cells and towards targeting the LSC. 
The high expression of ABC-transporters involved in the extrusion of chemotherapeutical 
compounds on normal (hematopoietic) stem cells could have major consequences for 
the treatment of leukemia. If ABC transporter expression and function is conserved 
after malignant transformation of stem cells, this would be a major mechanism of drug 
resistance to these cells and prevent chemotherapeutical eradication of this tumor-initiating 
cell population. In the paradigm shift for the treatment of leukemia, ABC drug transport 
inhibitors might be thought of as “leukemia stem cell sensitizing agent” that allow the most 
crucial and drug-resistant cells in the leukemia-hierarchy to be destroyed. Whether ABC 
expression and function is conserved, however, is currently unknown. Though expression 
and function of ABCB1 and ABCG2 have been widely studied in AML, there is a remarkable 
lack of studies addressing expression and function in the critical CD34+38- hematopoietic 
stem cell population. Additionally, no studies exist aimed at comparing ABC transporter 
function between normal and malignant hematopoietic cells. The goal of the research 
performed and described in this thesis was to gain insight into the expression, function and 
role in drug resistance of ABC transporters in CD34+38- hematopoietic stem cells in AML 
in comparison to their normal counterparts. 
The first two chapters of this thesis are dedicated to the development and validation 
of essentials tools required to study ABC transporter expression and function in highly 
purified hematopoietic cells, precluding the use of standard protocols because of the small 
numbers of cells available for study;
In chapter 2 we present the use of a real-time quantitative RT-PCR method for the precise 
quantitation of gene expression in small subsets of human hematopoietic cells. Combining 
modified RNA isolation and adjusted PCR-protocols with the sensitivity and accuracy of real-
time quantitative PCR we were able to detect and to quantitate low-copy gene expression 
without the need of prior cDNA amplification or nested-PCR strategies in as little as 300 
highly purified CD34+38- hematopoietic cells from both normal bone marrow and AML. 
Validation experiments in cell lines showed efficient, representative and reproducible gene 
amplification using 300-cell real-time quantitative RT-PCR. Sensitivity was confirmed in 
dilution experiments and by the detection of the low-copy gene PBGD. GAPDH was found 
a useful reference gene in normal and leukemic CD34+CD38- cells. 18S rRNA, in contrast, 
varied 100-1000-fold in these populations, showing its inappropriateness as a reference 
gene in these progenitors. Finally, using this method we showed the preferential expression 
of ABCB1, ABCC1 and LRP in normal CD34+38- cells. The technique described in this 
study has facilitated other experiments addressing gene expression in hematopoietic stem 
cells both in our lab (chapter IV, V and VI) and in other labs(1). 
158
_____ CHAPTER 9 _____________________________________________________________________________________________________ ______________________________________________________________________________________ SUMMARY AND PERSPECTIVES _____ 
159
Chapter 3 describes the development of a method to study ABC transporter mediated efflux 
in highly purified single CD34+38- hematopoietic stem cells. We used epifluorescence 
microscopy in combination with single cell image analysis to quantify ABC transporter 
mediated efflux in CD34+38- cells sorted on adhesive biolayers. ABCB1 and ABCC1 
mediated efflux were quantified using fluorescent substrates (rhodamine 123 and calcein-
AM) and specific inhibitors (verapamil and probenecid). This method proved feasible and 
reproducible, although sensitivity is reduced in comparison to standard flow-cytometrical 
assessment of functional, ABC transporter conferred, efflux. Using single cell image analysis 
we demonstrated that ABCB1 is preferentially active in CD34+38- cells in comparison to 
committed CD34+38+ cells (in line with gene expression studies as described in chapter 
2) and the major molecular determinant of the rhodamine 123 dull phenotype of these 
cells. Additionally, significant ABCC1 mediated efflux was demonstrated in CD34+38- 
hematopoietic stem cells. 
In Chapter 4 and 5 we investigated expression and functional activity of ABCB1 and 
ABCG2 in hematopoietic CD34+38- hematopoietic stem cells in AML in comparison to 
their normal counterparts. We emphasized on studying ABCB1 and ABCG2 since these 
transporters are highly expressed on a variety of human stem cells and their wide substrate 
specificity includes drugs used in the treatment of AML (i.e. anthracyclins, mitoxantrone, 
vinca alkaloids). 
In chapter 4 we studied ABCB1 expression and function in CD34+38- cells in AML in 
comparison to their counterparts in human normal bone marrow. We demonstrate that 
ABCB1 is the major molecular determinant of the mitoxantrone and rhodamine123 dull 
phenotype of CD34+38- cells in normal bone marrow as evidenced by the blockage of 
transport of these compounds by ABCB1 inhibitors verapamil and PSC-833. Surprisingly, 
ABCB1 mediated transport was invariably impaired in the CD34+38- hematopoietic cell 
population in AML regardless of disease subtype. Impaired ABCB1 mediated transport 
preceded the development of leukemia in patients suffering from refractory anemia but was 
not found in autologous transplanted cells from patients in long-term remission constituting 
normal hematopoiesis, demonstrating that it is an early leukemic rather than a preleukemic 
characteristic of normal CD34+38- cells. In line with this, proof of principle is reported that 
ABCB1 efflux capacity can identify a subpopulation with residual normal CD34+38- cells 
in AML. Importantly, ABCB1 modulation abrogated drug efflux in normal but not leukemic 
CD34+38- cells due to activity of additional drug transporters in leukemic cells. 
Together these results demonstrate that reduced ABCB1 mediated transport in CD34+38- 
hematopoietic cells is an early characteristic and biological commonality of leukemic 
CD34+38- cells in AML. ABCB1 mediated efflux may identify a subpopulation of residual 
normal CD34+38- cells in this disease. These findings and the observation that redundant 
transport mechanisms, not inhibitable by ABCB1 modulators, mediate drug extrusion from 
leukemic CD34+38- cells, have to be taken into account when interpreting the overall 
disappointing results on ABCB1 modulation in clinical trials in AML. 
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The purpose of the investigations described in chapter 5 was to investigate the role of the 
Breast Cancer resistance Protein (BCRP/ABCG2) in drug resistance of leukemic stem cells 
and the effect of its modulation on stem cell eradication in AML.
BCRP was preferentially expressed (measured flow-cytometrically using the BXP21 
monoclonal antibody) in leukemic CD34+38- cells which represented a conserved 
physiological function after malignant transformation. Blockage of BCRP mediated drug 
extrusion by the novel fumitremorgin C analog KO143 resulted in increased intracellular 
mitoxantrone accumulation in these cells in the majority of patients. This increase, however, 
was much lower than in the mitoxantrone resistant breast cancer cell line MCF7-MR and 
significant drug extrusion occurred in the presence of BCRP blockage due to the presence 
of additional drug transport mechanisms, among which ABCB1 and ABCC1 (MRP). In 
line with these findings, selective blockage of BCRP by KO143 did not enhance in vitro 
chemosensitivity of leukemic CD34+38- cells. 
These results confirm that drug extrusion from leukemic stem cells is mediated by the 
promiscuous action of ABCB1, ABCG2 and additional transporters. 
The observation that additional drug efflux mechanisms are active in leukemic CD34+38- 
stem cells prompted us to investigate the expression of other ABC transporter in these 
cells.
In chapter 4 and 5 we found that in leukemic CD34+38- cells additional drug transport 
mechanisms are active to extrude chemotherapeutiacal compounds. To identify these 
drug efflux mechanisms, in chapter 6, we studied gene expression of 45 ABC-transporters 
(the complete ABCA, B, C, D and G family) in human hematopoietic CD34+38- cells in 
comparison to committed CD34+38+ progenitors in normal G-CSF mobilized and bone 
marrow cells (n=12) and their malignant counterparts in AML (n=10). Gene expression 
was assessed with a novel real-time quantitative RT-PCR approach using microfluidic 
low-density arrays. In normal CD34+38- cells 36 transporters were expressed of which 
24 displayed significant differential expression in comparison to committed progenitors. In 
addition to known stem cell transporters (ABCB1, ABCG2 and ABCC1) these differentially 
expressed genes included many members not previously associated with stem cell biology 
such as the family of ABCA6-like ABC transporters clustered on chromosome 17. The 
ABC transporter gene expression profile of CD34+38- cells was largely conserved in 
AML (although exceptions occurred) and included expression of all 13 members currently 
associated with drug extrusion and resistance. These data suggest an important role for 
previously unrecognized ABC-transporters in hematopoietic stem cell biology. Additionally, 
the identification of many, previously unidentified, drug transporters in leukemic stem cells 
prompts further research to test their role in drug resistance and value as potential new 
targets to enhance chemotherapeutical eradication of leukemic stem cells in AML
In the studies described in chapter 2-6, CD34 and CD38 membrane markers were used to 
identify hematopoietic stem cells from bone marrow. CD38 not only identifies populations 
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of hematopoietic stem cells but is also used to identify the CD34-38+++ plasma cells in 
bone marrow. Chapter 7 and 8 describe the expression and clinical significance of the 
drug resistance genes ABCG2 and the Lung Resistance related Protein (LRP) in CD34-
38+++ plasma cells in normal bone marrow and in their malignant counterparts in multiple 
myeloma. Chapter 7 describes the expression and clinical significance of LRP, a protein 
associated with MDR (multiple drug resistance) in myeloma. It is demonstrated that LRP 
is frequently expressed in plasma cells in untreated disease and that it is an important 
negative prognostic factor regarding response induction, event free survival and overall 
survival in patients treated with convential dose melphalan and prednisone . Interestingly, 
dose intensification (intravenous intermediate/high dose melphalan) abrogated the 
prognostic significance of LRP likely by overcoming LRP mediated drug resistance of 
malignant plasma cells. LRP thus identifies a subpopulation of myeloma patients with a 
poor probability of response to standard MP chemotherapy (18%) that could benefit from 
dose intensification (response rate 81%). In chapter 8 it is demonstrated that ABCG2 is 
preferentially expressed and functionally active in normal plasma cells but that its function is 
significantly impaired in plasma cells in newly diagnosed MM. In line with deficient function 
of the protein in malignant plasma cells, no relation was found between ABCG2 expression 
and response to VAD chemotherapy. The data presented argue against a role for ABCG2 
in primary drug resistance in multiple myeloma and the utilization as a molecular target as 
such.
Concluding remarks and perspectives
I.  ABC transporters and drug resistance of leukemic stem cells: Implications for the 
 clinical use of ABC transporter modulation and future research
In this thesis it is demonstrated that in primitive leukemic CD34+38- cells ABCB1 mediated 
transport is reduced in comparison to normal hematopoietic stem cells. ABCB1 mediated 
drug efflux identifies residual normal hematopoietic stem cells in AML. Additionally it is 
shown that drug efflux in leukemic CD34+38- cells is conferred by the simultaneous action 
of many, previously unrecognized, redundant ABC transporters. What implications do 
these laboratory findings have on the current practice of ABCB1 modulation to enhance 
chemosensitivity of leukemic (stem) cells in AML? Based on these laboratory lessons 
it seems justified to critically re-assess the use of ABCB1 modulation as a therapeutic 
strategy in AML from the standing point of the leukemic stem cells asking three questions. 
1. Is ABCB1 modulation an effective strategy to eradicate leukemic stem cells?
 Extrapolating these in vitro data it seems unlikely that modulation of a single drug 
efflux mechanism, such as ABCB1 or ABCG2, will result in sufficient increase in drug 
accumulation, circumvent drug resistance and eventually eradicate this leukemic stem 
cell population. Additionally, in this context, it has to be realized that drug extrusion 
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is only one way of cancer cells to evade chemotoxicity. Many other mechanisms are 
probably active and it is reasonable to assume that these mechanisms, in parallel to 
ABC transporters, preferentially protect the long lived hematopoietic stem cells and their 
malignant counterparts(2).
2. Is ABCB1 modulation a leukemia- specific targeting therapy?
 The data in this thesis demonstrate that ABCB1 mediated drug efflux identifies a 
population of residual normal stem cells in AML. In leukemic CD34+38- cells ABCB1 
efflux is actually reduced in comparison to their normal counterparts. These findings 
demonstrate that ABCB1 modulation is not a leukemia-specific targeted therapy and 
in fact, may preferentially target normal rather than leukemic stem cells. Additionally, 
although not the subject of this thesis, ABCB1 modulation targets its physiological role 
in many other tissues especially those involved in drug detoxification.
 The negative answers to both answers challenge the rationale for the use of ABCB1 
modulation as a strategy to target leukemic stem cells in AML and have to be taken 
into account when interpreting the disappointing results from clinical trials showing no 
benefit of ABCB1 modulation at the cost of increased toxicity. The clinical observation 
that ABCB1 modulation has not resulted in increased overall and relapse free survival in 
AML, as would be anticipated if ABC drug transport inhibitors function as “leukemia stem 
cell sensitizing agent” that kill the leukemia-initiating cell population, seems congruent 
with the laboratory findings described in this thesis.
 On the other hand our data do not definitely exclude the possibility that “true” leukemic 
stem cells harbor in the ABCB1 mediated CD34+38- mitoxantrone dull population that is 
described in chapter 4 of this thesis. This would imply that ABCB1 mediated drug efflux 
(or rather verapamil and PSC inhibitable drug efflux) is indeed the major xenobiotic 
transport mechanism in these cells, despite the expression of other ABC transporters, 
comparable to normal hematopoietic stem cells. To definitively address this question 
NOD-SCID experiments need to be performed transplanting the CD34+38- mitoxantrone 
dull population to see whether it engrafts normal or leukemic hematopoiesis. If true 
leukemic stem cells harbor in the ABCB1 efflux ++ population, ABCB1 modulation is 
likely to augment chemotherapy induced eradication of leukemic stem cells and could 
be related to improved OS but this will be at the cost of severe hematological toxicity.
3. Does challenging the role of ABCB1 in drug resistance of leukemic stem cells dismiss 
the value of ABCB1 as a prognostic marker in AML, one of the hallmark rationales for 
ABCB1 modulation in this disease? 
 First it has to be stated that its prognostic significance is demonstrated for induction of 
remission, a prognostic value for DFS and OS is less clear. When extrapolated to the 
hierarchy of AML it is conceivable that ABCB1 modulation can enhance chemosensitivity 
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of the bulk of leukemic blasts but not the leukemic stem cell population that is protected 
by redundant mechanisms. Indeed, our observations in chapter 4 demonstrated that 
ABCB1 modulation is capable of abrogating mitoxantrone efflux from CD34+38+ cells 
but not the CD34+38- leukemia-initiating cell population. This will result in remission 
induction but eventually relapse will occur from the leukemic stem cell population. 
 Alternatively, it is conceivable that expression and activity of ABCB1 is a pleiotropic 
marker of prognosis; it may be a marker of immature (CD34+38-) leukemias as 
suggested by the differential expression of ABCB1 in CD34+38- cells as demonstrated 
in chapter IV. These cells are likely characterized by the conserved function of other 
innate drug resistance and anti-apoptotic mechanisms that protect primitive progenitor 
cells, including many drug-resistance related ABC-transporters as demonstrated in 
chapter VI. The prognostic value of ABCB1 may reflect the innate drug resistance 
conferred by these associated drug resistance and anti-apoptotic mechanisms, rather 
than functional activity of a single drug extrusion mechanism. The observation that 
ABCB1 is not upregulated at relapse and that ABCB1 related clonal selection does not 
occur after failure of standard therapy is congruent with these alternative explanations 
of the prognostic value of ABCB1 in AML.
Future studies investigating the role of ABC transporter in chemoresistance of 
malignant stem cells 
The observation that drug efflux in leukemic CD34+38- cells is conferred by the 
simultaneous action of several redundant transport mechanisms suggests that the use of 
broad-spectrum inhibitors for ABC transporter modulation is required for the eradication 
leukemic stem cells rather than the modulation of single efflux mechanisms. However, the 
strategy of broad spectrum modulation of ABC transporters is likely to encounter enhanced 
hematological toxicity since the expression of the majority of these transporters in leukemic 
stem cells represents a conserved physiological function of normal hematopoietic stem 
cells as demonstrated in this thesis. Additionally non-hematological toxicity is anticipated 
since many of these transporters serve important functions in detoxification processes. 
Therefore it is essential to first elucidate the role of the novel stem cell transporters identified 
in this thesis in drug resistance of leukemic stem cells. Studies comparing ABC transporter 
profiles in refractory leukemia and at relapse will be of crucial importance to identify those 
transporters involved in clinical drug resistance and relapse and are currently ongoing at 
our laboratory. Additionally, in vitro and in vivo studies using ABC transporter-null mice 
could give definitive insights into the role of individual ABC transporters in (malignant) stem 
cell protection against chemotherapeutical agents.
It will be important to unravel the regulatory pathways of ABC transporter expression 
in normal and malignant hematopoietic stem cells to identify specific targets that may 
distinguish leukemic stem cells from their normal counterparts and ABC transporter 
regulatory pathways in other tissues and their stem cells. 
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Finally, when performing these investigations it remains important to realize that ABC 
transporters are only a player in the wide spectrum of drug resistance in cancer stem 
cells. These long-lived cells are likely to be naturally resistant to chemotherapy through 
their quiescence, precluding efficacy of drugs that target either the cell cycle or rapidly 
dividing cells, their capacity for DNA repair and reluctance to enter apoptosis. Tackling drug 
resistance in cancer requires ongoing research into all mechanisms of drug resistance 
which should continue focusing on the cancer stem cell rather than (or in addition to) its 
progeny to offer future patients an increasing change on cure from this disease. 
II.  ABC transporters and stem cell biology
Besides determining the role of ABC transporters in drug resistance of cancer stem cells, 
an even greater challenge for future research will be the elucidation of the physiological 
function of these molecules in human normal and malignant stem cells. Characterization 
of molecules with tightly controlled expression patterns during differentiation represents an 
important approach to understanding regulation of hematopoietic stem cell commitment. In 
this thesis we describe the expression of many ABC transporters not previously associated 
with stem cell biology in hematopoietic stem cells. The physiological function of these 
ABC transporters in human stem cell biology is currently unknown. Important insights 
to its potential function has come from studies in Dictyostelium demonstrating that a 
rhodamine-123 cellular efflux pump with the properties of an ABC transporter prevents 
differentiation of prespore cells(3), possibly by exporting differentiating factors from the 
cell interior. This led to the hypothesis that a cell’s response to a signal that can diffuse 
across the plasma membrane depends, in part, on the cell’s ability to remove it from the 
cytoplasm. According to this hypothesis, hematopoietic stem cells might escape the effect 
of cell fate determination and differentiation factors present in the bone marrow. The idea 
that ABC transporters regulate the cellular concentration of signaling molecules may prove 
to be a general way for developing organisms to control their response to signals and 
regulate cell fate decisions. However, no such a role has been demonstrated for the ABC-
transporters identified on human (hematopoietic) stem cells thus far. The ABC transporter 
gene expression profile of hematopoietic stem cells as described in chapter 6 of this 
thesis has revealed a number of transporter candidates that may serve these functions in 
human stem cells. The differential expression of 5 members of the ABCA family (ABCA6-
like subfamily on chromosome 17q24 and ABCA13) within the top ten ranking order of 
differentially expressed ABC transporter genes may be of particular importance since 
recent studies have led to the concept that transporters of the ABCA subclass serve critical 
physiological functions in the transmembrane transport of endogenous lipid substrates 
such as phospolipids and essential fatty-acids, substrates involved in the regulation of 
differentiation of hematopoietic cells (reviewed in(4)). 
It will be important to establish a “stemness” profile for ABC transporters, investigating 
their expression not only in hematopoietic stem cells but also stem cells from different 
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sources, including mesenchymal and embryonic stem cells. These investigations will 
identify ABC transporters that are crucial to stem cell biology. Subsequently the role of 
these transporters, including the ABCA6-like family members, in stem cell biology and 
hematopoiesis must be characterized functionally using both in vitro RNA inhibition and 
vector overexpression studies and in vivo transplantation models. These studies are 
currently ongoing at our laboratory. The increasing recognition that cancer originates from 
normal stem cells prompts these investigations since the developmental programs that 
regulate gene expression profiles are tightly controlled and may lead to cancer if perturbed. 
It is conceivable that molecules involved in cell fate decisions and differentiation of these 
stem cells have a key role in carcinogenesis, a process characterized by the failure of 
differentiation. Consequently, members with aberrant expression in malignant stem cells, 
such as ABCA13 as described in chapter 6, are among the first candidates that functional 
characterization. 
Ultimately, elucidation of the role of ABC transporters in and stem cells biology and 
malignant hematopoiesis may provide novel targets for stem cell eradication in leukemia 
and other forms of cancer independent from their role in drug resistance. 
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Nederlandse samenvatting 
Acute myeloide leukemie is een beenmergziekte die onstaat door maligne transformatie van 
normale bloedvormende stamcellen. Deze veranderingen in de normale hematopoietische 
stamcel leiden uiteindelijk tot leukemie, gekenmerkt door opeenstapeling van grote 
hoeveelheden leukocyten in beenmerg en perifeer bloed. De leukemische stamcel kan 
gezien worden als de “moedercel” en onderhoudt de leukemische kloon. Incomplete 
eradicatie van de leukemische stamcel zal uiteindelijk leiden tot relapse van de ziekte. Dit 
wordt frequent waargenomen in patienten met AML waarbij meestal wel een remissie wordt 
bereikt maar vaak later een relapse optreedt. Kennelijk zijn de huidige chemotherapeutische 
behandelingen derhalve wel in staat tot eradicatie van de bulk van leukemische cellen 
maar overleeft de leukemische stamcel. Inzicht in de mechanismen waarmee deze cel 
zich verdedigt tegen chemotherapeutische behandeling en de ontwikkeling van strategieen 
om deze mechanismen te omzeilen zijn daarom van cruciaal belang in de toekomstige 
behandeling van AML en waarschijnlijk vele andere vormen van kanker.
Een van de mechanismen waarmee de leukemische stamcel zich zou kunnen vededigen 
tegen chemotherapeutische behandelingen is de expressie van membraaneiwitten die een 
groot aantal structureel onverwante stoffen, waaronder vele chemotherapeutica, de cel 
uitpompen, de zogenaamde ATP-binding cassette (ABC) transporters. 
Doel van dit proefschrift is inzicht te krijgen in de rol van ABC transporters in de resistentie 
van leukemische stamcellen tegen chemotherapie en het effect van ABC transporter 
modulatie op stamcel-eradicatie in AML.
Onderzoek van resistentie-mechanismen in leukemische stamcellen wordt bemoeilijkt 
door het zeer zeldzame karakter van deze cellen in normaal en leukemisch beenmerg. 
Ongeveer 1/ 100.000-1000.000 cellen in beenmerg betreft een stamcel. “Standaard” 
onderzoeksmethoden zijn niet toepasbaar op zulke kleine aantallen cellen. De eerste 
twee hoofdstukken van dit proefschrift beschrijven de ontwikkeling van methodologie om 
het onderzoek naar de expressie en functie van ABC-transporters in hematopoietische 
stamcellen mogelijk te maken. 
In hoofdstuk 2 wordt de ontwikkeling beschreven van een real-time quantitatieve reverse-
transcriptase polymerase chain reaction (real-time RT-PCR) techniek voor het precies 
kwantificeren van genexpresie in kleine hematopoietische celpopulaties die sterk verrijkt 
zijn voor normale en leukemische stamcellen. In deze techniek worden kleine aantallen 
hematopoietische progenitorcellen, gekenmerkt door membraanexpressie van CD34 maar 
afwezigheid van CD38 (CD34+38-), flow-cytometrisch gesorteerd. Door een gemodificeerde 
RNA isolatie-procedure en PCR-protocol te combineren met de sensitiviteit en precisie van 
real-time quantitatieve RT-PCR, kunnen genen die laag tot expressie komen kwantitatief 
gedetecteerd worden in slechts 300 normale of leukemische CD34+38- cellen, zonder de 
noodzaak tot cDNA amplificatie of “nested” PCR technieken. Validatie experimenten in 
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cellijnen laten efficiente, representatieve en reproduceerbare gen-amplificatie zien met 
behulp van deze 300-cell RT-PCR methode. De sensitiviteit ervan werd bevestigd in 
cDNA dilutie-experimenten en detectie van het low-copy gen PBGD. GAPDH bleek een 
geschikt referentie-gen voor de relatieve kwantificering van targetgenen omdat het gelijke 
niveaus van expressie heeft in zowel normale als leukemische CD34+38- cellen en hun 
meer gedifferentieerde CD34+38+ nakomelingen. De expressie van ribosomaal RNA 
(18S), een veelgebruikt referentiegen, daarentegen bleek 100-1000 voudig te varieren 
en is daarom ongeschikt als referentiegen in deze celpopulaties. Tot slot tonen we met 
behulp van deze nieuwe RT-PCR techniek de preferentiele expressie aan van de ABC-
transporters ABCB1 en ABCC1 in normale hematopoietische stamcellen in vergelijking tot 
meer gedifferentieerde CD34+38+ cellen.
Hoofdstuk 3 beschrijft de ontwikkeling van een methode om ABC-transporter gemedieerde 
efflux in CD34+38- hemtopoietische progenitorcellen te bestuderen. ABC tranporter 
gemedieerde efllux wordt gekwantificeerd in gesorteerde en op biolayers geimmobiliseerde 
CD34+38- cellen met behulp van epi-fluorescentie-microscopie en beeld-analyse van 
individuele cellen. De activiteit van specifieke ABC transporters ( ABCB1 en ABCC1) 
wordt bepaald door specifieke fluorescente substraten ( rhodamine 123 en calceine-AM 
respectievelijk) in combinatie met specifieke inhibitoren van deze pompen (verapamil 
en probenecid). Deze methode bleek goed uitvoerbaar en reproduceerbaar, hoewel de 
sensitiviteit van fluorescentie-microscopie minder was dan van flow-cytometrische bepaling 
van efflux van fluorescente substaten. Aangetoond wordt dat ABCB1 is de belangrijkste 
rhodamine-123 transporter is in normale CD34+38- cellen en dat, in overeenkomst met de 
genexpressieprofielen uit hoofdstuk 1, ook ABCC1 preferentieel actief is in deze cellen.
De resultaten van het onderzoek beschreven in hoofdstuk 2 en 3 postuleren ABCB1, 
in overeenkomst met data in de literatuur, als een belangrijke transporter in normale 
CD34+38- cellen. De geconserveerde expressie en functie van deze drug-transporter 
na maligne transformatie in AML zou een belangrijk reistentiemechanisme vormen 
tegen chemotherapeutische eradicatie van de leukemische stamcel in AML. Of ABCB1 
inderdaad geconserveerd is en wat het effect is van de modulatie van deze transporter om 
de accumulatie van chemotherapie in de leukemische stamcel cel is het onderwerp van 
studie in hoofdstuk 4.
In dit hoofdstuk bestudeerden we ABCB1 expressie en functie in leukemische CD34+38- 
cellen in vergelijking tot hun normale tegenhangers. De resultaten bevestigen dat 
ABCB1 de belangrijkste transporter van rhodamine 123 en het chemotherapeuticum 
mitoxantrone is in normale CD34+38- cellen. Inhibitie van ABCB1 met verapamil en PSC-
833 leidde tot blokkade van het transport van deze stoffen uit deze cellen. In tegenstelling 
tot onze veronderstellingen bleek dit echter niet het geval in leukemische CD34+38- 
cellen. ABCB1 gemedieerde efflux was zonder uitzondering verminderd in deze cellen 
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ondanks vergelijkbare membraanexpressie van het eiwit. Inhibitie van ABCB1 leidde 
niet tot blokkade van efflux in deze cellen, wijzend op de aanwezigheid van additionele, 
redundante, mitoxantrone transporters in leukemische stamcellen. Van belang, residuaal 
normale CD34+38- cellen konden in AML beenmerg geidentificeerd worden op basis van 
hun geconserveerde ABCB1 gemedieerde mitoxantrone transport. 
Deze bevindingen impliceren dat modulatie van ABCB1 niet leidt tot omzeilen van drug 
efflux uit leukemische stamcellen en mogelijk juist de residuaal normale stamcelpopulatie 
schaadt in deze ziekte. Deze bevindingen vormen een belangrijke verklaring voor de 
overwegend teleurstellende resultaten van ABCB1 modulatie op overleving in klinische 
trials in deze ziekte en pleiten tegen verder gebruik van deze strategie om stamcellen te 
eradiceren in leukemie. 
De opvallende bevinding dat ABCB1 gemedieerd transport verminderd is in de cellen van 
waaruit leukemie ontstaat leidt tot de hypothese dat constitutief verminderde activiteit 
van de belangrijkste xenobiotica-transporter in deze cellen mogelijk betrokken is bij een 
verhoogde gevoeligheid voor genotoxische schade door xenobiotica, voorafgaand aan het 
ontstaan van leukemie. Om deze hypothese te toetsen werd onderzocht of het verminderd 
ABCB1 gemedieerde efflux aanwezig is in normale CD34+38- cellen in patienten met AML. 
ABCB1 functie in cytogenetisch normale CD34+38- cellen in autoloog getransplanteerd 
beenmerg in langdurige remissie met normale hematopoiese bleek vergelijkbaar met 
autoloog getransplanteerde CD34+38- cellen in de niet- stamcelziekte multiple myeloma 
hetgeen suggereert dat het defect in ABCB1 transport niet constitutief aanwezig is maar 
een leukemische verandering van deze cellen. Deze bevinding is congruent met de 
bevinding dat residuaal normale progenitorcellen in AML gekenmerkt worden door een 
geconserveerde ABCB1 transportcapaciteit zoals beschreven in het eerste gedeelte van 
dit hoofdstuk. 
Verminderd ABCB1 transport ging wel vooraf aan het ontstaan van klinisch overte leukemie 
in patienten die lijden aan refractaire anemie. In patienten die geen leukemie ontwikkelden 
werd zonder uitzondering een normale ABCB1 gemedieerde efflux in CD34+38- celllen 
waargenomen op het moment van de diagnose refractaire anemie. 
Deze resultaten tonen aan dat verminderd ABCB1 gemedieerd transport in hematopoietische 
progenitorcellen een vroeg-leukemische verandering is die voorafgaat aan het ontstaan 
van klinisch overte leukemie in patienten met refractaire anemie. Toekomstig onderzoek 
zal moeten aantonen of verminderde werkzaamheid van deze belangrijke xenobiotica-
tranporter daadwerkelijk betrokken is bij het onstaan van leukemie of een “bystander” 
fenomeen betreft in leukemische transformatie.
De bevinding dat in leukemische CD34+38- progenitorcellen mitoxantrone transport 
plaatsvindt in de aanwezigheid van ABCB1 blokkade suggereert de aanwezigheid van 
additionele drug transporters in deze cellen.
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In hoofdstuk 5 wordt de rol van ABCG2, een multiple-drug ABC transporter met 
gedocumenteerde expressie in humane stamcellen van diverse origine, bestudeerd in 
drug resistentie van leukemische CD34+38- progenitorcellen.
ABCG2, gemeten middels flow-cytometrie met het BXP21 monoclonaal antilichaam en 
real time RT-PCR, kwam preferentieel tot expressie in zowel normale als leukemische 
CD34+38- cellen. Blokkade van ABCG2 gemedieerde efflux met de nieuwe, specifieke 
en potente inhibitor KO143 resulteerde in toegenomen accumulatie van mitoxantrone 
in leukemische CD34+38- cellen in de meerderheid van AML patienten. Deze toename 
was echter gering in vergelijking tot de toename in de ABCG2 positieve cellijn MCF7-MR 
en significante efflux van mitoxantrone vond plaats in de aanwezigheid van KO143 in 
leukemische CD34+38- cellen. In overeenstemming met deze bevindingen leidde blokkade 
va ABCG2 met KO143 niet tot toename van de in vitro chemosensitiviteit van leukemische 
CD34+38- cellen.
De resultaten van deze studie bevestigen dat drug extrusie uit leukemische progenitorcellen 
tot stand komt door de redundante activiteit van additionele transportmechanismen en 
dat modulatie van een enkele transporter waarschijnlijk niet leidt tot voldoende toename 
van intracellulaire accumulatie van chemotherapeutica en vervolgens drug-geinduceerde 
celdood.
Om deze additionele drug transport- mechanismen te identificeren wordt in hoofdstuk 6 
de studie beschreven waarin we de genexpressie van 45 ABC transporters (de complete 
ABCA, B, C, D en G familie) in normale en leukemische CD34+38- cellen bepalen 
gebruik makend van real-time kwantitatieve RT-PCR op microfluente “low-density” arrays. 
Genexpressie werd bestudeerd in CD34+38- progenitorcellen in vergelijking tot meer 
gedifferentieerde CD34+38+ cellen in normale, G-CSF gemobiliseerde, CD34+ cellen en 
AML. In normale CD34+38- cellen werd expressie gevonden van 36 transporters waarvan 
er 24 significant hoger tot expressie kwamen in vergelijking tot CD34+38+ cellen. Naast 
ABCB1 en ABCG2 betrof het veel familieleden van ABC-transporter families die niet eerder 
in verbinding gebracht zijn met stamcel-biologie, zoals de ABCA6 subfamilie waarvan de 
leden geclusterd zijn op chromosoom 17. Het ABC transporter genexpressie profiel van 
normale CD34+38- cellen bleek grotendeels geconserveerd in deze cellen in AML inclusief 
de expressie van de 13 ABC-transporters die momenteel in verband worden gebracht met 
efflux van chemotherapeutische agentia. 
Deze data suggeren een belangrijke rol voor veel, tevoren onbekende, ABC transporers 
in hematopoietische stamcelbiologie. Aanvullend onderzoek is nodig om de rol van 
deze transporters in resistentie van de leukemische stamcel verder te ontleden maar 
de bevinding dat vele drug-transport gerelateerde transporters tot expressie komen in 
leukemische progenitorcellen bevestigd de stelling dat gelijktijdige modulatie van deze 
mechanismen, mogelijk door te richten op gemeenschappelijke pathways, nodig is on drug 
efflux uit deze cellen te omzeilen.
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In de studies beschreven in de hoofdstukken 2-6 van dit proefschrift werden CD34 en 
CD38 monoclonale antilichamen gebruikt voor de flow-cytometrische identificatie van 
hematopoietische stamcellen. CD38 is tevens een belangrijke marker voor de identificatie 
van plasmacellen (CD34-CD38++). In hoofdstuk 7 en 8 wordt hiervan gebruik gemaakt 
en de expressie en klinische betekenis beschreven van ABCG2 en het Lung-resistance 
Related Protein (LRP) in plasmacellen in normaal beenmerg en hun maligne tegenhangers 
in patienten met multiple myeloom (MM).
Hoofdstuk 7 beschrijft de expressie en klinische betekenis van LRP, een eiwit geassocieerd 
met multiple drug resistentie, in MM. Aangetoond wordt dat LRP frequent tot expressie 
komt op plasmacellen in onbehandelde ziekte en dat dit een belangrijke negatieve 
prognostische factor is met betrekking tot repons- inductie, event-vrije overleving en 
totale overleving in patienten die behandeld worden met conventionele doses melfalan en 
prednison. Intensificatie van de dosering (intermediaire of hoge dosis melfalan) deed de 
prognostische waarde van LRP verdwijnen, mogelijk door LRP gemedieerde resistentie 
van maligne plasmacellen te omzeilen. LRP identificeert dus een populatie MM patienten 
die slecht respondeert op conventionele doses melfalen (18% respondeert) maar baat zou 
kunnen hebben bij dosis-intensivering (respons 81% in LRP positieve patienten).
In hoofdstuk 8 wordt tenslotte de rol van ABCG2 in primaire resistentie van MM 
patienten onderzocht. ABCG2 komt hoog tot expressie en is functioneel actief in normale 
plasmacellen maar de functie van het eiwit blijkt significant verminderd in MM op het 
moment van diagnose. Er bleek dan ook geen correlatie tussen expressie van ABCG2 op 
maligne plasmacellen en de respons op VAD (vincristine, adriamycine en dexamethason) 
therapie in deze patienten. De data pleiten tegen een rol van ABCG2 in primaire resistentie 
van MM patienten tegen VAD chemotherapie en derhalve het gebruik van dit eiwit als 
een target in het omzeilen van resistentie in deze ziekte. De opvallend hoge expressie en 
functionele activiteit in normale plasmacellen waarborgt verder onderzoek naar de rol van 
dit eiwit in deze gespecialiseerde cellen.
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Er zijn vele mensen die mij geholpen hebben dit proefschrift tot een goed eind te 
brengen.
Allereerst mijn promotor, 
Prof. Dr. T.J.M. de Witte,  beste Theo 
Jij was diegene die me naar Nijmegen haalde en vertrouwen stelde in mijn kwaliteiten 
als onderzoeker. Je gaf me de ruimte deze kwaliteiten verder te ontplooien en mijn eigen 
wegen te kiezen in het onderzoek. Hierin wist ik me altijd gesteund door jouw belangstelling 
en positivisme. Voor al deze zaken ben ik je dankbaar. 
Mijn co-promotores, 
Dr. R.A.P. Raymakers, beste Reinier 
Van alle mensen in dit dankwoord ben jij zeker diegene die het meest direct betrokken 
geweest is bij de wetenschappelijke vormgeving van dit proefschrift. Je hebt me echter 
ook in een vroeg stadium de vrijheid gegeven om mijn eigen onderzoeksinstincten te 
volgen. Ik heb je leren kennen als een duizendpoot, veelzijdig, ruimhartig, integer, met een 
groot relativeringsvermogen en iemand die in de dagelijkse hektiek van het academische 
wezen nooit de menselijke maat uit het oog verliest. Deze eigenschappen maken je tot een 
bijzonder mens. Ik had me geen betere co-promotor kunnen wensen.
Dr. J.H. Jansen, beste Joop, sta me toe jouw naam in een adem te noemen met die 
van Bert van der Reijden. Met jullie komst naar Nijmegen is ons onderzoek en mijn 
horizon verruimd met kennis van moleculaire biologie en de introductie van elementaire 
onderzoekstechnieken. Jullie kritische, maar altijd opbouwende, geest heeft geleid tot vele 
inspirerende discussies die ik als hoogtepunten in het doen van onderzoek beschouw en 
elementair zijn voor de progressie ervan. Daarnaast getuigt de manier waarop jullie het 
lab hebben opgezet van het feit dat gedrevenheid en ambitie hand in hand kunnen gaan 
met oog voor menselijke verhoudingen. Mede dankzij jullie werk van de afgelopen jaren 
is de basis geschapen voor verder basaal wetenschappelijk en translationeel onderzoek 
naar “ABC transporters in hematopoietische stamcellen” op het Centraal Hematologisch 
laboratorium in Nijmegen. 
Vanaf mijn eerste stap op het Centraal Hematologisch Laboratorium tot op de dag van 
vandaag is dit een omgeving gebleken waar ik me thuis heb gevoeld. Dit gevoel heeft 
naast de liefde voor het basale onderzoek alles te maken met de mensen met wie ik op het 
lab heb kunnen werken en leven;
Allereerst de mensen die met analytische ondersteuning en het verrichten van experimenten 
direct bij hebben gedragen aan het onderzoek:
Gerard van de Bosch: Jij was diegene die me heeft geleerd een pipet vast te houden. Ik 
dank je voor het  geduld, de toegewijdheid en het fanatisme  waarmee je dit deed en de 
experimenten met de fluorescentie-microscopie volbracht. 
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Liesbeth van Emst en Leonie Heuver,  dank voor jullie accurate analytische ondersteuning. 
Samenwerking met jullie leverde behalve een grote hoeveelheid wetenschappelijke data 
een zo mogelijk nog grotere hoeveelheid “sociale” data op. 
Gerty Vierwinden: Dank voor je tomeloze inzet, warme belangstelling en sociale 
betrokkenheid. Jouw aanwezigheid  op het lab is altijd sfeerbepalend geweest.
Elke de Grouw wil ik  bedanken voor het verrichten van de weerbarstige transport-assays 
en het voortzetten van andere experimenten. Sterkte met de laatste loodjes van jouw 
proefschrift.
Tot slot, Arie Pennings.  Meer nog dan een bekwaam flow-cytometrist die de hoeksteen 
vormde van de flow-cytometrische bepalingen in dit proefschrift is met jouw overlijden ook 
de bezielende kracht verdwenen die zo bepalend was voor de sfeer op het lab. 
Het onderzoek beschreven in dit proefschrift integreerde veel verschillende geledingen 
binnen het CHL (moleculaire hematologie, flow-cytometrie en beeldverwerking en de 
beenmergtransplantatie-unit). Van alle mensen uit deze geledingen heb ik niet anders 
dan hartelijkheid, bereidwilligheid en medewerking ervaren. Zonder de mensen die deze 
geledingen gezicht geven zou dit proefschrift er niet zijn geweest. De laagdrempeligheid 
en uitstekende onderlinge sfeer (zoals tot uiting komend in de jaarlijkse labdag) zijn 
bijzonder en moeten gekoesterd worden. 
Een aantal mensen wil ik met name noemen. Allereerst de mensen “van het eerste uur” die 
me onmiddellijk in hun midden hebben opgenomen: Peter Linssen, Carel Trilsbeek, Gerard 
van de Bosch en later ook Paul Brans en Jos Paardekoper. Dank voor het openhouden 
van het venster naar de wereld met onze dagelijkse besprekingen van “de toestand in 
de wereld” tijdens de lunch wat zo noodzakelijk is in de tijdelijke hypomanie van het 
onderzoeksbestaan.  
Jan Boezeman. Steun en toeverlaat in het oplossen van problemen op het gebied van de 
flow-cytometrie, beeldverwerking en niet in de laatste plaats statistiek. 
Louis van de Locht voor technische hulp en discussies met betrekking tot PCR, en
Ewald Mensink voor de waardevolle discussies die belangrijk waren voor hoofdstuk twee 
van dit proefschrift.
Verder ben ik dank verschuldigd aan:
De mede-auteurs voor hun bijdrage aan het onderzoek beschreven in dit proefschrift.
De opleiders Interne Geneeskunde (Prof. dr. Jos van der Meer, Prof. dr. Paul Stuyt en dr. 
Jacqueline de Graaf). Onderzoek doen naast klinische taken is complex maar waarschijnlijk 
beter mogelijk in Nijmegen dan elders in Nederland. Dank voor het organiseren van de 
opleiding en het scheppen van de voorwaarden die noodzakelijk zijn voor het combineren 
van basaal wetenschappelijk onderzoek met klinische taken. 
Frans Russel en Roos Masereeuw (Afdeling Farmacologie en Toxicologie) voor de 
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voortdurende samenwerking. In de nabije toekomst hoop ik in de gelegenheid te zijn onze 
samenwerking verder gestalte te geven.
De Staf Hematologie, voor het recruteren van, en de zorg voor de patienten zoals 
beschreven in de studies in dit proefschrift; Datacentrum Hematologie voor het onderhouden 
en beschikbaar stellen van klinische data; Henk Lokhorst voor mijn introductie in de wereld 
van de ABC-transporters.
 
Tot slot,
onderzoek doen is een uitgesproken absorberend proces gebleken dat de neiging heeft je 
het zicht te ontnemen op de dingen die wezenlijker zijn dan wetenschappelijke inzichten 
en verdiensten. Het bewegen in het continue spanningsveld tussen de aantrekkingskracht 
van het onderzoek en de aandacht voor de belangrijkste mensen om je heen is de grootste 
uitdaging gebleken waarmee ik in mijn  promotie-onderzoek geconfronteerd ben. De 
meeste dank ben ik verschuldigd aan de mensen die me geholpen hebben hierin de goede 
weg te vinden;
Allereerst mijn ouders , 
Dank voor jullie voortdurende en onvoorwaardelijke steun door de jaren heen. Jullie 
zijn erin geslaagd mij de kansen te geven die jullie nooit hebben gehad zonder mij met 
verwachtingen te belasten. Een bezoek aan jullie vormt voor mij altijd een terugkeer naar 
de wortels en het perspectief van alledag. Een warme deken. Mijn zus: lieve Doreen, ook 
jou ben ik hiervoor dankbaar.
Mijn paranimfen,  
Tijd met jullie doorbrengen is waarschijnlijk hetgeen wat het meest heeft geleden onder de 
onderzoeksperikelen en zeker een van de dingen die ik het meest heb gemist. Gelukkig 
zijn jullie nooit te beroerd gebleken me op subtiele en zonodig minder verfijnde wijze aan 
te geven wanneer ik te lang uit het zicht verdwijn. Deze directheid beschouw ik als het 
belangrijkste teken van de vitaliteit van onze vriendschap.
Lieve Karin, 
Niemand kent de hoogte- en dieptepunten bij de totstandkoming van dit proefschrift beter 
dan jij. Door deze momenten met jou te delen hebben ze eeuwigheidswaarde verkregen. 
Dank voor je liefde, geduld, begrip, steun, lach en een prachtige dochter.  
Lieve Emma, 
Dit proefschrift zal zeker jouw goedkeuring hebben want het behoort tot je favoriete genre; 
het is namelijk een boek “met letters”.  Tegen de tijd dat je het kunt lezen en begrijpen zul je 
het op de juiste waarde weten te schatten: Veel over weinig en dan nog lang niet compleet. 
De meeste dingen zijn relatief. Jij vormt daarop de belangrijkste uitzondering. 
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De auteur van dit proefschrift werd op 7 juni 1968 geboren te Veghel. Na afronding van het 
Gymnasium aan het Mgr. Zwijsencollege te Veghel werd in 1986 aangevangen met de studie 
Geneeskunde aan de Universiteit Utrecht. Gedurende de co-schappen deed hij onderzoek 
naar de rol van ABC- transporters in hematologische maligniteiten (dr. H.M. Lokhorst, 
afdeling Hematologie, Academisch Ziekenhuis Utrecht). In 1995 werd het artsexamen 
behaald waarna hij achtereenvolgens werkzaam was als arts-officier bij de Koninklijke 
Marine, arts-assistent Interne Geneeskunde (AGNIO) in het St. Antoniusziekenhuis te 
Nieuwegein en arts–assistent Klinische Microbiologie (AGIO) aan het Eijkman- Winkler 
Instituut voor Medische Microbiologie (opleider Prof. dr. J. Verhoef). 
In april 1999 werd de opleiding tot internist aangevangen aan het UMCN “St. Radboud” 
(opleider Prof. dr. J.W.M. van der Meer) in combinatie met het onderzoek zoals beschreven 
in dit proefschrift. Het onderzoek werd mede gefinancierd door een persoonlijke beurs 
verkregen van de Nederlandse Kankerbestrijding- Koningin Wilhelmina Fonds.
In 2005 vond registratie tot internist plaats en werd de opleiding tot internist-hematoloog 
aangevangen (opleider Prof. dr. T.J.M. de Witte). Sinds 2006 is hij verantwoordelijk voor het 
onderzoeksprogramma “ De rol van ABC-transporters in de biologie en chemoresistentie 
van normale en maligne stamcellen” op de afdeling Hematologie van het UMCN “St 
Radboud”. Hij woont samen met Karin van Oijen en is de trotse vader van Emma Felicia. 
Begin 2006 wordt hun tweede kind verwacht.
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The cover illustration: on the analogy between the honeybee 
queen and the hematopoietic stem cell
“Inter omnia insecta principatus apibus, et jure praecipua admiratio. Pliny. Lib. 11.c.5
The cover illustration of this thesis shows the queen of the Western Honey bee (Apis 
mellifera). Apis mellifera, unlike many other insects, has taken remarkable steps along 
the evolutionary road from a purely solitary existence to the highly developed colony 
organisation exhibited by the honeybees today. The hierarchy of the honeybee society 
resembles that of the human bone marrow and interesting parallels exist between the role 
of the queen in the honeybee hierarchy and the hematopoietic stem cell in human bone 
marrow. 
The honey bee queen and “stem cell” characteristics
A typical bee colony consist of about 40.000-50.000 bees. All these bees are the progeny 
of a single queen. (which actually resembles the stem cell frequency in human normal bone 
marrow that is estimated on 1-10.000-100.000 mononuclear cells). This progeny consists 
of differentiated bees, i.e. both worker bees and drones (which sole function is fertilizing the 
queen). In this respect the queen resembles one of the key characteristics of hematopoietic 
stem cells, i.e. the ability to give rise to progeny capable of multilineage differentiation. In 
contrast to the hierarchy in human bone marrow were different functions are performed 
by distinct terminally differentiated cells, worker bees perform differentiated activities (and 
congruent phenotypic changes) during subsequent stages with increasing age. 
In addition to multilineage differentiation, the honeybee queen possesses abilities that 
resemble the capacity for self-renewal and engraftment, characteristics that define the 
hematopoietic stem cell; the queen is able to a form of “self-renewal” by laying eggs in so-
called queen-cells that are subsequently bred into new queens on a special diet provided 
by worker bees. Each year about half a dozen queens are bred in case the queen leaves 
the hive to start another colony (“swarming” of the bees). The queen that has left the colony 
is able to “engraft” a new colony, although this is only possible when about half the bees of a 
colony join her (“accessory” bees) to establish a new nest (“micro-environment) to facilitate 
the engraftment. Interestingly, the fate of bee precursors (i.e. larva differentiation towards 
worker bees and new queens) essentially relies on micro-environmental circumstances 
such as the kind of cell an egg is laid in (worker cell vs. queen cell) and the amount and 
quality of food that is presented to the larva. Recent evidence in HSC suggests that the 
faith of early hematopoietic progenitors is similarly determined by the stem cell “niche” 
i.e. direct environmental factors, in addition to predefined (epi)- genetic differentiation 
programs found in hematopoietic precursors.
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Survival of the honey bee queen
One of the characteristics of a hematopoietic stem cell is that it is long-lived. This is 
paralleled in the bee-hierarchy in which the life expectancy of a bee queen is about 4-5 
years (the age is marked on their abdomen by bee-keepers with a spot of a particular 
colour, in case of the front cover red, indicating a 2-year old queen). This life span strikingly 
exceeds the lifespan of its progeny with drones living about 4-5 weeks and workers 4-
weeks to several months depending on the season in which it emerges from the brood-
cell. The mechanisms by which queen bees, and hematopoietic stem cells for that matter, 
survive for extended periods of time remain largely to be elucidated but the queen honey 
bee has become so highly specialized in creating progeny that it is quite unable to collect 
food for herself. She cannot, therefor,  survive for very long on her own and is dependent on 
its environment (nourishment by worker bees among other factors) for survival. This was 
recognized even by the first beekeepers as evidenced by their accounts;  
“A bee, like man cannot live alone, if she be alone she dies. Bees 
conserve community unto their last. They express if not great reverence, 
yet I am sure great love to their Commander”. Samuel Purchas (1657). 
A theatre of Political Flying-insects.
The dependence on external factors for survival resembles the hematopoietic stem cells 
that cannot be cultured and maintained without the support of stromal layers and other 
bone marrow cells that create the required microenvironment and produce numerous 
growth factors required for stem cell survival ex vivo. Mounting evidence suggests that, 
similarly, in vivo, hematopoietic stem cells are dependent on the appropriate survival 
signalling factors from their microenvironment (stem cell niche). This is of key importance 
to realize when examining intrinsic mechanisms of resistance and survival of both normal 
and malignant stem cells alike.
So what do we learn from all this? Clearly, the differences outweigh the similarities when 
comparing bees with bone marrow cells. The variety in the principle organisation of 
complex networks, however, tends to be limited and follow repetitive patterns at molecular, 
cellular, multicellular, organism and social levels. It is worth taking notice of our natural 
environment and extrapolating knowledge in “simpler” systems to obtain novel insights in 
more complex ones. If not for this, the wonderful experiments performed by the zoologist 
Karl von Frisch(1) in order to gain insight in the communication of bees (deciphering the 
famous “dances of the bees”), for which he was awarded the Nobel Prize in 1973, are a 
masterpiece of empirical research and should be considered obligatory literature for any 
researcher, especially those trying to unravel the cross-talk between stem cells and other 
components of the complicated society called the human bone marrow.
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Chapter 4
Figure 1: Definition of CD34+38- hematopoietic cells in normal bone marrow and acute myeloid leukemia. 
Representative example of normal bone marrow (NBM) and acute myeloid leukemia (AML). CD34+38- cells were 
defined flow-cytrometrically as the CD34-FITC+ cells (indicated in blue) with CD38-PE expression within the first 
decade of fluorescence emission (indicated in red) and compared with CD34+38+ cells (indicated as blue gated) 
with exclusion of a decade between CD38- and CD38+ cells. CD34- cells are shown in gray. CD34+38- cells 
exhibited restricted light-scattering characteristics (SSC) confirming the lymphoid appearance of these cells (inset). 
The median frequency of CD34+38- cells was 0.1 % of mononuclear cells (MNC) (range 0.1%-0.3%) in NBM and 0.2 
% of MNC (range 0.1%- 10%) in AML. No difference existed in average CD38 density between normal and leukemic 
CD34+38- cells (MFI 0.57 ± 0.05 SD, range 0.40-0.70 and MFI 0.53 ± 0.12 SD, range 0.30-0.70).
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Figure 3: ABCB1 is the major mitoxantrone and rhodamine-123 transporter in hematopoietic CD34+38- 
cells in human normal bone marrow. A1 Representative example of flow-cytometric assessment of ABCB1 
mediated mitoxantrone transport in CD34+38- cells in NBM. CD34+38- cells display low intracellular mitoxantrone 
fluorescence in comparison to CD34+38+ cells (inset) which can be increased significantly by blockage of ABCB1 
mediated transport by verapamil/PSC833. A2 Average mitoxantrone fluorescence (n=16) (depicted as mean 
fluorescence intensity (MFI) in CD34+ cells in the absence (shaded bars) or presence (black bars) of verapamil. 
B1 Representative example of the effect of ABCB1 inhibition by verapamil on rhodamine-123 fluorescence in 
CD34+38- cells assessed by single cell image analysis. B2. Average values ± S.D. of rhodamine-123 fluorescence 
(n=5)(depicted as arbitrary units) in the absence (shaded bars) or presence (black bars) of verapamil. Rhodamine-
123 accumulation was significantly lower in CD34+CD38- cells compared to CD34+CD38+ cells (rhodamine-123 
fluorescence 2820 ± 501 AU vs. 9369 ± 2367 AU). Blockage of ABCB1 mediated transport significantly increases 
rhodamine-123 accumulation in CD34+38- cells.
Figure 5: ABCB1 transport is impaired in hematopoietic CD34+38- cells in acute myeloid leukemia. A1 
Representative example demonstrating increased intracellular mitoxantrone accumulation in comparison to 
CD34+38- cells from normal bone marrow due to impaired ABCB1 mediated transport in CD34+38- cells illustrated 
by a lack of effect of verapamil/PSC833 on intracellular mitoxantrone fluorescence. A2. Average mitoxantrone 
fluorescence (depicted as mean fluorescence intensity (MFI) in CD34+ cells in the absence (shaded bars) or 
presence (black bars) of verapamil. B1. Representative example of impaired ABCB1 mediated rhodamine-123 
extrusion from CD34+38- cells, illustrated by the lack of effect of ABCB1 inhibition by verapamil on intracellular 
rhodamine-123 fluorescence assessed by single cell image analysis. B2. Average values ± S.D. Rhodamine-123 
fluorescence was significantly lower in CD34+CD38- cells compared to CD34+CD38+ cells (3106 ± 267 AU vs. 
4594 ± 373 AU) but blockage of ABCB1 by verapamil has no effect on rhodamine-123 fluorescence. 
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Figure 8: Representative examples of ABCB1 mediated mitoxantrone efflux in CD34+38- cells from 
autologous and allogeneic transplanted cells constituting normal hematopoiesis in long-term remission, 
refractory anemia (RA), refractory anemia progressing towards AML (RA-AML). 
Figure 9: ABCB1 mediated mitoxantrone transport identifies a subpopulation that harbors residual 
normal CD34+38- cells in a patient with CBFB-MYH11 AML. A patient was identified in which mitoxantrone 
discriminated a population of CD34+38- mitoxantrone dull cells. The dull phenotype was determined by strong 
ABCB1 mediated efflux (CD34+38- ABCB1 efflux ++), within the range observed in CD34+38- cells observed in 
normal bone marrow (EI=2.50). The CBFB-MYH11 (type D) transcript could be detected at the level of the positive 
control ( blast population from CBFB-MYH11 positive patient; Xn = 5.1. 10-3 copies CBFB-MYH11/Copy GAPDH) 
in the CD34+38- mitoxantrone bright population. CBFB-MYH11 transcripts were not detected in the CD34+38- 
ABCB1 efflux ++ population.
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Chapter 5
Figure 2 :Flow-cytometric assessment of BCRP expression and BCRP mediated mitoxantrone efflux in 
CD34+38- hematopoietic in normal bone marrow and AML. A.Definition of CD34+38- hematopoietic cells in 
human normal bone marrow (NBM) and AML. CD34+38- cells were defined flow-cytrometrically as the CD34 
expressing cells (indicated in blue) with CD38 expression within the first decade of fluorescence emission 
(indicated in red) and compared with CD34+38+ cells (indicated as blue gated) with an exclusion of a decade 
between CD38- and CD38+. CD34- cells are shown in grey. CD34+38- cells were found invariably in both normal 
bone marrow (A1) and both CD34+ (> 10% CD34+ cells in bone marrow by definition, A2) and CD34- leukemias 
(A3). The median frequency of CD34+38- cells was 0.1 % of mononuclear cells in normal bone marrow (range 
0.1%-0.3%) and 0.2 % in acute myeloid leukemia (range 0.1%- 10%). B. Cellular mitoxantrone fluorescence 
in different cell populations after 2 hrs incubation with mitoxantrone (10 uM) in the absence of BCRP inhibitor. 
CD34+38- cells have a mitoxantrone “dull” phenotype. C. BCRP protein expression in CD34+38- cells as 
determined by the BXP-21 antibody (dotted line) vs isotype control. D. Mitoxantrone fluorescence in CD34+38- 
cells in the presence (dotted line) or absence of the BCRP specific inhibitor KO143 (0.1 uM)
